"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,MX,A,MX 160078 A,093-531-280-940-706,1989-11-21,1989,MX 19727583 A,1983-05-13,GB 8214170 A,1982-05-14,PROCEDIMIENTO MEJORADO PARA EL BENEFICIO DE BENTONITA,,ECC INT LTD,GOODMAN HOWAR;;BLEAKLEY IAN STUART,,https://lens.org/093-531-280-940-706,Granted Patent,no,0,0,13,13,0,C01B33/26;;C01B33/26;;Y10S106/04;;Y10S106/04,C04B33/04;;B28C1/00;;B28C1/18;;C01B33/26,,0,0,,,,EXPIRED
2,GR,B,GR 77499 B,153-703-453-355-517,1984-09-24,1984,GR 830171347 A,1983-05-13,GB 8214170 A,1982-05-14,GR 77499 B,,ECC INT LTD,GOODMAN HOWARD;;BLEAKLEY IAN STUART,,https://lens.org/153-703-453-355-517,Granted Patent,no,0,0,13,13,0,C01B33/26;;C01B33/26;;Y10S106/04;;Y10S106/04,C04B33/04;;B28C1/00;;B28C1/18;;C01B33/26,,0,0,,,,EXPIRED
3,ES,T3,ES 2263742 T3,163-916-596-326-504,2006-12-16,2006,ES 02252171 T,2002-03-26,GB 0109033 A,2001-04-10,AMORTIGUADOR DE VIBRACIONES PARA TURBINA DE GAS.,"Un amortiguador de vibración (46) de álabe con álabe para un motor de turbina de gas, incluyendo el amortiguador (46) una primera superficie de fricción (48a) para entrar en contacto con una primera cara (22a) asociada con una álabe de turbina y una segunda superficie de fricción (48b) para entrar en contacto con una segunda cara (22b) asociada con una álabe de turbina adyacente, siendo dichas primera y segunda superficies de fricción (48a, 48b) y dichas primera y segunda caras (22a, 22b) planas, siendo dicha primera superficie de fricción (48a) y dicha segunda superficie de fricción (48b) convergentes, estando los extremos separados más próximos de dicha superficie de fricción (48a) y dicha segunda superficie de fricción (48b) separados por una distancia al menos tan grande como la separación circunferencial máxima entre los extremos radialmente exteriores de dicha primera cara (22a) y dicha segunda cara (22b), siendo el ángulo formado por dicha primera superficie de fricción (48a) y dichasegunda superficie de fricción (48b) más pequeño que el ángulo formado por dicha primera cara (22a) y dicha segunda cara (22b); caracterizado porque la masa del amortiguador (46) está dispuesta de manera que el centro de gravedad de dicho amortiguador (46) se sitúa en un plano que bisecta el ángulo formado por dichas superficie de fricción (48a, 48b) de manera que durante el uso, al menos parte de la amortiguación de vibración se efectúa mediante la oscilación del amortiguador (46) de manera que dicha primera y segunda superficies de fricción (48a, 48b) son llevadas alternativamente a contacto con las correspondientes primera y segunda caras (22a, 22b).",ROLLS ROYCE PLC,YEO STUART;;GOODMAN PETER JEFFREY,,https://lens.org/163-916-596-326-504,Granted Patent,no,0,0,9,9,0,F01D5/22;;F01D5/26;;Y10S416/50;;F01D5/22;;F01D5/26;;Y10S416/50,F01D5/22;;F01D5/26,,0,0,,,,EXPIRED
4,DE,D1,DE 60213150 D1,163-856-359-506-892,2006-08-31,2006,DE 60213150 T,2002-03-26,GB 0109033 A,2001-04-10,Schwingungsdämpfer für Gasturbinen,,ROLLS ROYCE PLC,YEO STUART;;GOODMAN PETER JEFFREY,,https://lens.org/163-856-359-506-892,Granted Patent,no,0,0,9,9,0,F01D5/22;;F01D5/26;;Y10S416/50;;F01D5/22;;F01D5/26;;Y10S416/50,F01D5/22;;F01D5/26,,0,0,,,,EXPIRED
5,GB,B,GB 2121017 B,052-698-969-556-023,1985-09-04,1985,GB 8214170 A,1982-05-14,GB 8214170 A,1982-05-14,PROCESS FOR BENEFICIATING BENTONITE,,ENGLISH CLAYS LOVERING POCHIN,GOODMAN HOWARD;;BLEAKLEY IAN STUART,,https://lens.org/052-698-969-556-023,Granted Patent,no,0,0,13,13,0,C01B33/26;;C01B33/26;;Y10S106/04;;Y10S106/04,C04B33/04;;B28C1/00;;B28C1/18;;C01B33/26,C1AM9;;C1APHS,0,0,,,,EXPIRED
6,EP,A2,EP 1249576 A2,026-296-655-476-720,2002-10-16,2002,EP 02252171 A,2002-03-26,GB 0109033 A,2001-04-10,Vibration damper for a gas turbine,A vibration damper 46 for a gas turbine engine has convergent friction surfaces 48a and 48b and is located radially inward of the platforms 20a and 20b of two adjacent turbine blades. The angle subtended by the friction surfaces 48a and 48b is smaller than that subtended by the angled faces 22a and 22b associated with the platforms 20a and 20b. The centre of mass of the damper 46 lies in a plane bisecting the angle subtended by the friction surfaces 48a and 48b. In use the damper 46 is urged radially outwards by centrifugal force so that at least one of the friction surfaces 48a and 48b makes planar contact with at least one of the angled faces 22a and 22b. Vibrational energy is dissipated by the resultant sliding movement between the friction surfaces 48a and 48b and the angled faces 22a and 22b. A secondary vibration damping mechanism arises from the oscillation of the damper 46 between the platforms 20a and 20b.,ROLLS ROYCE PLC,YEO STUART;;GOODMAN PETER JEFFREY,,https://lens.org/026-296-655-476-720,Patent Application,yes,0,2,9,9,0,F01D5/22;;F01D5/26;;Y10S416/50;;F01D5/22;;F01D5/26;;Y10S416/50,F01D5/26,,0,0,,,,EXPIRED
7,FR,A1,FR 2526779 A1,139-779-245-454-821,1983-11-18,1983,FR 8308086 A,1983-05-16,GB 8214170 A,1982-05-14,PROCEDE D'ENRICHISSEMENT DE LA BENTONITE,"<P>PROCEDE D'ENRICHISSEMENT OU D'AMELIORATION DE LA BENTONITE BRUTE.</P><P>IL CONSISTE A TRAITER UNE BENTONITE PRATIQUEMENT EXEMPTE D'OXYDE DE FER, SOUS FORME DE SUSPENSION AQUEUSE, PAR UN ALCALI A UNE TEMPERATURE D'AU MOINS 60C; A LAVER AU MOINS UNE FOIS A L'EAU LA BENTONITE TRAITEE, PUIS A SOUMETTRE UNE SUSPENSION DE LA BENTONITE LAVEE A DES FORCES DE CISAILLEMENT, DE FROTTEMENT ET D'IMPACT DANS UN HOMOGENEISEUR DU TYPE DANS LEQUEL LA SUSPENSION EST FORCEE SOUS LA FORME D'UNE PELLICULE A TRAVERS UN ORIFICE FIN, A SURFACE DURE, SOUS UNE PRESSION D'AU MOINS 1,7MPA ET A GRANDE VITESSE. LA SUSPENSION DE BENTONITE AINSI OBTENUE PEUT ENSUITE ETRE SECHEE EN DONNANT UN PRODUIT D'UN BON BLANC, PLUS RESISTANT AU DEVELOPPEMENT DE BACTERIES.</P>",ENGLISH CLAYS LOVERING POCHIN,GOODMAN HOWARD;;BLEAKLEY IAN STUART,,https://lens.org/139-779-245-454-821,Patent Application,no,6,3,13,13,0,C01B33/26;;C01B33/26;;Y10S106/04;;Y10S106/04,C04B33/04;;B28C1/00;;B28C1/18;;C01B33/26,,0,0,,,,EXPIRED
8,DE,A1,DE 3317333 A1,174-330-085-165-500,1983-11-17,1983,DE 3317333 A,1983-05-11,GB 8214170 A,1982-05-14,VERFAHREN ZUR AUFBEREITUNG VON BENTONIT,,ENGLISH CLAYS LOVERING POCHIN,GOODMAN HOWARD;;BLEAKLEY IAN STUART,,https://lens.org/174-330-085-165-500,Patent Application,no,3,0,13,13,0,C01B33/26;;C01B33/26;;Y10S106/04;;Y10S106/04,C04B33/04;;B28C1/00;;B28C1/18;;C01B33/26,,0,0,,,,DISCONTINUED
9,US,A1,US 2002/0146322 A1,193-937-744-153-416,2002-10-10,2002,US 10715302 A,2002-03-28,GB 0109033 A,2001-04-10,Vibration damping,"
    A vibration damper 46  for a gas turbine engine has convergent friction surfaces 48 a and 48 b and is located radially inward of the platforms 20 a and 20 b of two adjacent turbine blades. The angle subtended by the friction surfaces 48 a and 48 b is smaller than that subtended by the angled faces 22 a and 22 b associated with the platforms 20 a and 20 b . The center of mass of the damper 46  lies in a plane bisecting the angle subtended by the friction surfaces 48 a and 48 b . In use the damper 46  is urged radially outwards by centrifugal force so that at least one of the friction surfaces 48 a and 48 b makes planar contact with at least one of the angled faces 22 a and 22 b . Vibrational energy is dissipated by the resultant sliding movement between the friction surfaces 48 a and 48 b and the angled faces 22 a and 22 b . A secondary vibration damping mechanism arises from the oscillation of the damper 46  between the platforms 20 a and 20 b. 
",YEO STUART;;GOODMAN PETER J.,YEO STUART;;GOODMAN PETER J,ROLLS-ROYCE PLC (2002-02-26),https://lens.org/193-937-744-153-416,Patent Application,yes,3,11,9,9,0,F01D5/22;;F01D5/26;;Y10S416/50;;F01D5/22;;F01D5/26;;Y10S416/50,F01D5/26,41619;;416/219;;416/193;;X4165,0,0,,,,EXPIRED
10,EP,B1,EP 1249576 B1,196-734-814-036-24X,2006-07-19,2006,EP 02252171 A,2002-03-26,GB 0109033 A,2001-04-10,Vibration damper for a gas turbine,,ROLLS ROYCE PLC,YEO STUART;;GOODMAN PETER JEFFREY,,https://lens.org/196-734-814-036-24X,Granted Patent,yes,6,0,9,9,0,F01D5/22;;F01D5/26;;Y10S416/50;;F01D5/22;;F01D5/26;;Y10S416/50,F01D5/22;;F01D5/26,,1,0,,,"PATENT ABSTRACTS OF JAPAN vol. 008, no. 016 (M-270), 24 January 1984 (1984-01-24) -& JP 58 176402 A (TOKYO SHIBAURA DENKI KK), 15 October 1983 (1983-10-15)",EXPIRED
11,DE,T2,DE 60213150 T2,124-433-793-755-681,2006-11-16,2006,DE 60213150 T,2002-03-26,GB 0109033 A,2001-04-10,Schwingungsdämpfer für Gasturbinen,,ROLLS ROYCE PLC,YEO STUART;;GOODMAN PETER JEFFREY,,https://lens.org/124-433-793-755-681,Granted Patent,no,0,0,9,9,0,F01D5/22;;F01D5/26;;Y10S416/50;;F01D5/22;;F01D5/26;;Y10S416/50,F01D5/22;;F01D5/26,,0,0,,,,EXPIRED
12,EP,A3,EP 1249576 A3,150-748-041-788-201,2003-10-08,2003,EP 02252171 A,2002-03-26,GB 0109033 A,2001-04-10,Vibration damper for a gas turbine,A vibration damper 46 for a gas turbine engine has convergent friction surfaces 48a and 48b and is located radially inward of the platforms 20a and 20b of two adjacent turbine blades. The angle subtended by the friction surfaces 48a and 48b is smaller than that subtended by the angled faces 22a and 22b associated with the platforms 20a and 20b. The centre of mass of the damper 46 lies in a plane bisecting the angle subtended by the friction surfaces 48a and 48b. In use the damper 46 is urged radially outwards by centrifugal force so that at least one of the friction surfaces 48a and 48b makes planar contact with at least one of the angled faces 22a and 22b. Vibrational energy is dissipated by the resultant sliding movement between the friction surfaces 48a and 48b and the angled faces 22a and 22b. A secondary vibration damping mechanism arises from the oscillation of the damper 46 between the platforms 20a and 20b.,ROLLS ROYCE PLC,YEO STUART;;GOODMAN PETER JEFFREY,,https://lens.org/150-748-041-788-201,Search Report,yes,6,0,9,9,0,F01D5/22;;F01D5/26;;Y10S416/50;;F01D5/22;;F01D5/26;;Y10S416/50,F01D5/26,,1,0,,,"PATENT ABSTRACTS OF JAPAN vol. 008, no. 016 (M - 270) 24 January 1984 (1984-01-24)",EXPIRED
13,US,B2,US 6659725 B2,149-047-759-024-553,2003-12-09,2003,US 10715302 A,2002-03-28,GB 0109033 A,2001-04-10,Vibration damping,"
    A vibration damper  46  for a gas turbine engine has convergent friction surfaces  48  a and  48  b and is located radially inward of the platforms  20  a and  20  b of two adjacent turbine blades. The angle subtended by the friction surfaces  48  a and  48  b is smaller than that subtended by the angled faces  22  a and  22  b associated with the platforms  20  a and  20  b . The center of mass of the damper  46  lies in a plane bisecting the angle subtended by the friction surfaces  48  a and  48  b . In use the damper  46  is urged radially outwards by centrifugal force so that at least one of the friction surfaces  48  a and  48  b makes planar contact with at least one of the angled faces  22  a and  22  b . Vibrational energy is dissipated by the resultant sliding movement between the friction surfaces  48  a and  48  b and the angled faces  22  a and  22  b . A secondary vibration damping mechanism arises from the oscillation of the damper  46  between the platforms  20  a and  20  b. 
",ROLLS ROYCE PLC,YEO STUART;;GOODMAN PETER J,ROLLS-ROYCE PLC (2002-02-26),https://lens.org/149-047-759-024-553,Granted Patent,yes,9,25,9,9,0,F01D5/22;;F01D5/26;;Y10S416/50;;F01D5/22;;F01D5/26;;Y10S416/50,F01D5/26,416/190;;416/500,0,0,,,,EXPIRED
14,GB,A,GB 2121017 A,149-590-504-162-916,1983-12-14,1983,GB 8214170 A,1982-05-14,GB 8214170 A,1982-05-14,PROCESS FOR BENEFICIATING BENTONITE,,ENGLISH CLAYS LOVERING POCHIN,GOODMAN HOWARD;;BLEAKLEY IAN STUART,,https://lens.org/149-590-504-162-916,Patent Application,no,1,1,13,13,0,C01B33/26;;C01B33/26;;Y10S106/04;;Y10S106/04,C04B33/04;;B28C1/00;;B28C1/18;;C01B33/26,C1A AM9           APHS;;C1A APHS          APHS,0,0,,,,EXPIRED
15,FR,B3,FR 2961482 B3,195-929-180-506-177,2012-07-13,2012,FR 1155336 A,2011-06-17,HK 10106054 A,2010-06-17,SYSTEME DE CONTROLE POUR UNE AILE DE TRACTION,,PRYDE NEIL LTD,HASTILOW DAVID ROBERT;;GOODMAN PATRICK STUART,,https://lens.org/195-929-180-506-177,Limited Patent,no,0,0,5,5,0,B63H8/16;;B63H8/18;;B63H8/16;;B63H8/18,B64D17/34,,0,0,,,,ACTIVE
16,WO,A1,WO 2016/020672 A1,023-868-029-229-169,2016-02-11,2016,GB 2015052257 W,2015-08-04,GB 201413834 A,2014-08-05,PAYMENT HANDLING APPARATUS AND METHOD,"The present invention relates to payment handling apparatus (10) which is operable to effect payment from a purchaser to a vendor. The payment handling apparatus comprises a purchaser client (12) operable by the purchaser, a vendor client (16) operable by the vendor and a purchaser server (14) which stores bank account information of the purchaser and which is in data communication with the purchaser client. The payment handling apparatus (10) also comprises a vendor server (18) which stores bank account information of the vendor and which is in data communication with the vendor client (16) and the purchaser server (14). The payment handling apparatus (10) is configured such that there is no data communication between the purchaser server (14) and the vendor client (16) and between the vendor server (18) and the purchaser client (12). The purchaser client (12) is operative in dependence on purchaser operation to receive a unique code from the purchaser server 14. The vendor client (16) is operative in dependence on vendor operation to communicate the unique code and a sum to be paid to the vendor server (18). The purchaser and vendor servers (14, 18) are data communication to effect payment of the sum from the purchaser's bank account to the vendor's bank account in dependence on the unique code.",COMCARDE LTD,JAMIESON STUART;;GOODMAN JAMES;;SYMINGTON KEITH,,https://lens.org/023-868-029-229-169,Patent Application,yes,3,2,7,7,0,G06Q20/20;;G06Q20/327;;G06Q20/3274;;G06Q20/385;;G06Q20/387;;G06Q20/401;;G06Q20/3274;;G06Q20/385;;G06Q20/20;;G06Q20/327;;G06Q20/387;;G06Q20/3221;;G06Q20/3276;;G06Q20/401,G06Q20/20;;G06Q20/32;;G06Q20/38,,0,0,,,,PENDING
17,AU,B2,AU 2015/298533 B2,059-984-854-744-763,2020-08-06,2020,AU 2015/298533 A,2015-08-04,GB 201413834 A;;GB 2015052257 W,2014-08-05,Payment handling apparatus and method,"The present invention relates to payment handling apparatus (10) which is operable to effect payment from a purchaser to a vendor. The payment handling apparatus comprises a purchaser client (12) operable by the purchaser, a vendor client (16) operable by the vendor and a purchaser server (14) which stores bank account information of the purchaser and which is in data communication with the purchaser client. The payment handling apparatus (10) also comprises a vendor server (18) which stores bank account information of the vendor and which is in data communication with the vendor client (16) and the purchaser server (14). The payment handling apparatus (10) is configured such that there is no data communication between the purchaser server (14) and the vendor client (16) and between the vendor server (18) and the purchaser client (12). The purchaser client (12) is operative in dependence on purchaser operation to receive a unique code from the purchaser server 14. The vendor client (16) is operative in dependence on vendor operation to communicate the unique code and a sum to be paid to the vendor server (18). The purchaser and vendor servers (14, 18) are data communication to effect payment of the sum from the purchaser's bank account to the vendor's bank account in dependence on the unique code.",COMCARDE LTD,JAMIESON STUART;;GOODMAN JAMES;;SYMINGTON KEITH,,https://lens.org/059-984-854-744-763,Granted Patent,no,0,0,7,7,0,G06Q20/20;;G06Q20/327;;G06Q20/3274;;G06Q20/385;;G06Q20/387;;G06Q20/401;;G06Q20/3274;;G06Q20/385;;G06Q20/20;;G06Q20/327;;G06Q20/387;;G06Q20/3221;;G06Q20/3276;;G06Q20/401,G06Q20/20;;G06Q20/32;;G06Q20/38,,0,0,,,,ACTIVE
18,US,B1,US 8000584 B1,092-111-686-702-575,2011-08-16,2011,US 95867804 A,2004-10-04,US 95867804 A;;US 42533103 A;;US 42037103 A;;US 37562302 P;;US 50876903 P,2002-04-26,Approach for storing digital content onto digital versatile discs (DVDs),"According to an approach for storing digital content onto a DVD, digital content is received from a source, such as a DirecTV link, an over the air (OTA) broadcast, over a cable television link, or any other type of communications link, including the Internet. The digital content is formatted to comply with the MPEG standard to create MPEG digital content and stored on a non-volatile storage. Text-based information is received that describes one or more attributes of the received digital content. A set of DVD subpicture graphics is generated based upon the text-based information. The set of DVD subpicture graphics may represent a structure that can be navigated by a user when the DVD is played. The MPEG digital content is retrieved from the non-volatile storage, converted to DVD format and stored on the DVD with the DVD subpicture graphics.",TIVO INC,GOODMAN ANDREW MARTIN;;MOSKOWITZ ALAN STUART,ADEIA MEDIA SOLUTIONS INC (2022-08-15);;ROVI PRODUCT CORPORATION (2022-09-13),https://lens.org/092-111-686-702-575,Granted Patent,yes,23,2,1,326,0,G11B27/034;;G11B27/034;;G11B27/105;;G11B27/105;;G11B27/11;;G11B27/11;;G11B27/329;;G11B27/329;;G11B27/34;;G11B27/34;;G11B2220/218;;G11B2220/218;;G11B2220/2516;;G11B2220/2516;;G11B2220/2562;;G11B2220/2562;;G11B2220/41;;G11B2220/41;;G11B2220/455;;G11B2220/455;;H04N5/76;;H04N5/76;;H04N5/775;;H04N5/775;;H04N5/781;;H04N5/781;;H04N5/85;;H04N5/85;;H04N9/7921;;H04N9/7921;;H04N9/8042;;H04N9/8042,H04N5/84,386/335;;386/334;;386/341,14,0,,,"International Bureau, ""Notification Concerning Transmittal of International Preliminary Report on Patentability (Chapter I of the Patent Cooperation Treaty)."" PCT/US2004/010913, 5 pages, dated Nov. 3, 2005.;;Current Claims, PCT/US2004/010913, 5 pages.;;State Intellectual Property Office of P.R.C., ""Notification of the First Office Action"", Application No. 200480013487.1, dated Feb. 29, 2008, 5 pages.;;European Patent Office, ""Communication pursuant to Article 94(3) EPC"", Application No. 04759815.6-1247, dated May 5, 2008, 5 pages.;;Claims, Application No. 04759815.6-1247, 7 pages.;;""DVD Book Construction"", DVD Format/Logo Licensing Corporation, retrieved from internet : http://www.dvdflIc.co.jp , Retrieved on May 5, 2006, 1 page.;;""How to Order a DVD Book"", DVD Format/Logo Licensing Corporation, retrieved from internet : http://www.dvdfllc.co.jp/howto/howto.htm , Retrieved on Mar. 3, 2004, 1 page.;;Taylor, Jim, ""DVD Demystified"", 2nd Edition, McGraw-Hill, 2001, 4 pages.;;International Search Report and Written Opinion, International Application No. PCT/US04/10913 dated Sep. 2, 2005, (8 pgs)-attached.;;Current Claims in PCT application No. PCT/US04/1913 (7 pgs)-attached.;;Japanese Patent Office, ""Official Notice for Preliminary Rejection"", Application No. 2006-509833, dated Sep. 10, 2008, 9 pages.;;Claims, Application No. 2006-509833, 8 pages.;;English Translation of Japanese ""Official Notice for Preliminary Rejection"" dated Sep. 3, 2009, application No. 2006-509833, Applicant: TiVo Inc., 2 pages.;;Current Claims for Japanese application No. 2006-509833, amended on Feb 10, 2009, 7 pages.",ACTIVE
19,AU,A1,AU 2015/298533 A1,188-460-052-319-781,2017-03-23,2017,AU 2015/298533 A,2015-08-04,GB 201413834 A;;GB 2015052257 W,2014-08-05,Payment handling apparatus and method,"The present invention relates to payment handling apparatus (10) which is operable to effect payment from a purchaser to a vendor. The payment handling apparatus comprises a purchaser client (12) operable by the purchaser, a vendor client (16) operable by the vendor and a purchaser server (14) which stores bank account information of the purchaser and which is in data communication with the purchaser client. The payment handling apparatus (10) also comprises a vendor server (18) which stores bank account information of the vendor and which is in data communication with the vendor client (16) and the purchaser server (14). The payment handling apparatus (10) is configured such that there is no data communication between the purchaser server (14) and the vendor client (16) and between the vendor server (18) and the purchaser client (12). The purchaser client (12) is operative in dependence on purchaser operation to receive a unique code from the purchaser server 14. The vendor client (16) is operative in dependence on vendor operation to communicate the unique code and a sum to be paid to the vendor server (18). The purchaser and vendor servers (14, 18) are data communication to effect payment of the sum from the purchaser's bank account to the vendor's bank account in dependence on the unique code.",COMCARDE LTD,JAMIESON STUART;;GOODMAN JAMES;;SYMINGTON KEITH,,https://lens.org/188-460-052-319-781,Patent Application,no,0,0,7,7,0,G06Q20/20;;G06Q20/327;;G06Q20/3274;;G06Q20/385;;G06Q20/387;;G06Q20/401;;G06Q20/3274;;G06Q20/385;;G06Q20/20;;G06Q20/327;;G06Q20/387;;G06Q20/3221;;G06Q20/3276;;G06Q20/401,G06Q20/20;;G06Q20/32;;G06Q20/38,,0,0,,,,ACTIVE
20,US,A1,US 2017/0228719 A1,028-612-928-632-042,2017-08-10,2017,US 201515329024 A,2015-08-04,GB 201413834 A;;GB 2015052257 W,2014-08-05,PAYMENT HANDLING APPARATUS AND METHOD,"The present invention relates to payment handling apparatus ( 10 ) which is operable to effect payment from a purchaser to a vendor. The payment handling apparatus comprises a purchaser client ( 12 ) operable by the purchaser, a vendor client ( 16 ) operable by the vendor and a purchaser server ( 14 ) which stores bank account information of the purchaser and which is in data communication with the purchaser client. The payment handling apparatus ( 10 ) also comprises a vendor server ( 18 ) which stores bank account information of the vendor and which is in data communication with the vendor client ( 16 ) and the purchaser server ( 14 ). The payment handling apparatus ( 10 ) is configured such that there is no data communication between the purchaser server ( 14 ) and the vendor client ( 16 ) and between the vendor server ( 18 ) and the purchaser client ( 12 ). The purchaser client ( 12 ) is operative in dependence on purchaser operation to receive a unique code from the purchaser server 14. The vendor client ( 16 ) is operative in dependence on vendor operation to communicate the unique code and a sum to be paid to the vendor server ( 18 ). The purchaser and vendor servers ( 14, 18 ) are data communication to effect payment of the sum from the purchaser's bank account to the vendor's bank account in dependence on the unique code.",COMCARDE LTD,JAMIESON STUART;;GOODMAN JAMES;;SYMINGTON KEITH,COMCARDE LIMITED (2017-01-24),https://lens.org/028-612-928-632-042,Patent Application,yes,6,1,7,7,0,G06Q20/20;;G06Q20/327;;G06Q20/3274;;G06Q20/385;;G06Q20/387;;G06Q20/401;;G06Q20/3274;;G06Q20/385;;G06Q20/20;;G06Q20/327;;G06Q20/387;;G06Q20/3221;;G06Q20/3276;;G06Q20/401,G06Q20/32;;G06Q20/40,,0,0,,,,DISCONTINUED
21,CA,A1,CA 2993279 A1,035-345-125-772-332,2016-02-11,2016,CA 2993279 A,2015-08-04,GB 201413834 A;;GB 2015052257 W,2014-08-05,PAYMENT HANDLING APPARATUS AND METHOD,"The present invention relates to payment handling apparatus (10) which is operable to effect payment from a purchaser to a vendor. The payment handling apparatus comprises a purchaser client (12) operable by the purchaser, a vendor client (16) operable by the vendor and a purchaser server (14) which stores bank account information of the purchaser and which is in data communication with the purchaser client. The payment handling apparatus (10) also comprises a vendor server (18) which stores bank account information of the vendor and which is in data communication with the vendor client (16) and the purchaser server (14). The payment handling apparatus (10) is configured such that there is no data communication between the purchaser server (14) and the vendor client (16) and between the vendor server (18) and the purchaser client (12). The purchaser client (12) is operative in dependence on purchaser operation to receive a unique code from the purchaser server 14. The vendor client (16) is operative in dependence on vendor operation to communicate the unique code and a sum to be paid to the vendor server (18). The purchaser and vendor servers (14, 18) are data communication to effect payment of the sum from the purchaser's bank account to the vendor's bank account in dependence on the unique code.",COMCARDE LTD,JAMIESON STUART;;GOODMAN JAMES;;SYMINGTON KEITH,,https://lens.org/035-345-125-772-332,Patent Application,no,0,0,7,7,0,G06Q20/20;;G06Q20/327;;G06Q20/3274;;G06Q20/385;;G06Q20/387;;G06Q20/401;;G06Q20/3274;;G06Q20/385;;G06Q20/20;;G06Q20/327;;G06Q20/387;;G06Q20/3221;;G06Q20/3276;;G06Q20/401,G06Q20/20;;G06Q20/32;;G06Q20/38,,0,0,,,,PENDING
22,FR,A3,FR 2961482 A3,056-253-908-104-510,2011-12-23,2011,FR 1155336 A,2011-06-17,HK 10106054 A,2010-06-17,SYSTEME DE CONTROLE POUR UNE AILE DE TRACTION,"Système de contrôle pour une aile de traction comprenant : une barre (10) avec des moyens de fixation (14) à chacune de ses extrémités reliée respectivement à chaque ligne arrière (11, 12) ; une ouverture transversale (15) à travers la barre ; une ligne centrale (13) à connecter à l'utilisateur (17) à travers l'ouverture transversale (15), la ligne centrale bifurquant dans deux lignes frontales ; au moins une prise (26, 27) montée pour glisser le long de la ligne centrale et actionnable afin de faire varier la longueur de la ligne centrale pour l'ajustement de l'équilibre, et des moyens élastiques (29) pour pousser la prise (26, 27) vers la barre (10).",PRYDE NEIL LTD,HASTILOW DAVID ROBERT;;GOODMAN PATRICK STUART,,https://lens.org/056-253-908-104-510,Patent Application,no,0,0,5,5,0,B63H8/16;;B63H8/18;;B63H8/16;;B63H8/18,B64D17/34,,0,0,,,,ACTIVE
23,US,A1,US 2011/0309199 A1,096-399-664-342-178,2011-12-22,2011,US 201113162729 A,2011-06-17,HK 10106054 A,2010-06-17,CONTROL SYSTEM FOR A TRACTION WING,A control system for a traction wing or a surfing kite includes a bar that is gripped by a person carried in the wind by the wing or kite. Fixtures on the opposed ends of the bar are connected to respective lines that are attached to the wing. A central line attached to the wing passes through a hole located in the bar and divides into two lines that are connected to the user. A grip slides along the central line and the grip is biased toward the bar.,HASTILOW DAVID ROBERT;;GOODMAN PATRICK STUART;;PRYDE NEIL LTD,HASTILOW DAVID ROBERT;;GOODMAN PATRICK STUART,ADEVENTURE SPORTS INC (2022-05-12);;WATER BOUND INVESTMENTS LLC (2022-05-12);;NEIL PRYDE LIMITED (2011-08-05),https://lens.org/096-399-664-342-178,Patent Application,yes,6,2,5,5,0,B63H8/16;;B63H8/18;;B63H8/16;;B63H8/18,B64C31/06,244155 A,0,0,,,,ACTIVE
24,US,B2,US 8814098 B2,000-964-315-581-759,2014-08-26,2014,US 201113162729 A,2011-06-17,HK 10106054 A,2010-06-17,Control system for a traction wing,A control system for a traction wing or a surfing kite includes a bar that is gripped by a person carried in the wind by the wing or kite. Fixtures on the opposed ends of the bar are connected to respective lines that are attached to the wing. A central line attached to the wing passes through a hole located in the bar and divides into two lines that are connected to the user. A grip slides along the central line and the grip is biased toward the bar.,HASTILOW DAVID ROBERT;;GOODMAN PATRICK STUART;;PRYDE NEIL LTD,HASTILOW DAVID ROBERT;;GOODMAN PATRICK STUART,ADEVENTURE SPORTS INC (2022-05-12);;WATER BOUND INVESTMENTS LLC (2022-05-12);;NEIL PRYDE LIMITED (2011-08-05),https://lens.org/000-964-315-581-759,Granted Patent,yes,17,2,5,5,0,B63H8/16;;B63H8/18;;B63H8/16;;B63H8/18,B64C31/00;;B63B35/79,244155A;;114/39.16,0,0,,,,ACTIVE
25,EP,A1,EP 3178049 A1,129-314-299-433-177,2017-06-14,2017,EP 15756444 A,2015-08-04,GB 201413834 A;;GB 2015052257 W,2014-08-05,PAYMENT HANDLING APPARATUS AND METHOD,,COMCARDE LTD,JAMIESON STUART;;GOODMAN JAMES;;SYMINGTON KEITH,COMCARDE LIMITED (2019-06-12),https://lens.org/129-314-299-433-177,Patent Application,yes,0,0,7,7,0,G06Q20/20;;G06Q20/327;;G06Q20/3274;;G06Q20/385;;G06Q20/387;;G06Q20/401;;G06Q20/3274;;G06Q20/385;;G06Q20/20;;G06Q20/327;;G06Q20/387;;G06Q20/3221;;G06Q20/3276;;G06Q20/401,G06Q20/20;;G06Q20/32;;G06Q20/38,,0,0,,,,DISCONTINUED
26,WO,A1,WO 2023/147055 A1,079-887-651-531-427,2023-08-03,2023,US 2023/0011740 W,2023-01-27,US 202263303757 P,2022-01-27,COMPOSITIONS COMPRISING A NON-BIOABSORBABLE POLYMER AND METABOLIC INHIBITOR,"Disclosed herein are compositions comprising a polymer and a metabolic inhibitor, as well as a method of using the composition to modulate an immune response. The composition may be produced in the form of a synthetic tissue for provision in a subject. The composition or synthetic tissue may further comprise additional therapeutic agents.",UNIV MICHIGAN STATE;;UNIV LELAND STANFORD JUNIOR,MADUKA CHIMA V;;CONTAG CHRISTOPHER;;GOODMAN STUART,,https://lens.org/079-887-651-531-427,Patent Application,yes,3,0,2,2,0,A61K45/06;;A61K31/444;;A61K31/7004;;A61K31/195;;A61K31/352;;A61K31/155;;A61K31/365;;A61K9/0019;;A61K9/5176,A61K31/33;;A61K31/341;;A61K31/395;;C12N15/113,,1,1,039-765-108-347-971,10.1016/j.msec.2016.05.082;;27524014,"CATAURO MICHELINA; BOLLINO FLAVIA; NOCERA PAOLA; PICCOLELLA SIMONA; PACIFICO SEVERINA: ""Entrapping quercetin in silica/polyethylene glycol hybrid materials: Chemical characterization and biocompatibility"", MATERIALS SCIENCE AND ENGINEERING C, ELSEVIER SCIENCE S.A., CH, vol. 68, 19 May 2016 (2016-05-19), CH , pages 205 - 212, XP029684620, ISSN: 0928-4931, DOI: 10.1016/j.msec.2016.05.082",PENDING
27,CA,A,CA 412503 A,121-646-917-943-589,1943-05-18,1943,CA 412503D A,,CA 412503T A,,MOTION CO-ORDINATION MEANS,,FRAZER-NASH ARCHIBALD GOODMAN;;PROCTOR STUART RUSSELL,FRAZER-NASH ARCHIBALD GOODMAN;;PROCTOR STUART RUSSELL,,https://lens.org/121-646-917-943-589,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
28,US,A,US 2347900 A,068-390-053-101-870,1944-05-02,1944,US 38907841 A,1941-04-17,GB 2347900X A,1939-11-07,Motion transmitting and co-ordinating means,,GOODMAN FRAZER-NASH ARCHIBALD;;RUSSELL PROCTOR STUART,GOODMAN FRAZER-NASH ARCHIBALD;;RUSSELL PROCTOR STUART,,https://lens.org/068-390-053-101-870,Granted Patent,no,0,11,1,1,0,F16H7/02;;Y10T74/1888;;Y10T74/1888;;F16H7/02,F16H7/02,,0,0,,,,EXPIRED
29,US,B2,US 11529393 B2,113-437-689-916-384,2022-12-20,2022,US 201716340319 A,2017-10-06,US 201716340319 A;;US 201662406342 P;;US 2017/0055502 W,2016-10-10,Mesenchymal stem cells expressing anti-inflammatory cytokines and methods of use,"Provided are compositions and methods for production of anti-inflammatory cytokines, growth factors, or chemokines. Provided are nucleic acids (e.g., expression vectors) that include an NFκB inflammation response element operably linked to a nucleotide sequence encoding an anti-inflammatory cytokine (e.g., IL-4). In some cases, the nucleic acid is an expression vector selected from: a linear expression vector, a circular expression vector, a plasmid, and a viral expression vector. Also provided are cells (e.g., mesenchymal stem cells—MSCs) comprising a nucleic acid that includes an NFκB inflammation response element operably linked to a nucleotide sequence encoding an anti-inflammatory cytokine. In some cases, the nucleic acid is integrated into the cell's genome. Also provided are methods for treating an individual having an inflammation-associated ailment, which can include administering an MSC to the individual, where the MSC includes an NFκB inflammation response element operably linked to a nucleotide sequence encoding an anti-inflammatory cytokine.",UNIV LELAND STANFORD JUNIOR,LIN TZUHUA;;PAJARINEN JUKKA;;GOODMAN STUART B,THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (2017-11-03),https://lens.org/113-437-689-916-384,Granted Patent,yes,7,0,3,3,25,A61K38/18;;A61K38/20;;A61K38/2026;;A61K35/28;;C12Q1/6897;;C12N5/0693;;C12N2529/10;;C12N5/0663;;C12N2501/2304;;C12N2501/60;;C12N2510/00;;C07K14/5406;;C07K14/4705;;A61P19/02;;A61P19/10;;A61P21/00;;A61P29/00;;A61P3/10;;A61P21/00;;A61P19/02;;A61P3/10;;A61P29/00;;A61P19/10;;A61K9/0019;;A61K35/28;;A61K38/1825;;A61K38/1841;;A61K38/1866;;A61K38/195;;A61K38/2026;;A61K38/204;;A61K38/2066;;A61K38/2073;;A61K38/2086;;A61K2035/124;;C12N15/86;;C12N2740/15043;;C12N2510/00;;C12N5/0663;;C12N5/0693;;C12N2501/2304;;C12Q1/6897;;A61K38/18;;C07K14/5406;;C12N2529/10;;C12N2501/60;;C07K14/4705;;A61K38/20,A01N63/00;;A61K9/00;;A61K35/12;;A61K35/28;;A61K38/18;;A61K38/19;;A61K38/20;;A61P3/10;;A61P19/02;;A61P19/10;;A61P21/00;;A61P29/00;;C07K14/47;;C07K14/54;;C12N5/0775;;C12N5/09;;C12N15/86;;C12Q1/6897,,22,18,077-740-529-784-640;;093-256-044-949-596;;009-535-725-957-343;;000-333-554-287-206;;047-809-159-210-790;;093-652-091-414-863;;087-137-679-673-651;;022-474-410-261-194;;072-236-904-059-121;;088-705-991-378-197;;012-921-351-664-565;;059-944-192-468-379;;050-476-227-829-372;;031-282-811-929-618;;043-451-240-151-717;;083-682-746-271-264;;001-426-166-775-485;;017-323-110-671-459,10.1038/nri2395;;19172693;;26255210;;10.1016/j.cyto.2015.05.018;;10.1189/jlb.0412214;;22782966;;pmc3441310;;pmc4320647;;24561556;;10.1038/nbt.2816;;24000286;;10.1155/2013/732742;;pmc3755386;;pmc3338109;;22129134;;10.1089/ten.tea.2011.0545;;10.1016/j.biomaterials.2012.02.003;;22364730;;pmc3309459;;10.1002/jbm.a.34981;;24123855;;pmc4035458;;12716446;;10.1186/ar614;;pmc154434;;pmc5019943;;27651799;;10.1155/2016/6901286;;22568986;;pmc3427232;;10.4161/cam.20341;;10.1155/2014/856019;;24864261;;pmc4016942;;pmc2492894;;18713142;;10.1111/j.1365-2249.2008.03683.x;;27272202;;10.1002/jgm.2888;;19796605;;10.2310/7290.2009.00026;;pmc2856067;;1698283;;10.1093/nar/18.17.5322;;pmc332193;;10.1182/blood.v96.10.3392.h8003392_3392_3398;;11071633;;10.1182/blood.v96.10.3392;;pmc2868906;;20485554;;10.1371/journal.pone.0010611,"Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. Sep. 2008;8(9):726-36. (Year: 2008).;;May RD, Fung M. Strategies targeting the IL-4/IL-13 axes in disease. Cytokine. Sep. 2015;75(1):89-116. (Year: 2015).;;Luzina IG, Keegan AD, Heller NM, Rook GA, Shea-Donohue T, Atamas SP. Regulation of inflammation by interleukin-4: a review of “alternatives”. J Leukoc Biol. Oct. 2012;92(4):753-64. (Year: 2012).;;Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol. Mar. 2014;32(3):252-60. (Year: 2014).;;Kean TJ, Lin P, Caplan AI, Dennis JE. MSCs: Delivery Routes and Engraftment, Cell-Targeting Strategies, and Immune Modulation. Stem Cells Int. 2013;2013:732742. (Year: 2013).;;Gibon, et al. “MC3T3-E1 Osteoprogenitor Cells Systemically Migrate to a Bone Defect and Enhance Bone Healing”; Tissue Engineering: Part A; vol. 18, Nos. 9 & 10; 2012; pp. 968-973.;;Gibon, et al. “Effect of a CCR1 receptor antagonist on systemic trafficking of MSCs and polyethylene particle-associated bone loss”; Biomaterials; May 2012; 33(14): pp. 3632-3638.;;Zwingenberger, et al. “Stem cell attraction via SDF-1α expressing fat tissue grafts”; J Biomed Mater Res A.; Jul. 2013; 101(7): 2067-2074.;;Yao, et al. “Mutant monocyte chemoattractant protein 1 protein attenuates migration of and inflammatory cytokine release by macrophages exposed to orthopedic implant wear particles”; J Biomed Mater Res A.; Sep. 2014; 102(9): 3291-3297.;;Tuan, et al. “Adult mesenchymal stem cells and cell-based tissue engineering”; Arthritis Res Ther; 2003; 5:32-45.;;Arutyunyan, et al. “Umbilical Cord as Prospective Source for Mesenchymal Stem Cell-Based Therapy”; Stem Cells International; vol. 2016; Article ID 6901286; 17 pages.;;Payne, et al. “Early intervention with gene-modified mesenchymal stem cells overexpressing interleukin-4 enhances anti-inflammatory responses and functional recovery in experimental autoimmune demyelination”; Cell Adhesion & Migration; May/Jun. 2012; 6:3; 179-189.;;Tan, et al. “Exogenous IL-4-Expressing Bone Marrow Mesenchymal Stem Cells for the Treatment of Autoimmune Sensorineural Hearing Loss in a Guinea Pig Model”; BioMed Research International; vol. 2014; Article ID 856019; 10 pages.;;Choi, et al. “Mesenchymal stem cells overexpressing interleukin-10 attenuate collagen-induced arthritis in mice”; Clinical and Experimental Immunology; Apr. 7, 2008; 153: 269-276.;;Gabner, et al. “Inflammation-induced transgene expression in genetically engineered equine mesenchymal stem cells”; J Gene Med.; Aug. 2016; 18(8): 26 pgs.;;Badr, et al. “Real-time monitoring of NF-kappaB activity in cultured cells and in animal models”; Mol Imaging; 2009; 8(5): pp. 1-19.;;Carlsen, et al. “In Vivo Imaging of NF-κB Activity”; J Immunol; 2002; 168:1441-1446.;;Magness, et al. “In Vivo Pattern of Lipopolysaccharide and Anti-CD3-Induced NF-κB Activation Using a Novel Gene-Targeted Enhanced GFP Reporter Gene Mouse”; J Immunol; 2004; 173:1561-1570.;;Lin, et al., “Establishment of NF-κB sensing and IL-4 secreting mesenchymal stromal cells as an “on-demand” drug delivery system to modulate inflammation”, Cytotheraphy, (2017); 19(9): 1025-1034.;;Mizushima, et al., “pEF-BOS, a powerful mammalian expression vector”, Nucleic Acids Research, (1990); vol. 18, No. 17, 5322.;;Salmon, et al., “High-level transgene expression in human hematopoietic progenitors and differentiated blood lineages after transduction with improved lentiviral vectors”, Gene Therapy, Blood, (2000); vol. 92, No. 10, pp. 3392-3398.;;Qin, et al., “Systematic Comparison of Constitutive Promoters and the Doxycycline-Inducible Promoter”, PLoS One, (2010), vol. 5, Issue 5, e10611, pp. 1-4.",ACTIVE
30,US,A1,US 2018/0043062 A1,171-719-595-882-063,2018-02-15,2018,US 201615559550 A,2016-03-18,US 201615559550 A;;US 201562135725 P;;US 2016/0023290 W,2015-03-20,Customized load-bearing and bioactive functionally-graded implant for treatment of osteonecrosis,"An engineered medical device for treatment of osteonecrosis is provided where the size, porosity and ceramic content of the device can be personalized based on an individual patient's anatomical and physiological condition. The device distinguishes different segments mimicking anatomically-relevant cortical and cancellous segments, in which the cortical segments of the device can sustain mechanical loading, and the cancellous segment of the device can promote bone ingrowth, osteogenesis and angiogenesis.",UNIV LELAND STANFORD JUNIOR,YANG YUNZHI;;GOODMAN STUART B;;SHANJANI YASER,THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (2015-03-20),https://lens.org/171-719-595-882-063,Patent Application,yes,7,3,3,5,0,A61L27/56;;A61L2430/02;;A61B17/742;;A61F2310/00179;;A61F2310/00293;;A61L27/56;;A61L2430/02;;A61B17/742;;A61F2/30942;;A61F2/3609;;A61F2002/30011;;A61F2002/30062;;A61F2002/30224;;A61F2002/30985;;A61F2002/3611;;A61F2310/00179;;A61F2310/00293;;A61L27/10;;A61L27/12;;A61L27/18;;A61L27/54;;A61L27/58;;A61L2300/414,A61L27/58;;A61F2/36;;A61L27/10;;A61L27/12;;A61L27/18;;A61L27/54;;A61L27/56,,0,0,,,,ACTIVE
31,WO,A1,WO 2016/154063 A1,019-023-843-435-865,2016-09-29,2016,US 2016/0023290 W,2016-03-18,US 201562135725 P,2015-03-20,CUSTOMIZED LOAD-BEARING AND BIOACTIVE FUNCTIONALLY-GRADED IMPLANT FOR TREATMENT OF OSTEONECROSIS,"An engineered medical device for treatment of osteonecrosis is provided where the size, porosity and ceramic content of the device can be personalized based on an individual patient's anatomical and physiological condition. The device distinguishes different segments mimicking anatomically-relevant cortical and cancellous segments, in which the cortical segments of the device can sustain mechanical loading, and the cancellous segment of the device can promote bone ingrowth, osteogenesis and angiogenesis.",THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERISTY,YANG YUNZHI;;GOODMAN STUART B;;SHANJANI YASER,,https://lens.org/019-023-843-435-865,Patent Application,yes,8,2,3,5,0,A61L27/56;;A61L2430/02;;A61B17/742;;A61F2310/00179;;A61F2310/00293;;A61L27/56;;A61L2430/02;;A61B17/742;;A61F2/30942;;A61F2/3609;;A61F2002/30011;;A61F2002/30062;;A61F2002/30224;;A61F2002/30985;;A61F2002/3611;;A61F2310/00179;;A61F2310/00293;;A61L27/10;;A61L27/12;;A61L27/18;;A61L27/54;;A61L27/58;;A61L2300/414,A61F2/28;;A61F2/30;;A61F2/36;;A61L27/10;;A61L27/56,,0,0,,,,PENDING
32,US,A1,US 2019/0255151 A1,190-604-456-835-186,2019-08-22,2019,US 201716340319 A,2017-10-06,US 201716340319 A;;US 201662406342 P;;US 2017/0055502 W,2016-10-10,Methods and Compositions for Inducible Production of Anti-Inflammatory Cytokines,"Provided are compositions and methods for production of anti-inflammatory cytokines, growth factors, or chemokines. Provided are nucleic acids (e.g., expression vectors) that include an NFκB inflammation response element operably linked to a nucleotide sequence encoding an anti-inflammatory cytokine (e.g., IL-4). In some cases, the nucleic acid is an expression vector selected from: a linear expression vector, a circular expression vector, a plasmid, and a viral expression vector. Also provided are cells (e.g., mesenchymal stem cells—MSCs) comprising a nucleic acid that includes an NF κ B inflammation response element operably linked to a nucleotide sequence encoding an anti-inflammatory cytokine. In some cases, the nucleic acid is integrated into the cell's genome. Also provided are methods for treating an individual having an inflammation-associated ailment, which can include administering an MSC to the individual, where the MSC includes an NF κ B inflammation response element operably linked to a nucleotide sequence encoding an anti-inflammatory cytokine.",UNIV LELAND STANFORD JUNIOR,LIN TZUHUA;;PAJARINEN JUKKA;;GOODMAN STUART B,THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (2017-11-03),https://lens.org/190-604-456-835-186,Patent Application,yes,0,1,3,3,25,A61K38/18;;A61K38/20;;A61K38/2026;;A61K35/28;;C12Q1/6897;;C12N5/0693;;C12N2529/10;;C12N5/0663;;C12N2501/2304;;C12N2501/60;;C12N2510/00;;C07K14/5406;;C07K14/4705;;A61P19/02;;A61P19/10;;A61P21/00;;A61P29/00;;A61P3/10;;A61P21/00;;A61P19/02;;A61P3/10;;A61P29/00;;A61P19/10;;A61K9/0019;;A61K35/28;;A61K38/1825;;A61K38/1841;;A61K38/1866;;A61K38/195;;A61K38/2026;;A61K38/204;;A61K38/2066;;A61K38/2073;;A61K38/2086;;A61K2035/124;;C12N15/86;;C12N2740/15043;;C12N2510/00;;C12N5/0663;;C12N5/0693;;C12N2501/2304;;C12Q1/6897;;A61K38/18;;C07K14/5406;;C12N2529/10;;C12N2501/60;;C07K14/4705;;A61K38/20,A61K38/20;;A61K9/00;;A61K35/28;;A61K38/18;;A61K38/19;;A61P3/10;;A61P19/02;;A61P19/10;;A61P21/00;;A61P29/00;;C12N15/86,,0,0,,,,ACTIVE
33,WO,A1,WO 2018/071295 A1,050-981-849-503-630,2018-04-19,2018,US 2017/0055502 W,2017-10-06,US 201662406342 P,2016-10-10,METHODS AND COMPOSITIONS FOR INDUCIBLE PRODUCTION OF ANTI-INFLAMMATORY CYTOKINES,"Provided are compositions and methods for production of anti-inflammatory cytokines, growth factors, or chemokines. Provided are nucleic acids (e.g., expression vectors) that include an NFκB inflammation response element operably linked to a nucleotide sequence encoding an anti-inflammatory cytokine (e.g., IL-4). In some cases, the nucleic acid is an expression vector selected from: a linear expression vector, a circular expression vector, a plasmid, and a viral expression vector. Also provided are cells (e.g., mesenchymal stem cells - MSCs) comprising a nucleic acid that includes an NFκB inflammation response element operably linked to a nucleotide sequence encoding an anti-inflammatory cytokine. In some cases, the nucleic acid is integrated into the cell's genome. Also provided are methods for treating an individual having an inflammation-associated ailment, which can include administering an MSC to the individual, where the MSC includes an NFκB inflammation response element operably linked to a nucleotide sequence encoding an anti-inflammatory cytokine.",UNIV LELAND STANFORD JUNIOR,LIN TZUHUA;;PAJARINEN JUKKA;;GOODMAN STUART B,,https://lens.org/050-981-849-503-630,Patent Application,yes,5,4,3,3,25,A61K38/18;;A61K38/20;;A61K38/2026;;A61K35/28;;C12Q1/6897;;C12N5/0693;;C12N2529/10;;C12N5/0663;;C12N2501/2304;;C12N2501/60;;C12N2510/00;;C07K14/5406;;C07K14/4705;;A61P19/02;;A61P19/10;;A61P21/00;;A61P29/00;;A61P3/10;;A61P21/00;;A61P19/02;;A61P3/10;;A61P29/00;;A61P19/10;;A61K9/0019;;A61K35/28;;A61K38/1825;;A61K38/1841;;A61K38/1866;;A61K38/195;;A61K38/2026;;A61K38/204;;A61K38/2066;;A61K38/2073;;A61K38/2086;;A61K2035/124;;C12N15/86;;C12N2740/15043;;C12N2510/00;;C12N5/0663;;C12N5/0693;;C12N2501/2304;;C12Q1/6897;;A61K38/18;;C07K14/5406;;C12N2529/10;;C12N2501/60;;C07K14/4705;;A61K38/20,A61K38/20;;C12N5/10;;C12N15/09;;C12N15/63;;C12Q1/68;;G01N33/564,,0,0,,,,PENDING
34,US,B2,US 10729816 B2,000-470-794-499-874,2020-08-04,2020,US 201615559550 A,2016-03-18,US 201615559550 A;;US 201562135725 P;;US 2016/0023290 W,2015-03-20,Customized load-bearing and bioactive functionally-graded implant for treatment of osteonecrosis,"An engineered medical device for treatment of osteonecrosis is provided where the size, porosity and ceramic content of the device can be personalized based on an individual patient's anatomical and physiological condition. The device distinguishes different segments mimicking anatomically-relevant cortical and cancellous segments, in which the cortical segments of the device can sustain mechanical loading, and the cancellous segment of the device can promote bone ingrowth, osteogenesis and angiogenesis.",UNIV LELAND STANFORD JUNIOR,YANG YUNZHI;;GOODMAN STUART B;;SHANJANI YASER,THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (2015-03-20),https://lens.org/000-470-794-499-874,Granted Patent,yes,13,0,3,5,0,A61L27/56;;A61L2430/02;;A61B17/742;;A61F2310/00179;;A61F2310/00293;;A61L27/56;;A61L2430/02;;A61B17/742;;A61F2/30942;;A61F2/3609;;A61F2002/30011;;A61F2002/30062;;A61F2002/30224;;A61F2002/30985;;A61F2002/3611;;A61F2310/00179;;A61F2310/00293;;A61L27/10;;A61L27/12;;A61L27/18;;A61L27/54;;A61L27/58;;A61L2300/414,A61L27/58;;A61B17/74;;A61F2/30;;A61F2/36;;A61L27/10;;A61L27/12;;A61L27/18;;A61L27/54;;A61L27/56,,1,1,004-795-586-242-928,12568964;;10.1016/s0736-0266(02)00157-2,"Determination of cortical bone porosity and pore size distribution using a low field pulsed NMR approach, Wang et al. 2003 Journal of Orthopaedic Research 21:312-319.",ACTIVE
35,US,B1,US 6299649 B1,020-575-715-512-169,2001-10-09,2001,US 36092699 A,1999-07-26,US 36092699 A;;US 49350296 A,1996-06-22,Unbalanced prosthetic device for providing side-dependent twisting-rotational axial-loading coupling,"The present invention discloses a side-dependent prosthetic device. The side-dependent prosthetic device is a composite prosthetic device with a longitudinal direction. The composite prosthetic device includes a plurality of plies wherein each ply being composed of a plurality of reinforced fibers aligned in a ply orientational angle .theta.i relative to the longitudinal direction of the prosthetic device, where i=1,2,3, . . . ,N and N being the number of the plies. The plurality of plies are laminated together for forming the prosthetic device wherein the ply orientational angles being arranged such that .theta.1+.theta.2+.theta.3+ . . . +.theta..sub.N -0 thus forming an unbalanced composite prosthetic device. In another preferred embodiment, the ply orientational angles .theta.i forming a sequence which is represented by ((.theta..sup.1 /.theta..sup.2).sub.s).sub.n where a first ply with orientational angle .theta..sup.1 being followed by a second ply with orientational angle .theta..sup.2 wherein such a sequence repeated n-times and arranged to be symmetrical to a mid-plane, wherein .theta..sup.1 being an angle close to -10.sub.i and .theta..sup.2 being an angle close to -20.sub.i.",CHANG FU-KUO;;YILDIZ HASAN;;GOODMAN STUART B.,CHANG FU-KUO;;YILDIZ HASAN;;GOODMAN STUART B,,https://lens.org/020-575-715-512-169,Granted Patent,yes,6,25,1,1,0,A61F2/3094;;A61F2/30942;;A61F2/30965;;A61F2/36;;A61F2/3662;;A61F2002/30009;;A61F2002/30014;;A61F2002/30065;;A61F2002/30955;;A61F2002/30957;;A61F2002/30971;;A61F2002/3625;;A61F2210/0071;;A61F2250/0018;;A61F2250/0028;;A61F2310/00173;;A61F2002/30084;;A61F2/30942;;A61F2/36;;A61F2/3094;;A61F2002/30971;;A61F2/30965;;A61F2002/30957;;A61F2002/3625;;A61F2002/30065;;A61F2002/30955;;A61F2210/0071;;A61F2310/00173;;A61F2250/0028;;A61F2002/30014;;A61F2002/30009;;A61F2250/0018;;A61F2/3662;;A61F2002/30084,A61F2/00;;A61F2/30;;A61F2/36,623/23.34;;623/23.44;;623/23.51,0,0,,,,EXPIRED
36,WO,A1,WO 2013/126294 A1,006-727-136-491-60X,2013-08-29,2013,US 2013/0026506 W,2013-02-15,US 201261602477 P,2012-02-23,INJECTABLE HYDROGEL SYSTEM TO MODULATE HOST RESPONSE AT BONE IMPLANT INTERFACE,A bone implant primer is provided. A biodegradable hydrogel component is provided. A plurality of biomolecule release depots are dispersed within the biodegradable hydrogel component wherein the plurality of biomolecule release depots comprise biomolecules for aiding implant osseointegration or biomolecules for mitigation of foreign body response. Different biomolecules may be released by the microspheres at different times.,UNIV LELAND STANFORD JUNIOR,KEENEY MICHAEL GERARD;;YANG FAN;;GOODMAN STUART BARRY,,https://lens.org/006-727-136-491-60X,Patent Application,yes,0,4,3,3,0,A61L27/52;;A61L27/58;;A61F2/4675;;A61F2002/30075;;A61F2002/30677;;A61F2002/4676;;A61L27/54;;A61L2300/412;;A61L2400/06;;A61L2430/02;;A61K38/1825;;A61K38/1858;;A61K38/1866;;A61K38/1875;;A61K38/19;;A61L27/52;;A61L27/58;;A61F2/4675;;A61F2002/30075;;A61F2002/30677;;A61F2002/4676;;A61L27/54;;A61L2300/412;;A61L2400/06;;A61L2430/02;;A61K9/0024;;A61K9/06;;A61K9/16;;A61K38/1825;;A61K38/1858;;A61K38/1866;;A61K38/1875;;A61K38/19;;A61K47/10;;C12N15/11,A61F2/28;;A61L27/52;;A61L27/58,,5,5,016-184-421-129-102;;007-496-420-549-347;;047-259-139-577-487;;081-401-847-651-518;;000-422-483-496-880,10707043;;10.1016/s1461-5347(00)00242-x;;10.1016/s0169-409x(97)00048-3;;pmc6741343;;15784166;;10.1111/j.1582-4934.2005.tb00338.x;;18087117;;20143194;;pmc2844517;;10.1208/s12248-010-9175-3,"TABATA, Y.: ""The importance of drug delivery systems in tissue engineering"", PHARMACEUTICAL SCIENCE & TECHNOLOGY TODAY, vol. 3, 2000, pages 80 - 89, XP002544869, DOI: doi:10.1016/S1461-5347(00)00242-X;;ANDERSON, J. M. ET AL.: ""Biodegradation and biocompatibility of PLA and PLGA microspheres"", ADVANCED DRUG DELIVERY REVIEWS, vol. 28, 1997, pages 5 - 24, XP009002299, DOI: doi:10.1016/S0169-409X(97)00048-3;;LNGEART-AVRAMOGLOU, D. ET AL.: ""Engineering bone: challenges and obstacles"", JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, vol. 9, 2005, pages 72 - 84;;KARKAR, A. ET AL.: ""Modulation of renal inflammation: therapeutic strategies"", SAUDI JOURNAL OF KIDNEY DISEASES AND TRANSPLANTATION, vol. 19, 2008, pages 1 - 19;;MORAIS, J. M. ET AL.: ""Biomaterials/tissue interactions: possible solutions to overcom foreign body response"", THE AAPS JOUNAL, vol. 12, 2010, pages 188 - 196",PENDING
37,US,A1,US 2015/0024051 A1,090-788-438-245-362,2015-01-22,2015,US 201314378945 A,2013-02-15,US 201314378945 A;;US 201261602477 P;;US 2013/0026506 W,2012-02-23,INJECTABLE HYDROGEL SYSTEM TO MODULATE HOST RESPONSE AT BONE IMPLANT INTERFACE,A bone implant primer is provided. A biodegradable hydrogel component is provided. A plurality of biomolecule release depots are dispersed within the biodegradable hydrogel component wherein the plurality of biomolecule release depots comprise biomolecules for aiding implant osseointegration or biomolecules for mitigation of foreign body response. Different biomolecules may be released by the microspheres at different times.,UNIV LELAND STANFORD JUNIOR,KEENEY MICHAEL GERARD;;YANG FAN;;GOODMAN STUART BARRY,THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (2014-11-10),https://lens.org/090-788-438-245-362,Patent Application,yes,4,1,3,3,0,A61L27/52;;A61L27/58;;A61F2/4675;;A61F2002/30075;;A61F2002/30677;;A61F2002/4676;;A61L27/54;;A61L2300/412;;A61L2400/06;;A61L2430/02;;A61K38/1825;;A61K38/1858;;A61K38/1866;;A61K38/1875;;A61K38/19;;A61L27/52;;A61L27/58;;A61F2/4675;;A61F2002/30075;;A61F2002/30677;;A61F2002/4676;;A61L27/54;;A61L2300/412;;A61L2400/06;;A61L2430/02;;A61K9/0024;;A61K9/06;;A61K9/16;;A61K38/1825;;A61K38/1858;;A61K38/1866;;A61K38/1875;;A61K38/19;;A61K47/10;;C12N15/11,A61K9/00;;A61F2/46;;A61K9/06;;A61K9/16;;A61K38/18;;A61K38/19;;A61K47/10;;C12N15/11,424/489;;X514 44  R;;424/85.1;;514/8.8;;514/8.1;;514/8.2;;514/9.1,1,1,026-881-883-916-254,10.1016/j.biomaterials.2013.09.028;;pmc4018195;;24075408,Keeney et al. Mutant MCP-1 Protein Delivery from Layer-by-Layer Coatings on Orthopaedic Implants to Modulate Inflammatory Response. Biomaterials. 2013 December ; 34(38): 10287â10295.,ACTIVE
38,US,B2,US 9682035 B2,134-147-530-647-676,2017-06-20,2017,US 201314378945 A,2013-02-15,US 201314378945 A;;US 201261602477 P;;US 2013/0026506 W,2012-02-23,Injectable hydrogel system to modulate host response at bone implant interface,A bone implant primer is provided. A biodegradable hydrogel component is provided. A plurality of biomolecule release depots are dispersed within the biodegradable hydrogel component wherein the plurality of biomolecule release depots comprise biomolecules for aiding implant osseointegration or biomolecules for mitigation of foreign body response. Different biomolecules may be released by the microspheres at different times.,UNIV LELAND STANFORD JUNIOR,KEENEY MICHAEL GERARD;;YANG FAN;;GOODMAN STUART BARRY,THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (2014-11-10),https://lens.org/134-147-530-647-676,Granted Patent,yes,14,0,3,3,0,A61L27/52;;A61L27/58;;A61F2/4675;;A61F2002/30075;;A61F2002/30677;;A61F2002/4676;;A61L27/54;;A61L2300/412;;A61L2400/06;;A61L2430/02;;A61K38/1825;;A61K38/1858;;A61K38/1866;;A61K38/1875;;A61K38/19;;A61L27/52;;A61L27/58;;A61F2/4675;;A61F2002/30075;;A61F2002/30677;;A61F2002/4676;;A61L27/54;;A61L2300/412;;A61L2400/06;;A61L2430/02;;A61K9/0024;;A61K9/06;;A61K9/16;;A61K38/1825;;A61K38/1858;;A61K38/1866;;A61K38/1875;;A61K38/19;;A61K47/10;;C12N15/11,A61K9/00;;A61F2/30;;A61F2/46;;A61K9/06;;A61K9/16;;A61K38/18;;A61K38/19;;A61K47/10;;A61L27/52;;A61L27/54;;A61L27/58;;C12N15/11,,12,11,026-881-883-916-254;;007-496-420-549-347;;081-401-847-651-518;;047-259-139-577-487;;000-422-483-496-880;;016-184-421-129-102;;002-683-118-233-896;;001-558-814-883-981;;023-250-382-430-408;;145-185-481-806-859;;002-915-449-388-614,10.1016/j.biomaterials.2013.09.028;;pmc4018195;;24075408;;10.1016/s0169-409x(97)00048-3;;18087117;;pmc6741343;;15784166;;10.1111/j.1582-4934.2005.tb00338.x;;20143194;;pmc2844517;;10.1208/s12248-010-9175-3;;10707043;;10.1016/s1461-5347(00)00242-x;;10.1016/0142-9612(93)90211-j;;8312463;;10.1002/app.10310;;7651403;;10.1128/mcb.15.9.4851;;pmc230730;;10.1161/01.cir.103.16.2096;;11319201;;10.1007/springerreference_32654;;10.1016/s0021-9258(17)40768-x;;8195247,"Keeney et al. Mutant MCP-1 Protein Delivery from Layer-by-Layer Coatings on Orthopaedic Implants to Modulate Inflammatory Response. Biomaterials. Dec. 2013 ; 34(38): 10287-10295.;;Anderson et al., “Biodegradation and biocompatibility of PLA and PLGA microspheres,” Advanced Drug Delivery Reviews, 28, 1997, pp. 5-24.;;Ayman Karkar, “Modulation of Renal Inflammation: Therapeutic Strategies,” Saudi J Kidney Dis Transpl 2008; 19(1), pp. 1-19.;;Logeart-Avramoglou et al., “Engineering bone: challenges and obstacles,” J. Cell. Mol. Med., vol. 9, No. 1, 2005, pp. 72-84.;;Morais et al., “Biomaterials/Tissue Interaction: Possible Solutions to Overcome foreign Body Response,” The AAPS Journal, vol. 12, No. 2, Jun. 2010, pp. 188-196.;;Yasuhiko Tabata, “The importance of drug delivery systems in tissue engineering,” PSTT, vol. 3, No. 3, Mar. 2000, pp. 80-89.;;International Search Report and Written Opinion dated Jun. 3, 2013 from International Application No. PCT/US2013/026506.;;Netti et al., “Hydrogels as an interface between bone and an implant” Biomaterials 1993. vol. 14 No. 14, pp. 1098-1104.;;Sivakumar et al., “Synthesis, Characterization, and In Vitro Release of Ibuprofen from Poly (MMA-HEMA) Copolymeric Core-Shell Hydrogel Microspheres for Biomedical Applications” Journal of Applied Polymer Science, vol. 83, pp. 3045-3054 (2002).;;Zhang et al, “A Dominant Negative Inhibitor Indicates that Monocyte Chemoattractant Protein 1 Functions as a Dimer”, Molecular and Cellular Biology, Sep. 1995, vol. 15, No. 9, pp. 4851-4855.;;Ni et al, “New Anti-Monocyte Chemoattractant Protein-1 Gene Therapy Attenuates Atherosclerosis in Apolipoprotein E-Knockout Mice” http://circ.ahajournals.org, 2001, pp. 2096-2101.;;Zhang et al, “Structure/Activity Analysis of Human Monocyte Chemoattractant Protein-1 (MCP-1) by Mutagenesis: Identification of a Mutated Protein that Inhibits MCP-1 Mediated Monocyte Chemotaxis”, The Journal of Biological Chemistry, 1994, vol. 269, No. 22, pp. 15918-15924.",ACTIVE
39,US,B2,US 9498627 B2,025-607-399-584-683,2016-11-22,2016,US 201414156181 A,2014-01-15,US 201414156181 A,2014-01-15,Wireless closed-loop and system to detect and treat sleep apnea,"A wireless implantable system is provided that is externally powered and comprises of a closed-loop feedback for treating both patients with obstructive and central sleep apnea. A method is provided for treating sleep apnea using an implantable device. The method comprises sensing an inspiration (IN) signal representative of inspiration experienced by a patient from a respiratory surrogate signal and sensing a respiratory effort (RE) signal representative of an amount of effort exerted by the patient during respiration. The method also comprises analyzing the inspiration signal relative to an IN baseline, that corresponds to normal respiratory behavior, to identify an IN indicator, analyzing the RE signal relative to an RE baseline, that corresponds to a normal amount of respiratory exerted by the patient, to identify an RE indicator, declaring a central sleep apnea (CSA) state or an obstructive sleep apnea (OSA) state based on the IN and RE indicators, and delivering at least one of a CSA therapy when the CSA state is declared or an OSA therapy when the OSA state is declared.",PACESETTER INC,ROSENBERG STUART;;KEISER MELANIE GOODMAN;;VENKATESAN LALIT;;THERET DIDIER,PACESETTER INC (2013-01-14),https://lens.org/025-607-399-584-683,Granted Patent,yes,14,7,2,2,0,A61N1/36139;;A61N1/36139;;A61B5/021;;A61B5/021;;A61B5/0215;;A61B5/0215;;A61B5/0533;;A61B5/0533;;A61B5/0826;;A61B5/0826;;A61B5/14542;;A61B5/14542;;A61B5/4818;;A61B5/4818;;A61B5/4836;;A61B5/4836;;A61B5/682;;A61B5/682;;A61B2505/07;;A61B2505/07;;A61N1/3601;;A61N1/3601;;A61N1/3611;;A61N1/3611,A61N1/00;;A61B5/00;;A61B5/021;;A61B5/0215;;A61B5/053;;A61B5/08;;A61B5/145;;A61N1/36,,0,0,,,,ACTIVE
40,WO,A2,WO 2003/105776 A2,016-849-121-797-153,2003-12-24,2003,US 0319019 W,2003-06-13,US 38962202 P,2002-06-17,ANALOGUES OF LIPID MEDIATORS DERIVED FROM OMEGA-3 PUFAs AND METHODS OF USE,"The present invention is directed to compounds that are analogues of lipid mediators derived from a fish oil-derived fatty acid, eicosapentaenoic acid ⏧C20:5&ohgr;-3; EPA&rsqb;, but with a longer tissue half-life and enhanced bioactivity. These analogues may be used to treat inflammatory, angioproliferative, cardiovascular, thrombophlebotic, vascular, ocular, dermatologic, neurodegenerative, pulmonary, endocrine, reproductive, rheumatologic and gastrointestinal diseases.",RESOLVYX PHARMACEUTICALS;;GOODMAN DANIEL W;;HANLEY MICHAEL R;;BURSTEN STUART L,GOODMAN DANIEL W;;HANLEY MICHAEL R;;BURSTEN STUART L,,https://lens.org/016-849-121-797-153,Patent Application,yes,0,0,15,15,0,C07C59/42;;C07C59/48;;C07C59/64;;C07C59/68;;C07C69/732;;C07C69/736;;C07C235/28;;C07C235/34;;A61P1/04;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P37/08;;C07C59/68;;C07C59/64;;C07C235/28;;C07C69/732;;C07C59/42;;C07C59/48;;C07C69/736;;C07C235/34,A61P1/04;;A61K31/164;;A61K31/232;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P37/08;;C07C59/42;;C07C59/48;;C07C59/64;;C07C59/68;;C07C69/732;;C07C69/736;;C07C235/28;;C07C235/34,,0,0,,,,PATENTED
41,AT,T1,AT E382597 T1,071-560-328-191-084,2008-01-15,2008,AT 03737135 T,2003-06-13,US 38962202 P,2002-06-17,ANALOGA VON OMEGA-3-PUFAS ABGELEITETEN LIPIDMEDIATOREN UND ANWENDUNGSVERFAHREN,"The present invention is directed to compounds that are analogues of lipid mediators derived from a fish oil-derived fatty acid, eicosapentaenoic acid [C20:5 omega-3; EPA], but with a longer tissue half-life and enhanced bioactivity. These analogues may be used to treat inflammatory, angioproliferative, cardiovascular, thrombophlebotic, vascular, ocular, dermatologic, neurodegenerative, pulmonary, endocrine, reproductive, rheumatologic and gastrointestinal diseases.",RESOLVYX PHARMACEUTICALS;;BRIGHAM & WOMENS HOSPITAL,GOODMAN DANIEL;;HANLEY MICHAEL;;BURSTEN STUART;;SERHAN CHARLES N,,https://lens.org/071-560-328-191-084,Granted Patent,no,0,0,15,15,0,C07C59/42;;C07C59/48;;C07C59/64;;C07C59/68;;C07C69/732;;C07C69/736;;C07C235/28;;C07C235/34;;A61P1/04;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P37/08;;C07C59/68;;C07C59/64;;C07C235/28;;C07C69/732;;C07C59/42;;C07C59/48;;C07C69/736;;C07C235/34,A61P1/04;;A61K31/164;;A61K31/232;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P37/08;;C07C59/42;;C07C59/48;;C07C59/64;;C07C59/68;;C07C69/732;;C07C69/736;;C07C235/28;;C07C235/34,,0,0,,,,EXPIRED
42,US,A1,US 2004/0044050 A1,029-339-782-502-852,2004-03-04,2004,US 46091303 A,2003-06-13,US 46091303 A;;US 38962202 P,2002-06-17,Analogues of lipid mediators derived from omega-3 PUFAs and methods of use,"
   The present invention is directed to compounds that are analogues of lipid mediators derived from a fish oil-derived fatty acid, eicosapentaenoic acid C20:5 -3; EPA, but with a longer tissue half-life and enhanced bioactivity. These analogues may be used to treat inflammatory, angioproliferative, cardiovascular, thrombophlebotic, vascular, ocular, dermatologic, neurodegenerative, pulmonary, endocrine, reproductive, rheumatologic and gastrointestinal diseases. 
",GOODMAN DANIEL W.;;HANLEY MICHAEL R.;;BURSTEN STUART L.,GOODMAN DANIEL W;;HANLEY MICHAEL R;;BURSTEN STUART L,RESOLVYX PHARMACEUTICALS INC (2006-02-13);;BRIGHAM AND WOMEN'S HOSPITAL INC (2007-02-15),https://lens.org/029-339-782-502-852,Patent Application,yes,2,43,15,15,0,C07C59/42;;C07C59/48;;C07C59/64;;C07C59/68;;C07C69/732;;C07C69/736;;C07C235/28;;C07C235/34;;A61P1/04;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P37/08;;C07C59/68;;C07C59/64;;C07C235/28;;C07C69/732;;C07C59/42;;C07C59/48;;C07C69/736;;C07C235/34,A61P1/04;;A61K31/164;;A61K31/232;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P37/08;;C07C59/42;;C07C59/48;;C07C59/64;;C07C59/68;;C07C69/732;;C07C69/736;;C07C235/28;;C07C235/34,514/357;;514/513;;514/549;;514/625;;514/521;;514/408;;546/334;;548/571;;554/61;;554/113;;554/85,0,0,,,,EXPIRED
43,WO,A3,WO 2003/105776 A3,161-327-150-349-885,2004-09-16,2004,US 0319019 W,2003-06-13,US 38962202 P,2002-06-17,ANALOGUES OF LIPID MEDIATORS DERIVED FROM OMEGA-3 PUFAs AND METHODS OF USE,"The present invention is directed to compounds that are analogues of lipid mediators derived from a fish oil-derived fatty acid, eicosapentaenoic acid ⏧C20:5&ohgr;-3; EPA&rsqb;, but with a longer tissue half-life and enhanced bioactivity. These analogues may be used to treat inflammatory, angioproliferative, cardiovascular, thrombophlebotic, vascular, ocular, dermatologic, neurodegenerative, pulmonary, endocrine, reproductive, rheumatologic and gastrointestinal diseases.",RESOLVYX PHARMACEUTICALS;;GOODMAN DANIEL W;;HANLEY MICHAEL R;;BURSTEN STUART L,GOODMAN DANIEL W;;HANLEY MICHAEL R;;BURSTEN STUART L,,https://lens.org/161-327-150-349-885,Search Report,yes,3,0,15,15,0,C07C59/42;;C07C59/48;;C07C59/64;;C07C59/68;;C07C69/732;;C07C69/736;;C07C235/28;;C07C235/34;;A61P1/04;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P37/08;;C07C59/68;;C07C59/64;;C07C235/28;;C07C69/732;;C07C59/42;;C07C59/48;;C07C69/736;;C07C235/34,A61P1/04;;A61K31/164;;A61K31/232;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P37/08;;C07C59/42;;C07C59/48;;C07C59/64;;C07C59/68;;C07C69/732;;C07C69/736;;C07C235/28;;C07C235/34,,0,0,,,,PATENTED
44,EP,A4,EP 1537069 A4,055-343-622-606-868,2006-01-04,2006,EP 03737135 A,2003-06-13,US 0319019 W;;US 38962202 P,2002-06-17,ANALOGUES OF LIPID MEDIATORS DERIVED FROM OMEGA-3 PUFAs AND METHODS OF USE,"The present invention is directed to compounds that are analogues of lipid mediators derived from a fish oil-derived fatty acid, eicosapentaenoic acid [C20:5 omega-3; EPA], but with a longer tissue half-life and enhanced bioactivity. These analogues may be used to treat inflammatory, angioproliferative, cardiovascular, thrombophlebotic, vascular, ocular, dermatologic, neurodegenerative, pulmonary, endocrine, reproductive, rheumatologic and gastrointestinal diseases.",RESOLVYX PHARMACEUTICALS,GOODMAN DANIEL W;;HANLEY MICHAEL R;;BURSTEN STUART L,"RESOLVYX PHARMACEUTICALS (2007-12-26);;BRIGHAM AND WOMEN'S HOSPITAL, INC. (2007-12-26)",https://lens.org/055-343-622-606-868,Search Report,no,1,0,15,15,0,C07C59/42;;C07C59/48;;C07C59/64;;C07C59/68;;C07C69/732;;C07C69/736;;C07C235/28;;C07C235/34;;A61P1/04;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P37/08;;C07C59/68;;C07C59/64;;C07C235/28;;C07C69/732;;C07C59/42;;C07C59/48;;C07C69/736;;C07C235/34,A61P1/04;;A61K31/164;;A61K31/232;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P37/08;;C07C59/42;;C07C59/48;;C07C59/64;;C07C59/68;;C07C69/732;;C07C69/736;;C07C235/28;;C07C235/34,,1,1,050-929-669-590-409,11034610;;pmc2195872;;10.1084/jem.192.8.1197,"SERHAN C N ET AL: ""Novel Functional Sets of Lipid-derived Mediators with Antiinflammatory Actions Generated from Omega-3 Fatty Acids via Cyclooxygenase 2-Nonsteroidal Antiinflammatory Drugs and Transcellular Processing"", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 192, no. 8, 16 October 2000 (2000-10-16), pages 1197 - 1204, XP002267884, ISSN: 0022-1007",EXPIRED
45,AU,A8,AU 2003/238240 A8,088-401-682-996-781,2003-12-31,2003,AU 2003/238240 A,2003-06-13,US 38962202 P;;US 0319019 W,2002-06-17,Analogues of lipid mediators derived from omega-3 pufas and methods of use,"The present invention is directed to compounds that are analogues of lipid mediators derived from a fish oil-derived fatty acid, eicosapentaenoic acid [C20:5 omega-3; EPA], but with a longer tissue half-life and enhanced bioactivity. These analogues may be used to treat inflammatory, angioproliferative, cardiovascular, thrombophlebotic, vascular, ocular, dermatologic, neurodegenerative, pulmonary, endocrine, reproductive, rheumatologic and gastrointestinal diseases.",RESOLVYX PHARMACEUTICALS,HANLEY MICHAEL R;;BURSTEN STUART L;;GOODMAN DANIEL W,,https://lens.org/088-401-682-996-781,Patent Application,no,0,0,15,15,0,C07C59/42;;C07C59/48;;C07C59/64;;C07C59/68;;C07C69/732;;C07C69/736;;C07C235/28;;C07C235/34;;A61P1/04;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P37/08;;C07C59/68;;C07C59/64;;C07C235/28;;C07C69/732;;C07C59/42;;C07C59/48;;C07C69/736;;C07C235/34,A61P1/04;;A61K31/164;;A61K31/232;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P37/08;;C07C59/42;;C07C59/48;;C07C59/64;;C07C59/68;;C07C69/732;;C07C69/736;;C07C235/28;;C07C235/34,,0,0,,,,DISCONTINUED
46,US,A1,US 2015/0196766 A1,069-201-180-241-156,2015-07-16,2015,US 201414156181 A,2014-01-15,US 201414156181 A,2014-01-15,WIRELESS CLOSED-LOOP AND SYSTEM TO DETECT AND TREAT SLEEP APNEA,"A wireless implantable system is provided that is externally powered and comprises of a closed-loop feedback for treating both patients with obstructive and central sleep apnea. A method is provided for treating sleep apnea using an implantable device. The method comprises sensing an inspiration (IN) signal representative of inspiration experienced by a patient from a respiratory surrogate signal and sensing a respiratory effort (RE) signal representative of an amount of effort exerted by the patient during respiration. The method also comprises analyzing the inspiration signal relative to an IN baseline, that corresponds to normal respiratory behavior, to identify an IN indicator, analyzing the RE signal relative to an RE baseline, that corresponds to a normal amount of respiratory exerted by the patient, to identify an RE indicator, declaring a central sleep apnea (CSA) state or an obstructive sleep apnea (OSA) state based on the IN and RE indicators, and delivering at least one of a CSA therapy when the CSA state is declared or an OSA therapy when the OSA state is declared.",PACESETTER INC,ROSENBERG STUART;;KEISER MELANIE GOODMAN;;VENKATESAN LALIT;;THERET DIDIER,PACESETTER INC (2013-01-14),https://lens.org/069-201-180-241-156,Patent Application,yes,2,17,2,2,0,A61N1/36139;;A61N1/36139;;A61B5/021;;A61B5/021;;A61B5/0215;;A61B5/0215;;A61B5/0533;;A61B5/0533;;A61B5/0826;;A61B5/0826;;A61B5/14542;;A61B5/14542;;A61B5/4818;;A61B5/4818;;A61B5/4836;;A61B5/4836;;A61B5/682;;A61B5/682;;A61B2505/07;;A61B2505/07;;A61N1/3601;;A61N1/3601;;A61N1/3611;;A61N1/3611,A61N1/36,,0,0,,,,ACTIVE
47,AU,A1,AU 2003/238240 A1,193-863-963-288-645,2003-12-31,2003,AU 2003/238240 A,2003-06-13,US 38962202 P;;US 0319019 W,2002-06-17,ANALOGUES OF LIPID MEDIATORS DERIVED FROM OMEGA-3 PUFAs AND METHODS OF USE,"The present invention is directed to compounds that are analogues of lipid mediators derived from a fish oil-derived fatty acid, eicosapentaenoic acid [C20:5 omega-3; EPA], but with a longer tissue half-life and enhanced bioactivity. These analogues may be used to treat inflammatory, angioproliferative, cardiovascular, thrombophlebotic, vascular, ocular, dermatologic, neurodegenerative, pulmonary, endocrine, reproductive, rheumatologic and gastrointestinal diseases.",RESOLVYX PHARMACEUTICALS,BURSTEN STUART L;;GOODMAN DANIEL W;;HANLEY MICHAEL R,,https://lens.org/193-863-963-288-645,Patent Application,no,0,0,15,15,0,C07C59/42;;C07C59/48;;C07C59/64;;C07C59/68;;C07C69/732;;C07C69/736;;C07C235/28;;C07C235/34;;A61P1/04;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P37/08;;C07C59/68;;C07C59/64;;C07C235/28;;C07C69/732;;C07C59/42;;C07C59/48;;C07C69/736;;C07C235/34,A61P1/04;;A61K31/164;;A61K31/232;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P37/08;;C07C59/42;;C07C59/48;;C07C59/64;;C07C59/68;;C07C69/732;;C07C69/736;;C07C235/28;;C07C235/34,,0,0,,,,DISCONTINUED
48,US,A1,US 2020/0315801 A1,010-736-251-878-85X,2020-10-08,2020,US 202016904408 A,2020-06-17,US 202016904408 A;;US 201715559550 A;;US 2016/0023290 W;;US 201962904334 P;;US 201562135725 P,2015-03-20,Customized load-bearing and bioactive functionally-graded implant for treatment of osteonecrosis,"An engineered medical device for treatment of osteonecrosis is provided where the size, porosity and ceramic content of the device can be personalized based on an individual patient's anatomical and physiological condition. The device distinguishes different segments mimicking anatomically-relevant cortical and cancellous segments, in which the cortical segments of the device can sustain mechanical loading, and the cancellous segment of the device can promote bone ingrowth, osteogenesis and angiogenesis.",UNIV LELAND STANFORD JUNIOR,YANG YUNZHI;;GOODMAN STUART B;;SHANJANI YASER;;PAN CHI-CHUN,THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (2020-06-17),https://lens.org/010-736-251-878-85X,Patent Application,yes,2,1,2,5,0,A61F2310/00179;;A61F2310/00796;;A61F2/2846;;A61F2002/285;;A61F2002/30062;;A61F2002/30011;;A61F2002/30014;;A61F2002/30224;;A61F2002/30235;;A61F2002/3092;;A61F2002/3093;;A61F2002/30985;;A61F2002/30677;;A61F2310/00293;;A61F2/28;;A61F2002/2828;;A61F2310/00179;;A61F2310/00796;;A61F2002/2835,A61F2/28,,0,0,,,,ACTIVE
49,US,B2,US 11666445 B2,107-053-157-177-912,2023-06-06,2023,US 202016904408 A,2020-06-17,US 202016904408 A;;US 201715559550 A;;US 2016/0023290 W;;US 201962904334 P;;US 201562135725 P,2015-03-20,Customized load-bearing and bioactive functionally-graded implant for treatment of osteonecrosis,"An engineered medical device for treatment of osteonecrosis is provided where the size, porosity and ceramic content of the device can be personalized based on an individual patient's anatomical and physiological condition. The device distinguishes different segments mimicking anatomically-relevant cortical and cancellous segments, in which the cortical segments of the device can sustain mechanical loading, and the cancellous segment of the device can promote bone ingrowth, osteogenesis and angiogenesis.",UNIV LELAND STANFORD JUNIOR,YANG YUNZHI;;GOODMAN STUART B;;SHANJANI YASER;;PAN CHI-CHUN,THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (2020-06-17),https://lens.org/107-053-157-177-912,Granted Patent,yes,11,0,2,5,0,A61F2310/00179;;A61F2310/00796;;A61F2/2846;;A61F2002/285;;A61F2002/30062;;A61F2002/30011;;A61F2002/30014;;A61F2002/30224;;A61F2002/30235;;A61F2002/3092;;A61F2002/3093;;A61F2002/30985;;A61F2002/30677;;A61F2310/00293;;A61F2/28;;A61F2002/2828;;A61F2310/00179;;A61F2310/00796;;A61F2002/2835,A61F2/28,,1,1,004-795-586-242-928,12568964;;10.1016/s0736-0266(02)00157-2,"Determination of cortical bone porosity and pore size distribution using a low field pulsed NMR approach, Wang et al. 2003 Journal of Orthopaedic Research 21:312-319.",ACTIVE
50,US,A1,US 2009/0073957 A1,093-280-042-424-788,2009-03-19,2009,US 54178806 A,2006-10-03,US 54178806 A,2006-10-03,Apparatus and methods for data distribution devices having selectable power supplies,"A network apparatus includes an independent power supply providing a first power signal, and a data distribution device which is operably coupled to the independent power supply and a remote data distribution device, where the remote distribution data device exchanges data and provides a second power signal to the data distribution device, and further where the data distribution device selects the first power signal or the second power signal for operational power. A method includes scanning a plurality of sensors, each coupled to a plurality of power inputs, to ascertain if a power signal is present, determining whether a power signal associated with an independent power supply is present at a power input, sourcing power from the independent power supply if the power signal is associated with an independent power supply, and sourcing power from an alternative supply if the power signal is not associated with an independent power supply.",AVAYA TECH LLC,NEWLAND PAUL BENJAMIN;;GOODMAN DANIEL;;GROSS WOLF-DIETER;;CONKLIN STUART D,AVAYA TECHNOLOGY LLC (2007-01-16),https://lens.org/093-280-042-424-788,Patent Application,yes,5,74,2,2,0,G06F1/263;;G06F1/263;;H04L12/10;;H04L12/10,H04L12/56,370/352,0,0,,,,ACTIVE
51,US,B2,US 8046619 B2,110-274-857-936-622,2011-10-25,2011,US 54178806 A,2006-10-03,US 54178806 A,2006-10-03,Apparatus and methods for data distribution devices having selectable power supplies,"A network apparatus includes an independent power supply providing a first power signal, and a data distribution device which is operably coupled to the independent power supply and a remote data distribution device, where the remote distribution data device exchanges data and provides a second power signal to the data distribution device, and further where the data distribution device selects the first power signal or the second power signal for operational power. A method includes scanning a plurality of sensors, each coupled to a plurality of power inputs, to ascertain if a power signal is present, determining whether a power signal associated with an independent power supply is present at a power input, sourcing power from the independent power supply if the power signal is associated with an independent power supply, and sourcing power from an alternative supply if the power signal is not associated with an independent power supply.",AVAYA INC,NEWLAND PAUL BENJAMIN;;GOODMAN DANIEL;;GROSS WOLF-DIETER;;CONKLIN STUART D,AVAYA TECHNOLOGY LLC (2007-01-16),https://lens.org/110-274-857-936-622,Granted Patent,yes,7,8,2,2,0,G06F1/263;;G06F1/263;;H04L12/10;;H04L12/10,G06F1/26,713/340;;710/16,3,0,,,"Mar. 12, 2010, Office Action from Canadian Application No. 2,615,570.;;Feb. 2, 2010, Office Action from U.S. Appl. No. 11/649,913.;;Aug. 20, 2009, Office Action from U.S. Appl. No. 11/649,913.",ACTIVE
52,US,B2,US 11394662 B2,024-128-562-408-360,2022-07-19,2022,US 202017125866 A,2020-12-17,US 202017125866 A;;US 201916699309 A,2019-11-29,Availability groups of cloud provider edge locations,"Techniques are described for enabling users of a cloud provider network to discover “availability groups” provided by a cloud provider network and to request the launch of computing resources into selected availability groups. Some cloud provider networks are expanding the definition of traditional “availability zones” to include new types of availability zones representing various types of provider substrate extension edge locations—including, for example, cloud-provider managed substrate extensions associated with separate control planes, 5G-enabled provider substrate extensions connected to communications service provider networks, and the like. Availability groups can be used to represent various defined collections these new types of provider substrate extensions, where each availability group may be defined such that includes a set of provider substrate extensions with a similar set of characteristics and capabilities.",AMAZON TECH INC,GOODMAN ALAN HADLEY;;CHACHRA PRANAV;;GUPTA DIWAKAR;;BALLANTYNE DOUGAL STUART;;PARULKAR ISHWARDUTT,,https://lens.org/024-128-562-408-360,Granted Patent,yes,25,0,3,3,0,H04L47/822;;H04L47/828;;H04L47/76;;H04L47/783;;H04L47/828;;H04L47/822;;G06F16/29;;H04L47/783;;H04L47/821;;H04L47/76,G06F15/16;;G06F16/29;;H04L47/70;;H04L47/76;;H04L47/783,,3,0,,,"AT&T, “AT&T's Network and Microsoft's Cloud Deliver New Customer Offerings”, available online at <https://about.att.com/story/2019/microsoft.html>, Jul. 17, 2019, 3 pages.;;Microsoft, “AT&T Integrating 5G with Microsoft Cloud to Enable Next-Generation Solutions on the Edge”, available online at <https://news.microsoft.com/2019/11/26/att-integrating-5g-with-microsoft-cloud-to-enable-next-generation-solutions-on-the-edge/>, Microsoft News Center, Nov. 26, 2019, 6 pages.;;Notice of Allowance, U.S. Appl. No. 16/699,309, dated Aug. 21, 2020, 8 pages.",ACTIVE
53,DE,T2,DE 60318456 T2,033-728-681-389-217,2008-12-24,2008,DE 60318456 T,2003-06-13,US 38962202 P;;US 0319019 W,2002-06-17,ANALOGA VON OMEGA-3-PUFAs ABGELEITETEN LIPIDMEDIATOREN UND ANWENDUNGSVERFAHREN,"The present invention is directed to compounds that are analogues of lipid mediators derived from a fish oil-derived fatty acid, eicosapentaenoic acid [C20:5 omega-3; EPA], but with a longer tissue half-life and enhanced bioactivity. These analogues may be used to treat inflammatory, angioproliferative, cardiovascular, thrombophlebotic, vascular, ocular, dermatologic, neurodegenerative, pulmonary, endocrine, reproductive, rheumatologic and gastrointestinal diseases.",RESOLVYX PHARMACEUTICALS;;BRIGHAM & WOMENS HOSPITAL,GOODMAN DANIEL W;;HANLEY MICHAEL R;;BURSTEN STUART L;;SERHAN CHARLES N,,https://lens.org/033-728-681-389-217,Granted Patent,no,0,0,15,15,0,C07C59/42;;C07C59/48;;C07C59/64;;C07C59/68;;C07C69/732;;C07C69/736;;C07C235/28;;C07C235/34;;A61P1/04;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P37/08;;C07C59/68;;C07C59/64;;C07C235/28;;C07C69/732;;C07C59/42;;C07C59/48;;C07C69/736;;C07C235/34,A61P1/04;;C07C69/74;;A61K31/164;;A61K31/232;;A61K31/557;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P37/08;;C07C49/00;;C07C49/04;;C07C49/105;;C07C53/00;;C07C57/02;;C07C57/18;;C07C59/42;;C07C59/48;;C07C59/64;;C07C59/68;;C07C61/00;;C07C61/08;;C07C69/00;;C07C69/52;;C07C69/732;;C07C69/736;;C07C235/28;;C07C235/34,,0,0,,,,EXPIRED
54,EP,B1,EP 1537069 B1,195-276-835-201-310,2008-01-02,2008,EP 03737135 A,2003-06-13,US 0319019 W;;US 38962202 P,2002-06-17,ANALOGUES OF LIPID MEDIATORS DERIVED FROM OMEGA-3 PUFAs AND METHODS OF USE,"The present invention is directed to compounds that are analogues of lipid mediators derived from a fish oil-derived fatty acid, eicosapentaenoic acid [C20:5 omega-3; EPA], but with a longer tissue half-life and enhanced bioactivity. These analogues may be used to treat inflammatory, angioproliferative, cardiovascular, thrombophlebotic, vascular, ocular, dermatologic, neurodegenerative, pulmonary, endocrine, reproductive, rheumatologic and gastrointestinal diseases.",RESOLVYX PHARMACEUTICALS;;BRIGHAM & WOMENS HOSPITAL,GOODMAN DANIEL W;;HANLEY MICHAEL R;;BURSTEN STUART L;;SERHAN CHARLES N,"RESOLVYX PHARMACEUTICALS (2007-12-26);;BRIGHAM AND WOMEN'S HOSPITAL, INC. (2007-12-26)",https://lens.org/195-276-835-201-310,Granted Patent,yes,4,0,15,15,0,C07C59/42;;C07C59/48;;C07C59/64;;C07C59/68;;C07C69/732;;C07C69/736;;C07C235/28;;C07C235/34;;A61P1/04;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P37/08;;C07C59/68;;C07C59/64;;C07C235/28;;C07C69/732;;C07C59/42;;C07C59/48;;C07C69/736;;C07C235/34,A61P1/04;;C07C69/74;;A61K31/164;;A61K31/232;;A61K31/557;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P37/08;;C07C49/00;;C07C49/04;;C07C49/105;;C07C53/00;;C07C57/02;;C07C57/18;;C07C59/42;;C07C59/48;;C07C59/64;;C07C59/68;;C07C61/00;;C07C61/08;;C07C69/00;;C07C69/52;;C07C69/732;;C07C69/736;;C07C235/28;;C07C235/34,,1,0,,,"SERHAN C N ET AL: ""Novel Functional Sets of Lipid-derived Mediators with Antiinflammatory Actions Generated from Omega-3 Fatty Acids via Cyclooxygenase 2-Nonsteroidal Antiinflammatory Drugs and Transcellular Processing"" JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 192, no. 8, 16 October 2000 (2000-10-16), pages 1197-1204, XP002267884 ISSN: 0022-1007",EXPIRED
55,US,B2,US 7378444 B2,087-570-668-929-25X,2008-05-27,2008,US 46091303 A,2003-06-13,US 46091303 A;;US 38962202 P,2002-06-17,Analogues of lipid mediators derived from omega-3 PUFAs and methods of use,"The present invention is directed to compounds that are analogues of lipid mediators derived from a fish oil-derived fatty acid, eicosapentaenoic acid [C20:5 ω-3; EPA], but with a longer tissue half-life and enhanced bioactivity. These analogues may be used to treat inflammatory, angioproliferative, cardiovascular, thrombophlebotic, vascular, ocular, dermatologic, neurodegenerative, pulmonary, endocrine, reproductive, rheumatologic and gastrointestinal diseases.",BRIGHAM & WOMENS HOSPITAL;;RESOLVYX PHARMACEUTICALS INC,GOODMAN DANIEL W;;HANLEY MICHAEL R;;BURSTEN STUART L;;SERHAN CHARLES N,RESOLVYX PHARMACEUTICALS INC (2006-02-13);;BRIGHAM AND WOMEN'S HOSPITAL INC (2007-02-15),https://lens.org/087-570-668-929-25X,Granted Patent,yes,11,23,15,15,0,C07C59/42;;C07C59/48;;C07C59/64;;C07C59/68;;C07C69/732;;C07C69/736;;C07C235/28;;C07C235/34;;A61P1/04;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P37/08;;C07C59/68;;C07C59/64;;C07C235/28;;C07C69/732;;C07C59/42;;C07C59/48;;C07C69/736;;C07C235/34,A61K31/22;;A61P1/04;;A61K31/16;;A61K31/164;;A61K31/20;;A61K31/232;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P37/08;;C07C59/00;;C07C59/42;;C07C59/48;;C07C59/64;;C07C59/68;;C07C69/732;;C07C69/736;;C07C231/00;;C07C235/28;;C07C235/34,514/549;;514/560;;514/625;;554/61;;554/219,38,34,050-929-669-590-409;;102-660-008-665-149;;029-437-902-318-769;;050-433-275-323-990;;018-794-430-680-327;;064-861-866-551-708;;036-301-778-357-832;;026-664-501-280-158;;004-087-848-396-568;;068-300-655-239-349;;011-854-728-585-119;;168-923-961-610-640;;050-929-669-590-409;;019-061-485-475-687;;039-040-330-582-691;;033-621-606-162-178;;037-214-463-975-805;;057-226-642-512-973;;013-727-068-392-960;;009-882-492-221-146;;053-917-787-642-186;;023-910-788-928-012;;034-354-996-309-78X;;099-167-300-017-549;;099-168-892-040-738;;015-764-746-026-093;;033-793-690-554-983;;001-707-847-815-658;;002-818-442-336-665;;015-689-024-824-379;;012-122-118-853-414;;079-279-587-521-320;;093-417-046-929-817;;165-953-186-245-811,11034610;;pmc2195872;;10.1084/jem.192.8.1197;;pmc2063338;;9043019;;10.1038/bjc.1997.116;;10318669;;10.1161/01.cir.99.18.2452;;10511332;;10.1080/07315724.1999.10718888;;10.1016/s0140-6736(99)07072-5;;10465168;;10.1038/scientificamerican0191-84;;1899486;;7568157;;pmc40824;;10.1073/pnas.92.21.9475;;7578068;;10.1021/bi00044a041;;pmc408424;;10430612;;10.1172/jci7016;;10.1016/s0090-6980(99)90421-5;;9048568;;10.1021/bi962476u;;10.1073/pnas.96.14.8247;;pmc22220;;10393980;;11034610;;pmc2195872;;10.1084/jem.192.8.1197;;pmc50263;;10.1073/pnas.89.21.9991;;1279685;;3421158;;10.1007/978-1-4757-0937-7_6;;3161300;;10.1016/0076-6879(90)87022-u;;2233343;;9103484;;10.1002/j.1552-4604.1995.tb04045.x;;8750370;;7648372;;8924427;;10.1163/156856295x00526;;7667190;;10.1023/a:1016209020160;;10.1111/j.2042-7158.1997.tb06090.x;;9255709;;8860685;;10.3109/02652049609026017;;10.1093/ajhp/46.8.1576;;2672806;;10.1016/0090-6980(93)90111-j;;8388116;;10.1016/s0040-4039(01)81071-6;;10.1172/jci13375;;pmc200204;;11413151;;pmc2194036;;10.3410/f.13277075.14635217;;10.1084/jem.20020760;;12391014;;10.1100/tsw.2002.81;;pmc6009744;;12806051;;10837478;;10.1074/jbc.m002863200;;pmc2196289;;9151906;;10.1084/jem.185.9.1693;;9313867;;10.1016/s0968-0896(97)00090-4;;11192938,"Serhan et al, Novel functional sets of lipid-derived mediators, Oct. 2000, Rockfeller University press, 192(8), p. 1197-1204.;;Iigo et al. (1997), ""Inhibitory Effects of Docosahexaenoic Acid on Colon Carcinoma 26 Metastasis to the Lung"", Br. J. Cancer, 75:650.;;Billman et al., ""Prevention of Sudden Cardiac Death by Dietary Pure Omega-3 Polyunsaturated Fatty Acids in Dogs"" (1999), Circulation, 99:2452.;;Simopoulous, et al, ""Workshop on the Essentiality of and Recommended Dietary Intakes for Omega-6 and Omega-3 Fatty Acids""(1999), J. Am. Coll. Nutr., 18:487.;;Marchioloi et al. ""Dietary Supplementation with n-3 Polyunsaturated Fatty Acids and Vitamin E After Myocardial Infarction: Results of the GISSI-Prevenzione Trial"" (1999), Lancet, 354:447.;;Weissmann, G. ""Aspirin"" (1991), Sci, Am., 264:84.;;Marcus, A.J. (1999), ""Platelets: Their Roll in Hemostasis, Thrombosis, and Inflammation"" Inflammation: Basic Principles and Clinical Correlates, J.I. Gallin and R. Snyderman, Editors, Lippincott Williams & Wilkins, Philadelphia, pp. 77-79.;;Clária, J. et al. ""Aspirin Triggers Previously Undescribed Bioactive Eicosanoids by Human Endothelial Cell-Leukocyte Interactions"" (1995), Proc. Natl. Acad. Sci USA, 92:9475.;;Serhan et al. ""Design of Lipoxin A<SUB>4 </SUB>Stable Analogs That Block Transmigration and Adhesion of Human Neutrophils"" (1995), Biochemistry, 34:14609.;;Chiang et al. ""Leukotriene B<SUB>4 </SUB>Receptor Transgenic Mice Reveal Novel Protective Roles for Lipoxins and Aspirin-Triggered Lipoxins in Reperfusion"" (1999), J. Clin. Invest. 104:309.;;Chiang et al. ""Aspirin-Triggered 15-epi-Lipoxin A<SUB>4 </SUB>(ATL) Generation by Human Leukocytes and Murione Peritonitis Exudates: Development of a Specific 15-epi-LXA<SUB>4 </SUB>ELISA <SUP>1</SUP>"" (1998), J. Pharmacol. Exp. Ther., 287:779.;;Xiao et al. ""Analysis of Hydroperoxide-Induced Tyrosyl Radicals and Lipoxygenase Activity in Aspirin-Treated Human Prostaglandin H Synthase-2"" (1997), Biochemistry, 36:1836.;;Clish et al. ""Local and Systemic Delivery of a Stable Aspirin-Triggered Lipoxin Prevents Neutrophil Recruitment in vivo"" (1999), Proc. Natl. Acad. Sci USA, 96:8247.;;Serhan et al. ""Novel Functional Sets of Lipid-Derived Mediators with Antiinflammatory Actions Generated from Omega-3 Fatty Acids via Cyclooxygenase 2-Nonsteroidal Antiinflammatory Drugs and Transcellular Processing"" (2000), J. Exp. Med., 192:1197.;;Cronstein et al. ""A Mechanism For the Antiinflammatory Effects of Corticosteroids: The Glucocorticoid Receptor Regulates Leukocyte Adhesion to Endothelial Cells and Expression of Endothelial-Leukocyte Adhesion Molecule 1 and Intercellular Adhesion Molecule 1"" (1992), Proc. Natl. Acad. Sci USA, 89:9991.;;Webber et al. The Total Synthesis of the Lipoxins and Related Compounds (1988), Adv. Exp. Med. Biol., 229:61.;;Radüchel, B., et al. ""Prostagladin Analogs"" (1985), Adv. Prost. Thromb. Leuko. Res., 14:263.;;Kobayashi, Y. et al ""Highly Stereocontrolled Total Synthesis of Leukotriene B<SUB>4 </SUB>20-Hydroxyleukotriene B<SUB>4 </SUB>Leukotriene B<SUB>3 </SUB>and Their Analogues"" (1990), J. Org. Chem., 55:5324.;;Nicolaou, K.C. et al. ""Lipoxins and Related Eicosanoids: Biosynthesis, Biological Properties, and Chemical Synthesis"" (1991), Agnew Chem. Int. Ed. Engl., 30:1100.;;Serhan, C. et al. ""High-Performance Liquid Chromatography Separation and Determination of Lipoxins"" (1990), Meth. Enzymol., 187:167.;;Minto, C.F. et al., ""Pharmacokinetics and Pharmacodynamics of Nandrolone Esters in Oil Vehicle: Effects of Ester, Injection Site and Injection Volume<SUP>1</SUP>"" (1997), J. Pharmacol. Exp. Ther., 281:93.;;Rohatagi et al. ""Pharmacokinetic and Pharmacodynamic Evaluation of Triamcinolone Acetonide After Intravenous, Oral, and Inhaled Administration"" (1995), J. Clin. Pharmacol., 35:1187.;;Tjwa, Martin K.T. ""Budesonide Inhaled via Turbuhaler: A More Effective Treatement for Asthma Than Beclomethasone Dipropionate Via Rotahaler"" (1995), Ann. Allergy Asthma & Immunol., 75:107.;;Rao, K.P. ""Recent Developments of Collagen-Based Mterials for Medical Applications and Drug Delivery Systems"" (1995), J. Biomater Sci. Polym. Edn, 7:623.;;Gao, Z. et al. ""Controlled Release of a Contraceptive Steroid from Biodegradable and Injectable Gel Formulations: In Vitro Evaluation"" (1995), Pharm. Res., 12:857.;;Eyles et al. ""Oral Delivery and Fate of Poly(lactic Acid) Microsphere-Encapsulated Interferon in Rats"" (1997),J. Pharm. Pharmacol., 49:669.;;Al-Muhammed et al. ""In-Vivo Studies on Dexamethasone Sodium Phosphate Liposomes"" (1996), J. Microencapsul., 13:293.;;Ostro, M.J. et al. ""Use of Liposomes as Injectable-Drug Delivery Systems"" (1989), Am. J. Hosp. Pharm., 46:1576.;;Shimazaki et al., ""12 (<U STYLE=""SINGLE"">R)-Methyl-Leukotriene B<SUB>3</SUB>: A Stable Leukotriene B Analogue Toward the Reductase Metabolism"" (1993), Prostaglandins, 45:335.;;Kobayashi et al., ""Highly Stereocontrolled, Multigram Scale Synthesis of Leukotriene B<SUB>4</SUB>"" (1987), Tetrahedron Lett., 38:5849.;;Clissold D. ""The Potential For Prostaglandin Pharmaceuticals"" (1999), Lipids in Health and Nutrition, J.H.P. Tyman editor, Royal Society of Chemistry, Cambridge UK, pp. 115-129.;;Serhan et al., ""Unorthodox Routes to Prostanoid Formation: New Twists in Cyclooxygenase-Initiated Pathways"" (2001), J. Clin. Invest., 107:1481.;;Serhan et al., ""Resolvins: A Family of Bioactive Products of Omega-3 Fatty Acid Transformation Circuits Initiated by Aspirin Treatment that Counter Proinflammation Signals"" (2002), J. Exp. Med., 196:1025.;;Serhan et al., ""Lipid-Derived Mediators in Endogenous Anit-Inflammation and Resolution: Lipoxins and Asiprin-Triggered 15-epi-Lipoxins"" (2002), TheScientificWorldJOURNAL, 2:169.;;Clish et al., ""Oxidoreductases In Lipoxin A<SUB>4 </SUB>Metabolic Inactivation"" (2000), J. Bio Chem., 275:25372.;;Takano et al., ""Aspirin-Triggered 15-Epi-Lipoxin A<SUB>4 </SUB>(LXA<SUB>4</SUB>) and LXA<SUB>4 </SUB>Stable Analogues Are Potent Inhibitors of Acute Inflammation: Evidence for Anti-Inflammatory Receptors"" (1997), J. Exp. Med., 185:1693.;;Konno et al., ""Synthesis of Structural Analogues of Leukotriene B<SUB>4 </SUB>and their Receptor Binding Activity"" (1997), Biorg. & Med. Chem., 4:1621.;;Serhan et al., ""Anit-Microinflammatory Lipid Signals Generated from Dietary N-3 Fatty Acids Via Cyclooxygenase-2 and Transcellular Processing: A Novel Mechanism for Nsaid and N-3 PUFA Therapeutic Actions"" (2000), J. Physiol. Pharmacol. 51:643:54.",ACTIVE
56,US,A1,US 2021/0194825 A1,006-601-991-907-238,2021-06-24,2021,US 202017125866 A,2020-12-17,US 202017125866 A;;US 201916699309 A,2019-11-29,AVAILABILITY GROUPS OF CLOUD PROVIDER EDGE LOCATIONS,"Techniques are described for enabling users of a cloud provider network to discover “availability groups” provided by a cloud provider network and to request the launch of computing resources into selected availability groups. Some cloud provider networks are expanding the definition of traditional “availability zones” to include new types of availability zones representing various types of provider substrate extension edge locations—including, for example, cloud-provider managed substrate extensions associated with separate control planes, 5G-enabled provider substrate extensions connected to communications service provider networks, and the like. Availability groups can be used to represent various defined collections these new types of provider substrate extensions, where each availability group may be defined such that includes a set of provider substrate extensions with a similar set of characteristics and capabilities.",AMAZON TECH INC,GOODMAN ALAN HADLEY;;CHACHRA PRANAV;;GUPTA DIWAKAR;;BALLANTYNE DOUGAL STUART;;PARULKAR ISHWARDUTT,,https://lens.org/006-601-991-907-238,Patent Application,yes,0,2,3,3,0,H04L47/822;;H04L47/828;;H04L47/76;;H04L47/783;;H04L47/828;;H04L47/822;;G06F16/29;;H04L47/783;;H04L47/821;;H04L47/76,G06F16/29;;H04L47/76,,0,0,,,,ACTIVE
57,US,B2,US 7595341 B2,188-168-707-891-108,2009-09-29,2009,US 15079408 A,2008-04-30,US 15079408 A;;US 46091303 A;;US 38962202 P,2002-06-17,Analogues of lipid mediators derived from omega-3 PUFAs and methods of use,"The present invention is directed to compounds that are analogues of lipid mediators derived from a fish oil-derived fatty acid, eicosapentaenoic acid [C20:5 ω-3; EPA], but with a longer tissue half-life and enhanced bioactivity. These analogues may be used to treat inflammatory, angioproliferative, cardiovascular, thrombophlebotic, vascular, ocular, dermatologic, neurodegenerative, pulmonary, endocrine, reproductive, rheumatologic and gastrointestinal diseases.",RESOLVYX PHARMACUTICALS INC;;BRIGHAM & WOMENS HOSPITAL,GOODMAN DANIEL W;;HANLEY MICHAEL R;;BURSTEN STUART L;;SERHAN CHARLES N,RESOLVYX PHARMACEUTICALS INC (2006-02-13);;BRIGHAM AND WOMEN'S HOSPITAL INC. THE (2007-02-15),https://lens.org/188-168-707-891-108,Granted Patent,yes,11,9,15,15,0,C07C59/42;;C07C59/48;;C07C59/64;;C07C59/68;;C07C69/732;;C07C69/736;;C07C235/28;;C07C235/34;;A61P1/04;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P37/08;;C07C59/68;;C07C59/64;;C07C235/28;;C07C69/732;;C07C59/42;;C07C59/48;;C07C69/736;;C07C235/34,A61K31/22;;A61P1/04;;A61K31/16;;A61K31/164;;A61K31/20;;A61K31/232;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P37/08;;C07C59/00;;C07C59/42;;C07C59/48;;C07C59/64;;C07C59/68;;C07C69/732;;C07C69/736;;C07C231/00;;C07C235/28;;C07C235/34,514/549;;514/560;;514/625;;554/61;;554/219,37,34,099-167-300-017-549;;029-437-902-318-769;;068-300-655-239-349;;004-087-848-396-568;;036-301-778-357-832;;168-923-961-610-640;;012-122-118-853-414;;019-061-485-475-687;;034-354-996-309-78X;;023-910-788-928-012;;102-660-008-665-149;;033-793-690-554-983;;043-822-460-473-590;;093-417-046-929-817;;018-794-430-680-327;;057-226-642-512-973;;099-168-892-040-738;;033-621-606-162-178;;053-917-787-642-186;;013-727-068-392-960;;037-214-463-975-805;;165-953-186-245-811;;026-664-501-280-158;;015-689-024-824-379;;050-929-669-590-409;;002-818-442-336-665;;001-707-847-815-658;;015-764-746-026-093;;050-433-275-323-990;;079-279-587-521-320;;009-882-492-221-146;;039-040-330-582-691;;064-861-866-551-708;;011-854-728-585-119,8860685;;10.3109/02652049609026017;;10318669;;10.1161/01.cir.99.18.2452;;10.1016/s0090-6980(99)90421-5;;pmc408424;;10430612;;10.1172/jci7016;;7568157;;pmc40824;;10.1073/pnas.92.21.9475;;10.1073/pnas.96.14.8247;;pmc22220;;10393980;;10837478;;10.1074/jbc.m002863200;;pmc50263;;10.1073/pnas.89.21.9991;;1279685;;10.1111/j.2042-7158.1997.tb06090.x;;9255709;;7667190;;10.1023/a:1016209020160;;pmc2063338;;9043019;;10.1038/bjc.1997.116;;10.1016/s0040-4039(01)81071-6;;10.1021/jo00306a007;;9313867;;10.1016/s0968-0896(97)00090-4;;10.1016/s0140-6736(99)07072-5;;10465168;;9103484;;10.1093/ajhp/46.8.1576;;2672806;;3161300;;8924427;;10.1163/156856295x00526;;10.1002/j.1552-4604.1995.tb04045.x;;8750370;;10.1016/0076-6879(90)87022-u;;2233343;;11192938;;7578068;;10.1021/bi00044a041;;10.1100/tsw.2002.81;;pmc6009744;;12806051;;11034610;;pmc2195872;;10.1084/jem.192.8.1197;;pmc2194036;;10.3410/f.13277075.14635217;;10.1084/jem.20020760;;12391014;;10.1172/jci13375;;pmc200204;;11413151;;10.1016/0090-6980(93)90111-j;;8388116;;10511332;;10.1080/07315724.1999.10718888;;pmc2196289;;9151906;;10.1084/jem.185.9.1693;;7648372;;3421158;;10.1007/978-1-4757-0937-7_6;;10.1038/scientificamerican0191-84;;1899486;;9048568;;10.1021/bi962476u,"Al-Muhammed et al., ""In-Vivo Studies on Dexamethasone Sodium Phosphate Liposomes,"" J. Microencapsul., 13:293 (1996).;;Billman et al., ""Prevention of Sudden Cardiac Death by Dietary Pure Omega-3 Polyunsaturated Fatty Acids in Dogs,"" Circulation, 99:2452 (1999).;;Chiang et al., ""Aspirin-Triggered 15-epi-Lipoxin A4 (ATL) Generation by Human Leukocytes and Murione Peritonitis Exudates: Development of a Specific 15-epi-LXA4 ELISA,"" J. Pharmacol. Exp. Ther., 287:779 (1998).;;Chiang et al., ""Leukotriene B4 Receptor Transgenic Mice Reveal Novel Protective Roles for Lipoxins and Aspirin-Triggered Lipoxins in Reperfusion,"" J. Clin. Invest., 104:309 (1999).;;Claria, J. et al., ""Aspirin Triggers Previously Undescribed Bioactive Eicosanoids by Human Endothelial Cell-Leukocyte Interactions,"" Proc. Natl, Acad. Sci. USA, 92:9475 (1995).;;Clish et al., ""Local and Systemic Delivery of a Stable Aspirin-Triggered Lipoxin Prevents Neutrophil Recruitment in vivo,"" Proc. Natl. Acad. Sci. USA, 96:8247 (1999).;;Clish et al., ""Oxidoreductases In Lipoxin A4 Metabolic Inactivation,"" J. Bio. Chem., 275:25372 (2000).;;Clissold, D., ""The Potential For Prostaglandin Pharmaceuticals,"" Lipids in Health and Nutrition, J.H.P. Tyman editor, Royal Society of Chemistry, Cambridge, UK, pp. 115-129 (1999).;;Cronstein et al., ""A Mechanism for the Antiinflammatory Effects of Corticosteroids: The Glucocorticoid Receptor Regulates Leukocyte Adhesion to Endothelial Cells and Expression of Endothelial-Leukocyte Adhesion Molecule 1 and Intercellular Adhesion Molecule 1,"" Proc. Natl. Acad. Sci. USA, 89:9991 (1992).;;Eyles et al., ""Oral Delivery and Fate of Poly(lactic Acid) Microsphere-Encapsulated Interferon in Rats,"" J. Pharm. Pharmacol., 49:669 (1997).;;Gao, Z. et al., ""Controlled Release of a Contraceptive Steroid from Biodegradable and Injectable Gel Formulations: In Vitro Evaluation,"" Pharm. Res., 12:857 (1995).;;Iigo et al., ""Inhibitory Effects of Docosahexaenoic Acid on Colon Carcinoma 26 Metastasis to the Lung,"" Br. J. Cancer, 75:650 (1997).;;Kobayashi, Y. et al., ""Highly Stereocontrolled, Multigram Scale Synthesis of Leukotriene B4,"" Tetrahedron Lett., 28:5849 (1987).;;Kobayashi, Y. et al., ""Highly Stereocontrolled Total Synthesis of Leukotriene B4 20- Hydroxyleukotriene B4 Leukotriene B3 and Their Analogues,"" J. Org. Chem., 55:5324 (1990).;;Konno et al., ""Synthesis of Structural Analogues of Leukotriene B4 and their Receptor Binding Activity,"" Biorg. & Med. Chem., 5:1621 (1997).;;Marchioloi et al., Dietary Supplementation with n-3 Polyunsaturated Fatty Acids and Vitamin E After Myocardial Infarction: Results of the GISSI-Prevenzione Trial, Lancet, 354:447 (1999).;;Marcus, A. J., ""Platelets: Their Roll in Hemostasis, Thrombosis, and Inflammation,"" Inflammation: Basic Principles and Clinical Correlates, J. I. Gallin and R. Snyderman, Editors, Lippincott Williams & Wilkins, Philadelphia, pp. 77-79 (1999).;;Minto, C.F. et al., ""Pharmacokinetics and Pharmacodynamics of Nandrolone Esters in Oil Vehicle: Effects of Ester, Injection Site and Injection Volume,"" J. Pharmacol. Exp. Ther., 281:93 (1997).;;Nicolaou, K.C. et al., ""Lipoxins and Related Eicosanoids: Biosynthesis, Biological Properties, and Chemical Synthesis,"" Agnew Chem. Int. Ed. Engl., 30:1100 (1991).;;Ostro, M.J., et al., ""Use of Liposomes as Injectable-Drug Delivery Systems,"" Am. J. Hosp. Pharm., 46:1576 (1989).;;Raduchel, B. et al., ""Prostagladin Analogs,"" Adv. Prost. Thromb. Leuko. Res., 14:263 (1985).;;Rao, K.P., ""Recent Developments of Collagen-Based Materials for Medical Applications and Drug Delivery Systems,"" J. Biomater Sci. Polym. Edn., 7:623 (1995).;;Rohatagi et al., ""Pharmacokinetic and Pharmacodynamic Evaluation of Triamcinolone Acetonide After Intravenous, Oral, and Inhaled Administration,"" J. Clin. Pharmacol., 35:1187 (1995).;;Serhan C. et al., ""High-Performance Liquid Chromatography Separation and Determination of Lipoxins,"" Meth. Enzymol., 187:167 (1990).;;Serhan et al., ""Anti-Microinflammatory Lipid Signals Generated from Dietary N-3 Fatty Acids Via Cyclooxygenase-2 and Transcellular Processing: A Novel Mechanism for Nsaid and N-3 PUFA Therapeutic Actions,"" J. Physiol. Pharmacol., 51:643:54 (2000).;;Serhan et al., ""Design of Lipoxin A4 Stable Analogs That Block Transmigration and Adhesion of Human Neutrophils,"" Biochemistry, 34:14609 (1995).;;Serhan et al., ""Lipid-Derived Mediators in Endogenous Anti-Inflammation and Resolution: Lipoxins and Aspirin-Triggered 15-epi-Lipoxins,"" The Scientific World Journal, 2:169 (2002).;;Serhan et al., ""Novel Functional Sets of Lipid-Derived Mediators with Antiinflammatory Actions Generated from Omega-3 Fatty Acids via Cyclooxygenase 2-Nonsteroidal Antiinflammatory Drugs and Transcellular Processing,"" J. Exp. Med., 192(8):1197-1204 (2000).;;Serhan et al., ""Resolvins: A Family of Bioactive Products of Omega-3 Fatty Acid Transformation Circuits Initiated by Aspirin Treatment that Counter Proinflammation Signals,"" J. Exp. Med., 196:1025 (2002).;;Serhan et al., ""Unorthodox Routes to Prostanoid Formation: New Twists in Cyclooxygenase- Initiated Pathways,"" J. Clin. Invest., 107:1481 (2001).;;Shimazaki et al., ""12 (R)-Methyl-Leukotriene B3 : A Stable Leukotriene B Analogue Toward the Reductase Metabolism,"" Prostaglandins, 45:335 (1993).;;Simopoulous et al., ""Workshop on the Essentiality of and Recommended Dietary Intakes for Omega-6 and Omega-3 Fatty Acids,"" J. Am. Coll. Nutr., 18:487 (1999).;;Takano et al., ""Aspirin-Triggered 15-Epi-Lipoxin A4 (LXA4) and LXA4 Stable Analogues Are Potent Inhibitors of Acute Inflammation: Evidence for Anti-Inflammatory Receptors,"" J. Exp. Med., 185:1693 (1997).;;Tjwa, Martin K. T., ""Budesonide Inhaled via Turbuhaler: A More Effective Treatment for Asthma Than Beclomethasone Dipropionate Via Rotahaler,"" Ann. Allergy Asthma & Immunol., 75:107 (1995).;;Webber et al., ""The Total Synthesis of the Lipoxins and Related Compounds,"" Adv. Exp. Med. Biol., 229:61 (1988).;;Weissman, G., ""Aspirin,"" Sci. Am., 264:84 (1991).;;Xiao et al., ""Analysis of Hydroperoxide-Induced Tyrosyl Radicals and Lipoxygenase Activity In Aspirin-Treated Human Prostaglandin H Synthase-2,"" Biochemistry, 36:1836 (1997).",EXPIRED
58,US,B1,US 10880232 B1,150-382-624-218-944,2020-12-29,2020,US 201916699309 A,2019-11-29,US 201916699309 A,2019-11-29,Availability groups of cloud provider edge locations,"Techniques are described for enabling users of a cloud provider network to discover “availability groups” provided by a cloud provider network and to request the launch of computing resources into selected availability groups. Some cloud provider networks are expanding the definition of traditional “availability zones” to include new types of availability zones representing various types of provider substrate extension edge locations—including, for example, cloud-provider managed substrate extensions associated with separate control planes, 5G-enabled provider substrate extensions connected to communications service provider networks, and the like. Availability groups can be used to represent various defined collections these new types of provider substrate extensions, where each availability group may be defined such that includes a set of provider substrate extensions with a similar set of characteristics and capabilities.",AMAZON TECH INC,GOODMAN ALAN HADLEY;;CHACHRA PRANAV;;GUPTA DIWAKAR;;BALLANTYNE DOUGAL STUART;;PARULKAR ISHWARDUTT,AMAZON TECHNOLOGIES INC (2020-09-09),https://lens.org/150-382-624-218-944,Granted Patent,yes,10,11,3,3,0,H04L47/822;;H04L47/828;;H04L47/76;;H04L47/783;;H04L47/828;;H04L47/822;;G06F16/29;;H04L47/783;;H04L47/821;;H04L47/76,G06F15/16;;G06F16/29;;H04L47/76,,2,0,,,"AT&T, “AT&T's Network and Microsoft's Cloud Deliver New Customer Offerings”, available online at <https://about.att.com/story/2019/microsoft.html>, Jul. 17, 2019, 3 pages.;;Microsoft, “AT&T Integrating 5G with Microsoft Cloud to Enable Next-Generation Solutions on the Edge”, available online at <https://news.microsoft.com/2019/11/26/att-integrating-5g-with-microsoft-cloud-to-enable-next-generation-solutions-on-the-edge/>, Microsoft News Center, Nov. 26, 2019, 6 pages.",ACTIVE
59,EP,A2,EP 1537069 A2,149-159-423-359-241,2005-06-08,2005,EP 03737135 A,2003-06-13,US 0319019 W;;US 38962202 P,2002-06-17,ANALOGUES OF LIPID MEDIATORS DERIVED FROM OMEGA-3 PUFAs AND METHODS OF USE,"The present invention is directed to compounds that are analogues of lipid mediators derived from a fish oil-derived fatty acid, eicosapentaenoic acid [C20:5 omega-3; EPA], but with a longer tissue half-life and enhanced bioactivity. These analogues may be used to treat inflammatory, angioproliferative, cardiovascular, thrombophlebotic, vascular, ocular, dermatologic, neurodegenerative, pulmonary, endocrine, reproductive, rheumatologic and gastrointestinal diseases.",RESOLVYX PHARMACEUTICALS,GOODMAN DANIEL W;;HANLEY MICHAEL R;;BURSTEN STUART L;;SERHAN CHARLES N,"RESOLVYX PHARMACEUTICALS (2007-12-26);;BRIGHAM AND WOMEN'S HOSPITAL, INC. (2007-12-26)",https://lens.org/149-159-423-359-241,Patent Application,yes,0,0,15,15,0,C07C59/42;;C07C59/48;;C07C59/64;;C07C59/68;;C07C69/732;;C07C69/736;;C07C235/28;;C07C235/34;;A61P1/04;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P37/08;;C07C59/68;;C07C59/64;;C07C235/28;;C07C69/732;;C07C59/42;;C07C59/48;;C07C69/736;;C07C235/34,A61P1/04;;A61K31/164;;A61K31/232;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P37/08;;C07C59/42;;C07C59/48;;C07C59/64;;C07C59/68;;C07C69/732;;C07C69/736;;C07C235/28;;C07C235/34,,0,0,,,,EXPIRED
60,WO,A1,WO 2019/195142 A1,172-891-425-538-500,2019-10-10,2019,US 2019/0025135 W,2019-04-01,US 201862652176 P,2018-04-03,MESENCHYMAL STEM CELLS COMPRISING A CHIMERIC ANTIGEN RECEPTOR (CAR) FOR TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES,"Mesenchymal stromal cells are engineered to express a chimeric antigen receptor (CAR), that specifically binds a marker of activated myeloid cells, including without limitation folate receptor beta; and are administered to an individual for treatment of inflammation at sites characterized by the presence of activated myeloid cells.",UNIV LELAND STANFORD JUNIOR,LIN TZUHUA;;GOODMAN STUART;;TANG SAI-WEN;;MEYER EVERETT;;PEREZ CRUZ MAGDIEL,,https://lens.org/172-891-425-538-500,Patent Application,yes,5,0,3,3,0,A61P3/10;;C07K14/5406;;C07K2319/03;;C07K16/44;;C07K16/28;;C07K2317/622;;C07K14/7051;;C12N2510/00;;C07K2319/33;;A61K35/28;;A61K38/2026;;A61K2239/26;;A61K39/4631;;A61K39/4621;;A61K39/461;;A61K39/464402;;A61K39/46433;;A61K35/28;;A61K47/6849;;A61P3/10;;C07K14/5406;;C07K16/28;;A61K2039/5156,A61K48/00;;A61K9/127;;A61K39/00;;C12N5/071;;C12N5/16;;C12N15/00,,5,4,012-921-351-664-565;;005-412-652-838-769;;013-337-058-375-346;;069-215-913-922-280,22568986;;pmc3427232;;10.4161/cam.20341;;28583168;;pmc5460436;;10.1186/s13287-017-0593-3;;pmc4792550;;26496034;;10.18632/oncotarget.6175;;25887778;;10.1182/blood-2014-11-612721;;pmc4447861,"PAYNE ET AL.: ""Early intervention with gene -modified mesenchymal stem cells overexpressing interleukin-4 enhances anti-inflammatory responses and functional recovery in experimental autoimmune demyelination"", CELL ADHESION & MIGRATION, vol. 6, no. 3, 2012, pages 179 - 189, XP055641674;;BHATT ET AL.: ""Regulation of the NF-kB-mediated transcription of inflammatory genes"", FRONTIERS IN IMMUNOLOGY, vol. 5, no. 71, 2014, pages 1 - 9, XP055641677;;LU ET AL.: ""Mesenchymal stem cells for treating autoimmune dacryoadenitis"", STEM CELL RESEARCH & THERAPY, vol. 8, no. 1, 2017, XP055641680;;TANG ET AL.: ""Therapeutic potential of CAR-T cell -derived exosomes: a cell -free modality for targeted cancer therapy"", ONCOTARGET, vol. 6, no. 42, 2015, pages 44179 - 90, XP055585353, DOI: 10.18632/oncotarget.6175;;LYNN ET AL.: ""Targeting of folate receptor beta on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells"", BLOOD, vol. 125, no. 22, 2015, pages 3466 - 76, XP055562887, DOI: 10.1182/blood-2014-11-612721",PENDING
61,DE,D1,DE 60318456 D1,019-606-842-193-467,2008-02-14,2008,DE 60318456 T,2003-06-13,US 38962202 P;;US 0319019 W,2002-06-17,ANALOGA VON OMEGA-3-PUFAs ABGELEITETEN LIPIDMEDIATOREN UND ANWENDUNGSVERFAHREN,"The present invention is directed to compounds that are analogues of lipid mediators derived from a fish oil-derived fatty acid, eicosapentaenoic acid [C20:5 omega-3; EPA], but with a longer tissue half-life and enhanced bioactivity. These analogues may be used to treat inflammatory, angioproliferative, cardiovascular, thrombophlebotic, vascular, ocular, dermatologic, neurodegenerative, pulmonary, endocrine, reproductive, rheumatologic and gastrointestinal diseases.",RESOLVYX PHARMACEUTICALS;;BRIGHAM & WOMENS HOSPITAL,GOODMAN DANIEL W;;HANLEY MICHAEL R;;BURSTEN STUART L;;SERHAN CHARLES N,,https://lens.org/019-606-842-193-467,Granted Patent,no,0,0,15,15,0,C07C59/42;;C07C59/48;;C07C59/64;;C07C59/68;;C07C69/732;;C07C69/736;;C07C235/28;;C07C235/34;;A61P1/04;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P37/08;;C07C59/68;;C07C59/64;;C07C235/28;;C07C69/732;;C07C59/42;;C07C59/48;;C07C69/736;;C07C235/34,A61P1/04;;C07C69/74;;A61K31/164;;A61K31/232;;A61K31/557;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P37/08;;C07C49/00;;C07C49/04;;C07C49/105;;C07C53/00;;C07C57/02;;C07C57/18;;C07C59/42;;C07C59/48;;C07C59/64;;C07C59/68;;C07C61/00;;C07C61/08;;C07C69/00;;C07C69/52;;C07C69/732;;C07C69/736;;C07C235/28;;C07C235/34,,0,0,,,,EXPIRED
62,US,A1,US 2008/0207753 A1,076-767-670-443-232,2008-08-28,2008,US 15079408 A,2008-04-30,US 15079408 A;;US 46091303 A;;US 38962202 P,2002-06-17,Analogues of lipid mediators derived from omega-3 PUFAs and methods of use,"The present invention is directed to compounds that are analogues of lipid mediators derived from a fish oil-derived fatty acid, eicosapentaenoic acid [C20:5 ω-3; EPA], but with a longer tissue half-life and enhanced bioactivity. These analogues may be used to treat inflammatory, angioproliferative, cardiovascular, thrombophlebotic, vascular, ocular, dermatologic, neurodegenerative, pulmonary, endocrine, reproductive, rheumatologic and gastrointestinal diseases.",RESOLVYX PHARMACEUTICALS INC;;BRIGHAM & WOMENS HOSPITAL,GOODMAN DANIEL W;;HANLEY MICHAEL R;;BURSTEN STUART L;;SERHAN CHARLES N,RESOLVYX PHARMACEUTICALS INC (2006-02-13);;BRIGHAM AND WOMEN'S HOSPITAL INC. THE (2007-02-15),https://lens.org/076-767-670-443-232,Patent Application,yes,6,0,15,15,0,C07C59/42;;C07C59/48;;C07C59/64;;C07C59/68;;C07C69/732;;C07C69/736;;C07C235/28;;C07C235/34;;A61P1/04;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P37/08;;C07C59/68;;C07C59/64;;C07C235/28;;C07C69/732;;C07C59/42;;C07C59/48;;C07C69/736;;C07C235/34,A61K31/22;;A61P1/04;;A61K31/16;;A61K31/164;;A61K31/20;;A61K31/232;;A61P11/00;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P27/02;;A61P29/00;;A61P37/08;;C07C59/42;;C07C59/48;;C07C59/64;;C07C59/68;;C07C69/732;;C07C69/736;;C07C235/28;;C07C235/34,514/549;;514/560;;514/625,0,0,,,,EXPIRED
63,CA,C,CA 2364381 C,167-492-870-891-91X,2009-03-10,2009,CA 2364381 A,2000-12-20,US 17151099 P;;US 0034535 W,1999-12-22,"FLOW-THRU CHIP CARTRIDGE, CHIP HOLDER, SYSTEM AND METHOD THEREOF","A system for performing hybridization assays comprises a cartridge for housing a flow through device, where the cartridge includes a test fluid chamber for facilitating a substantially uniform floe of a test fluid mixture through the flow through device, and a fluidics station to deliver the test fluid mixture to the cartridge. The cartridge has a chip holder that holds the flows-through device, which has an array of microchannel passages. The chip holder has a support for placement of the flow though device, the test fluid chamber for directing a substantially uniform flow through device, and a first port that receives the test fluid mixture. The cartridge has a sealing system for preventing the leakage of the test fluid around the flow through device. The test fluid chamber is defined in part by a spade-like surface having an inlet for the test fluid mixture.",GENE LOGIC INC,MATEER DAVID G;;YANG HONGJUN;;GOODMAN JACK;;SMITH IAN STUART RICHARD;;TORRES MATTHEW,,https://lens.org/167-492-870-891-91X,Granted Patent,no,0,0,10,14,0,B01L3/5027;;B01L3/5027;;B01L3/502707;;B01L3/502707;;B01L3/502715;;B01L3/502715;;B01L3/502746;;B01L3/502746;;B01L7/00;;B01L7/00;;B01L7/52;;B01L7/52;;B01L9/527;;B01L9/527;;B01L2200/027;;B01L2200/027;;B01L2200/0689;;B01L2200/0689;;B01L2300/0636;;B01L2300/0636;;B01L2300/0816;;B01L2300/0816;;B01L2300/0877;;B01L2300/0877;;B01L2300/18;;B01L2300/18;;B01L2300/1822;;B01L2300/1822;;B01L2300/1838;;B01L2300/1838;;B01L2400/0478;;B01L2400/0478;;B01L2400/0481;;B01L2400/0481;;B01L2400/0487;;B01L2400/0487;;B01L2400/06;;B01L2400/06;;B01L2400/0622;;B01L2400/0622;;G01N21/253;;G01N21/253;;G01N21/05;;G01N21/05;;G01N2021/0346;;G01N2021/0346;;G01N2035/00158;;G01N2035/00158,G01N1/00;;B01L3/00;;B01L7/00;;B01L9/00;;C12Q1/68;;C40B60/00;;C40B60/12;;G01N21/05;;G01N21/25;;G01N33/53;;G01N35/00,,0,0,,,,EXPIRED
64,US,A1,US 2008/0194426 A1,138-382-155-284-679,2008-08-14,2008,US 6815008 A,2008-02-04,US 6815008 A;;US 92609403 A;;US 0034535 W;;US 17151099 P,1999-12-22,"Flow-thru chip cartridge, chip holder, system & method thereof","A system for performing hybridization assays comprises a cartridge for housing a flow through device, where the cartridge includes a test fluid chamber for facilitating a substantially uniform flow of a test fluid mixture through the flow through device, and a fluidics station to deliver the test fluid mixture to the cartridge. The cartridge has a chip holder that holds the flow-through device, which has an array of microchannel passages. The chip holder has a support for placement of the flow though device, the test fluid chamber for directing a substantially uniform flow of a test fluid mixture through the array of microchannel passages of the flow through device, and a first port that receives the test fluid mixture. The cartridge has a sealing system for preventing the leakage of the test fluid around the flow through device. The test fluid chamber is defined in part by a spade-like surface having an inlet for the test fluid mixture.",GOODMAN JACK;;TORRES MATTHEW;;YANG HONGJUN;;MATEER DAVID G;;SMITH IAN STUART RICHARD,GOODMAN JACK;;TORRES MATTHEW;;YANG HONGJUN;;MATEER DAVID G;;SMITH IAN STUART RICHARD,,https://lens.org/138-382-155-284-679,Patent Application,yes,0,4,10,14,0,B01L3/5027;;B01L3/5027;;B01L3/502707;;B01L3/502707;;B01L3/502715;;B01L3/502715;;B01L3/502746;;B01L3/502746;;B01L7/00;;B01L7/00;;B01L7/52;;B01L7/52;;B01L9/527;;B01L9/527;;B01L2200/027;;B01L2200/027;;B01L2200/0689;;B01L2200/0689;;B01L2300/0636;;B01L2300/0636;;B01L2300/0816;;B01L2300/0816;;B01L2300/0877;;B01L2300/0877;;B01L2300/18;;B01L2300/18;;B01L2300/1822;;B01L2300/1822;;B01L2300/1838;;B01L2300/1838;;B01L2400/0478;;B01L2400/0478;;B01L2400/0481;;B01L2400/0481;;B01L2400/0487;;B01L2400/0487;;B01L2400/06;;B01L2400/06;;B01L2400/0622;;B01L2400/0622;;G01N21/253;;G01N21/253;;G01N21/05;;G01N21/05;;G01N2021/0346;;G01N2021/0346;;G01N2035/00158;;G01N2035/00158,C40B60/12;;B01L3/00;;B01L7/00;;B01L9/00;;G01N21/05;;G01N21/25;;G01N35/00,506/39,0,0,,,,DISCONTINUED
65,AU,A,AU 2001/045026 A,158-697-819-717-564,2001-07-03,2001,AU 2001/045026 A,2000-12-20,US 17151099 P;;US 0034535 W,1999-12-22,"Flow-thru chip cartridge, chip holder, system and method thereof",,GENE LOGIC INC,TORRES MATTHEW;;SMITH IAN STUART RICHARD;;GOODMAN JACK;;YANG HONGJUN;;MATEER DAVID G,,https://lens.org/158-697-819-717-564,Patent Application,no,0,0,10,14,0,B01L3/5027;;B01L3/502707;;B01L3/502715;;B01L3/502746;;B01L7/00;;B01L7/52;;B01L9/527;;B01L2200/027;;B01L2200/0689;;B01L2300/0636;;B01L2300/0816;;B01L2300/0877;;B01L2300/18;;B01L2300/1822;;B01L2300/1838;;B01L2400/0478;;B01L2400/0481;;B01L2400/0487;;B01L2400/06;;B01L2400/0622;;G01N21/05;;G01N21/253;;G01N2035/00158;;G01N2021/0346;;G01N21/253;;B01L2400/0481;;B01L2400/0487;;B01L3/5027;;B01L2200/027;;G01N2035/00158;;B01L7/00;;B01L2300/1838;;B01L3/502715;;B01L2400/0478;;B01L2400/0622;;B01L2300/0636;;B01L2300/0816;;B01L7/52;;B01L2300/0877;;G01N21/05;;B01L3/502707;;B01L9/527;;B01L2200/0689;;B01L3/502746;;B01L2300/1822;;B01L2300/18;;B01L2400/06;;G01N2021/0346,B01L3/00;;B01L7/00;;B01L9/00;;G01N21/05;;G01N21/25;;G01N35/00,,0,0,,,,PENDING
66,WO,A2,WO 2001/045843 A2,187-441-645-573-478,2001-06-28,2001,US 0034535 W,2000-12-20,US 17151099 P,1999-12-22,"FLOW-THRU CHIP CARTRIDGE, CHIP HOLDER, SYSTEM AND METHOD THEREOF","A system for performing hybridization assays comprises a cartridge for housing a flow through device, where the cartridge includes a test fluid chamber for facilitating a substantially uniform floe of a test fluid mixture through the flow through device, and a fluidics station to deliver the test fluid mixture to the cartridge. The cartridge has a chip holder that holds the flows-through device, which has an array of microchannel passages. The chip holder has a support for placement of the flow though device, the test fluid chamber for directing a substantially uniform flow through device, and a first port that receives the test fluid mixture. The cartridge has a sealing system for preventing the leakage of the test fluid around the flow through device. The test fluid chamber is defined in part by a spade-like surface having an inlet for the test fluid mixture.",GENE LOGIC INC;;TORRES MATTHEW;;SMITH IAN STUART RICHARD;;GOODMAN JACK;;YANG HONGJUN;;MATEER DAVID G,TORRES MATTHEW;;SMITH IAN STUART RICHARD;;GOODMAN JACK;;YANG HONGJUN;;MATEER DAVID G,,https://lens.org/187-441-645-573-478,Patent Application,yes,0,37,10,14,0,B01L3/5027;;B01L3/5027;;B01L3/502707;;B01L3/502707;;B01L3/502715;;B01L3/502715;;B01L3/502746;;B01L3/502746;;B01L7/00;;B01L7/00;;B01L7/52;;B01L7/52;;B01L9/527;;B01L9/527;;B01L2200/027;;B01L2200/027;;B01L2200/0689;;B01L2200/0689;;B01L2300/0636;;B01L2300/0636;;B01L2300/0816;;B01L2300/0816;;B01L2300/0877;;B01L2300/0877;;B01L2300/18;;B01L2300/18;;B01L2300/1822;;B01L2300/1822;;B01L2300/1838;;B01L2300/1838;;B01L2400/0478;;B01L2400/0478;;B01L2400/0481;;B01L2400/0481;;B01L2400/0487;;B01L2400/0487;;B01L2400/06;;B01L2400/06;;B01L2400/0622;;B01L2400/0622;;G01N21/253;;G01N21/253;;G01N21/05;;G01N21/05;;G01N2021/0346;;G01N2021/0346;;G01N2035/00158;;G01N2035/00158,B01L3/00;;B01L7/00;;B01L9/00;;G01N21/05;;G01N21/25;;G01N35/00,,0,0,,,,PENDING
67,CA,A1,CA 2364381 A1,115-473-038-782-280,2001-06-28,2001,CA 2364381 A,2000-12-20,US 17151099 P;;US 0034535 W,1999-12-22,"FLOW-THRU CHIP CARTRIDGE, CHIP HOLDER, SYSTEM AND METHOD THEREOF","A system for performing hybridization assays comprises a cartridge for housi ng a flow through device, where the cartridge includes a test fluid chamber for facilitating a substantially uniform floe of a test fluid mixture through th e flow through device, and a fluidics station to deliver the test fluid mixtur e to the cartridge. The cartridge has a chip holder that holds the flows-throu gh device, which has an array of microchannel passages. The chip holder has a support for placement of the flow though device, the test fluid chamber for directing a substantially uniform flow through device, and a first port that receives the test fluid mixture. The cartridge has a sealing system for preventing the leakage of the test fluid around the flow through device. The test fluid chamber is defined in part by a spade-like surface having an inle t for the test fluid mixture.",GENE LOGIC INC,TORRES MATTHEW;;GOODMAN JACK;;SMITH IAN STUART RICHARD;;MATEER DAVID G;;YANG HONGJUN,,https://lens.org/115-473-038-782-280,Patent Application,no,0,0,10,14,0,B01L3/5027;;B01L3/5027;;B01L3/502707;;B01L3/502707;;B01L3/502715;;B01L3/502715;;B01L3/502746;;B01L3/502746;;B01L7/00;;B01L7/00;;B01L7/52;;B01L7/52;;B01L9/527;;B01L9/527;;B01L2200/027;;B01L2200/027;;B01L2200/0689;;B01L2200/0689;;B01L2300/0636;;B01L2300/0636;;B01L2300/0816;;B01L2300/0816;;B01L2300/0877;;B01L2300/0877;;B01L2300/18;;B01L2300/18;;B01L2300/1822;;B01L2300/1822;;B01L2300/1838;;B01L2300/1838;;B01L2400/0478;;B01L2400/0478;;B01L2400/0481;;B01L2400/0481;;B01L2400/0487;;B01L2400/0487;;B01L2400/06;;B01L2400/06;;B01L2400/0622;;B01L2400/0622;;G01N21/253;;G01N21/253;;G01N21/05;;G01N21/05;;G01N2021/0346;;G01N2021/0346;;G01N2035/00158;;G01N2035/00158,B01L3/00;;B01L7/00;;B01L9/00;;G01N21/05;;G01N21/25;;G01N35/00,,0,0,,,,EXPIRED
68,US,A1,US 2004/0137604 A1,183-387-934-679-738,2004-07-15,2004,US 92609403 A,2003-11-12,US 92609403 A;;US 17151099 P;;US 0034535 W,1999-12-22,"Flow-thru chip cartridge, chip holder, system and method thereof","
   A system for performing hybridization assays comprises a cartridge for housing a flow through device, where the cartridge includes a test fluid chamber for facilitating a substantially uniform flow of a test fluid mixture through the flow through device, and a fluidics station to deliver the test fluid mixture to the cartridge. The cartridge has a chip holder that holds the flow-through device, which has an array of microchannel passages. The chip holder has a support for placement of the flow though device, the test fluid chamber for directing a substantially uniform flow of a test fluid mixture through the array of microchannel passages of the flow through device, and a first port that receives the test fluid mixture. The cartridge has a sealing system for preventing the leakage of the test fluid around the flow through device. The test fluid chamber is defined in part by a spade-like surface having an inlet for the test fluid mixture. 
",GOODMAN JACK;;TORRES MATTHEW;;YANG HONGJUN;;MATEER DAVID G;;SMITH IAN STUART RICHARD,GOODMAN JACK;;TORRES MATTHEW;;YANG HONGJUN;;MATEER DAVID G;;SMITH IAN STUART RICHARD,MMV FINANCIAL INC (2008-02-15);;ANGLE EUROPE LIMITED (2009-10-04);;AXELA INC (2009-12-21),https://lens.org/183-387-934-679-738,Patent Application,yes,5,30,10,14,0,B01L3/5027;;B01L3/5027;;B01L3/502707;;B01L3/502707;;B01L3/502715;;B01L3/502715;;B01L3/502746;;B01L3/502746;;B01L7/00;;B01L7/00;;B01L7/52;;B01L7/52;;B01L9/527;;B01L9/527;;B01L2200/027;;B01L2200/027;;B01L2200/0689;;B01L2200/0689;;B01L2300/0636;;B01L2300/0636;;B01L2300/0816;;B01L2300/0816;;B01L2300/0877;;B01L2300/0877;;B01L2300/18;;B01L2300/18;;B01L2300/1822;;B01L2300/1822;;B01L2300/1838;;B01L2300/1838;;B01L2400/0478;;B01L2400/0478;;B01L2400/0481;;B01L2400/0481;;B01L2400/0487;;B01L2400/0487;;B01L2400/06;;B01L2400/06;;B01L2400/0622;;B01L2400/0622;;G01N21/253;;G01N21/253;;G01N21/05;;G01N21/05;;G01N2021/0346;;G01N2021/0346;;G01N2035/00158;;G01N2035/00158,B01L3/00;;B01L7/00;;B01L9/00;;G01N21/05;;G01N21/25;;G01N35/00,435 287200;;435 288300;;435 288700,0,0,,,,EXPIRED
69,EP,A2,EP 1202803 A2,194-837-463-248-230,2002-05-08,2002,EP 00992465 A,2000-12-20,US 0034535 W;;US 17151099 P,1999-12-22,"FLOW-THROUGH CHIP CARTRIDGE, CHIP HOLDER, SYSTEM & METHOD THEREOF",,GENE LOGIC INC,TORRES MATTHEW;;SMITH IAN STUART RICHARD;;GOODMAN JACK;;YANG HONGJUN;;MATEER DAVID G,,https://lens.org/194-837-463-248-230,Patent Application,yes,2,0,10,14,0,B01L3/5027;;B01L3/5027;;B01L3/502707;;B01L3/502707;;B01L3/502715;;B01L3/502715;;B01L3/502746;;B01L3/502746;;B01L7/00;;B01L7/00;;B01L7/52;;B01L7/52;;B01L9/527;;B01L9/527;;B01L2200/027;;B01L2200/027;;B01L2200/0689;;B01L2200/0689;;B01L2300/0636;;B01L2300/0636;;B01L2300/0816;;B01L2300/0816;;B01L2300/0877;;B01L2300/0877;;B01L2300/18;;B01L2300/18;;B01L2300/1822;;B01L2300/1822;;B01L2300/1838;;B01L2300/1838;;B01L2400/0478;;B01L2400/0478;;B01L2400/0481;;B01L2400/0481;;B01L2400/0487;;B01L2400/0487;;B01L2400/06;;B01L2400/06;;B01L2400/0622;;B01L2400/0622;;G01N21/253;;G01N21/253;;G01N21/05;;G01N21/05;;G01N2021/0346;;G01N2021/0346;;G01N2035/00158;;G01N2035/00158,B01L3/00;;B01L7/00;;B01L9/00;;G01N21/05;;G01N21/25;;G01N35/00,,1,0,,,See also references of WO 0145843A3,DISCONTINUED
70,US,A1,US 2009/0227487 A1,173-970-400-853-493,2009-09-10,2009,US 39792509 A,2009-03-04,US 39792509 A;;US 3408208 P,2008-03-05,METHODS FOR THE CONTROL OF MACROPHAGE-ASSOCIATED INFLAMMATION,Particle induced inflammatory diseases are treated by administration of an effective dose of an inhibitor of MyD88 adaptor protein.,PEARL JEREMY;;MA TING;;ROBINSON WILLIAM H;;SMITH R LANE;;GOODMAN STUART B,PEARL JEREMY;;MA TING;;ROBINSON WILLIAM H;;SMITH R LANE;;GOODMAN STUART B,THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (2009-04-01),https://lens.org/173-970-400-853-493,Patent Application,yes,0,7,1,1,0,A61K38/16;;A61P29/00;;A61K38/16,A61K38/02;;A61P29/00,514/2,3,2,025-803-227-909-451;;100-916-770-919-108,17548806;;10.1189/jlb.1206746;;10.1074/jbc.c400613200;;15755740,"Loiarro et al. Pivotal Advance: Inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound. J Leukoc Biol. 2007 Oct;82(4):801-10. Epub 2007 Jun 4.;;Loiarro et al. Peptide-mediated interference of TIR domain dimerization in MyD88 inhibits interleukin-1-dependent activation of NF-kappa B. J Biol Chem. 2005 Apr 22;280(16):15809-14. Epub 2005 Mar 8.;;MyD88 Homodimerization Inhibitory Peptide Set [online], 12/5/2006 [retrieved 12/29/2012]. Retrieved from Internet Archive Wayback Machine: .",DISCONTINUED
71,WO,A3,WO 2001/045843 A3,020-245-413-886-390,2002-02-28,2002,US 0034535 W,2000-12-20,US 17151099 P,1999-12-22,"FLOW-THRU CHIP CARTRIDGE, CHIP HOLDER, SYSTEM AND METHOD THEREOF","A system for performing hybridization assays comprises a cartridge for housing a flow through device, where the cartridge includes a test fluid chamber for facilitating a substantially uniform floe of a test fluid mixture through the flow through device, and a fluidics station to deliver the test fluid mixture to the cartridge. The cartridge has a chip holder that holds the flows-through device, which has an array of microchannel passages. The chip holder has a support for placement of the flow though device, the test fluid chamber for directing a substantially uniform flow through device, and a first port that receives the test fluid mixture. The cartridge has a sealing system for preventing the leakage of the test fluid around the flow through device. The test fluid chamber is defined in part by a spade-like surface having an inlet for the test fluid mixture.",GENE LOGIC INC;;TORRES MATTHEW;;SMITH IAN STUART RICHARD;;GOODMAN JACK;;YANG HONGJUN;;MATEER DAVID G,TORRES MATTHEW;;SMITH IAN STUART RICHARD;;GOODMAN JACK;;YANG HONGJUN;;MATEER DAVID G,,https://lens.org/020-245-413-886-390,Search Report,yes,4,0,10,14,0,B01L3/5027;;B01L3/5027;;B01L3/502707;;B01L3/502707;;B01L3/502715;;B01L3/502715;;B01L3/502746;;B01L3/502746;;B01L7/00;;B01L7/00;;B01L7/52;;B01L7/52;;B01L9/527;;B01L9/527;;B01L2200/027;;B01L2200/027;;B01L2200/0689;;B01L2200/0689;;B01L2300/0636;;B01L2300/0636;;B01L2300/0816;;B01L2300/0816;;B01L2300/0877;;B01L2300/0877;;B01L2300/18;;B01L2300/18;;B01L2300/1822;;B01L2300/1822;;B01L2300/1838;;B01L2300/1838;;B01L2400/0478;;B01L2400/0478;;B01L2400/0481;;B01L2400/0481;;B01L2400/0487;;B01L2400/0487;;B01L2400/06;;B01L2400/06;;B01L2400/0622;;B01L2400/0622;;G01N21/253;;G01N21/253;;G01N21/05;;G01N21/05;;G01N2021/0346;;G01N2021/0346;;G01N2035/00158;;G01N2035/00158,B01L3/00;;B01L7/00;;B01L9/00;;G01N21/05;;G01N21/25;;G01N35/00,,1,0,,,See also references of EP 1202803A2,PENDING
72,WO,A9,WO 2001/045843 A9,191-642-491-864-189,2002-05-16,2002,US 0034535 W,2000-12-20,US 17151099 P,1999-12-22,"FLOW-THRU CHIP CARTRIDGE, CHIP HOLDER, SYSTEM AND METHOD THEREOF","A system for performing hybridization assays comprises a cartridge for housing a flow through device, where the cartridge includes a test fluid chamber for facilitating a substantially uniform floe of a test fluid mixture through the flow through device, and a fluidics station to deliver the test fluid mixture to the cartridge. The cartridge has a chip holder that holds the flows-through device, which has an array of microchannel passages. The chip holder has a support for placement of the flow though device, the test fluid chamber for directing a substantially uniform flow through device, and a first port that receives the test fluid mixture. The cartridge has a sealing system for preventing the leakage of the test fluid around the flow through device. The test fluid chamber is defined in part by a spade-like surface having an inlet for the test fluid mixture.",GENE LOGIC INC;;TORRES MATTHEW;;SMITH IAN STUART RICHARD;;GOODMAN JACK;;YANG HONGJUN;;MATEER DAVID G,TORRES MATTHEW;;SMITH IAN STUART RICHARD;;GOODMAN JACK;;YANG HONGJUN;;MATEER DAVID G,,https://lens.org/191-642-491-864-189,Patent Application,no,0,4,10,14,0,B01L3/5027;;B01L3/5027;;B01L3/502707;;B01L3/502707;;B01L3/502715;;B01L3/502715;;B01L3/502746;;B01L3/502746;;B01L7/00;;B01L7/00;;B01L7/52;;B01L7/52;;B01L9/527;;B01L9/527;;B01L2200/027;;B01L2200/027;;B01L2200/0689;;B01L2200/0689;;B01L2300/0636;;B01L2300/0636;;B01L2300/0816;;B01L2300/0816;;B01L2300/0877;;B01L2300/0877;;B01L2300/18;;B01L2300/18;;B01L2300/1822;;B01L2300/1822;;B01L2300/1838;;B01L2300/1838;;B01L2400/0478;;B01L2400/0478;;B01L2400/0481;;B01L2400/0481;;B01L2400/0487;;B01L2400/0487;;B01L2400/06;;B01L2400/06;;B01L2400/0622;;B01L2400/0622;;G01N21/253;;G01N21/253;;G01N21/05;;G01N21/05;;G01N2021/0346;;G01N2021/0346;;G01N2035/00158;;G01N2035/00158,B01L3/00;;B01L7/00;;B01L9/00;;G01N21/05;;G01N21/25;;G01N35/00,,0,0,,,,PENDING
73,US,B2,US 7326561 B2,051-803-199-541-188,2008-02-05,2008,US 92609403 A,2003-11-12,US 92609403 A;;US 17151099 P;;US 0034535 W,1999-12-22,"Flow-thru chip cartridge, chip holder, system and method thereof","A system for performing hybridization assays comprises a cartridge for housing a flow through device, where the cartridge includes a test fluid chamber for facilitating a substantially uniform flow of a test fluid mixture through the flow through device, and a fluidics station to deliver the test fluid mixture to the cartridge. The cartridge has a chip holder that holds the flow-through device, which has an array of microchannel passages. The chip holder has a support for placement of the flow though device, the test fluid chamber for directing a substantially uniform flow of a test fluid mixture through the array of microchannel passages of the flow through device, and a first port that receives the test fluid mixture. The cartridge has a sealing system for preventing the leakage of the test fluid around the flow through device. The test fluid chamber is defined in part by a spade-like surface having an inlet for the test fluid mixture.",GOODMAN JACK;;TORRES MATTHEW;;YANG HONGJUN;;MATEER DAVID G;;SMITH IAN STUART RICHARD,GOODMAN JACK;;TORRES MATTHEW;;YANG HONGJUN;;MATEER DAVID G;;SMITH IAN STUART RICHARD,MMV FINANCIAL INC (2008-02-15);;ANGLE EUROPE LIMITED (2009-10-04);;AXELA INC (2009-12-21),https://lens.org/051-803-199-541-188,Granted Patent,yes,5,25,10,14,0,B01L3/5027;;B01L3/5027;;B01L3/502707;;B01L3/502707;;B01L3/502715;;B01L3/502715;;B01L3/502746;;B01L3/502746;;B01L7/00;;B01L7/00;;B01L7/52;;B01L7/52;;B01L9/527;;B01L9/527;;B01L2200/027;;B01L2200/027;;B01L2200/0689;;B01L2200/0689;;B01L2300/0636;;B01L2300/0636;;B01L2300/0816;;B01L2300/0816;;B01L2300/0877;;B01L2300/0877;;B01L2300/18;;B01L2300/18;;B01L2300/1822;;B01L2300/1822;;B01L2300/1838;;B01L2300/1838;;B01L2400/0478;;B01L2400/0478;;B01L2400/0481;;B01L2400/0481;;B01L2400/0487;;B01L2400/0487;;B01L2400/06;;B01L2400/06;;B01L2400/0622;;B01L2400/0622;;G01N21/253;;G01N21/253;;G01N21/05;;G01N21/05;;G01N2021/0346;;G01N2021/0346;;G01N2035/00158;;G01N2035/00158,C12M1/36;;B01L3/00;;B01L7/00;;B01L9/00;;G01N21/05;;G01N21/25;;G01N35/00,435/286.5;;435/287.2;;435/288.3;;435/288.6,0,0,,,,EXPIRED
74,WO,A3,WO 2008/130604 A3,036-318-965-069-052,2009-12-03,2009,US 2008/0004976 W,2008-04-17,US 92398807 P,2007-04-17,HYDROGEL ARTHROPLASTY DEVICE,"An arthroplasty device is provided having an interpenetrating polymer network (IPN) hydrogel that is strain-hardened by swelling and adapted to be held in place in a joint by conforming to a bone geometry. The strain-hardened IPN hydrogel is based on two different networks: (1) a non-silicone network of preformed hydrophilic non-ionic telechelic macromonomers chemically cross-linked by polymerization of its end-groups, and (2) a non-silicone network of ionizable monomers. The second network was polymerized and chemically cross-linked in the presence of the first network and has formed physical cross-links with the first network. Within the IPN, the degree of chemical cross-linking in the second network is less than in the first network. An aqueous salt solution (neutral pH) is used to ionize and swell the second network. The swelling of the second network is constrained by the first network resulting in an increase in effective physical cross-links within the IPN.",UNIV LELAND STANFORD JUNIOR;;MYUNG DAVID;;KOURTIS LAMPROS;;HARTMANN LAURA;;FRANK CURTIS W;;GOODMAN STUART B;;CARTER DENNIS R,MYUNG DAVID;;KOURTIS LAMPROS;;HARTMANN LAURA;;FRANK CURTIS W;;GOODMAN STUART B;;CARTER DENNIS R,,https://lens.org/036-318-965-069-052,Search Report,yes,4,0,16,58,0,A61F2/30756;;A61F2/32;;A61F2/34;;A61F2/3603;;A61F2/38;;A61F2/3859;;A61F2/389;;A61F2002/30075;;A61F2002/30077;;A61F2002/30324;;A61F2002/30616;;A61F2002/30673;;A61F2002/3092;;A61F2002/30937;;A61F2002/30971;;A61F2002/3225;;A61F2002/4631;;A61F2210/0061;;A61F2210/0066;;A61F2250/0036;;A61F2310/00796;;A61L27/425;;A61L27/52;;A61L27/56;;A61F2002/349,A61F2/30;;A61L27/52,,0,0,,,,PENDING
75,AU,A8,AU 2008/241487 A8,040-147-823-053-152,2014-07-24,2014,AU 2008/241487 A,2008-04-17,US 92398807 P;;US 2008/0004976 W,2007-04-17,Hydrogel arthroplasty device,"An arthroplasty device is provided having an interpenetrating polymer network (IPN) hydrogel that is strain-hardened by swelling and adapted to be held in place in a joint by conforming to a bone geometry. The strain-hardened IPN hydrogel is based on two different networks: (1) a non-silicone network of preformed hydrophilic non-ionic telechelic macromonomers chemically cross-linked by polymerization of its end-groups, and (2) a non-silicone network of ionizable monomers. The second network was polymerized and chemically cross-linked in the presence of the first network and has formed physical cross-links with the first network. Within the IPN, the degree of chemical cross-linking in the second network is less than in the first network. An aqueous salt solution (neutral pH) is used to ionize and swell the second network. The swelling of the second network is constrained by the first network resulting in an increase in effective physical cross-links within the IPN.",UNIV LELAND STANFORD JUNIOR;;US DEPT VETERANS AFFAIRS,CARTER DENNIS R;;MYUNG DAVID;;FRANK CURTIS W;;KOURTIS LAMPROS;;HARTMANN LAURA;;GOODMAN STUART B,THE BOARD OF TRUSTEES OF LELAND STANFORD JUNIOR UN (2011-03-17),https://lens.org/040-147-823-053-152,Patent Application,no,1,0,16,58,0,A61F2/30756;;A61F2/32;;A61F2/34;;A61F2/3603;;A61F2/38;;A61F2/3859;;A61F2/389;;A61F2002/30075;;A61F2002/30077;;A61F2002/30324;;A61F2002/30616;;A61F2002/30673;;A61F2002/3092;;A61F2002/30937;;A61F2002/30971;;A61F2002/3225;;A61F2002/4631;;A61F2210/0061;;A61F2210/0066;;A61F2250/0036;;A61F2310/00796;;A61L27/425;;A61L27/52;;A61L27/56;;A61F2002/349,A61F2/30;;A61L27/52,,0,0,,,,INACTIVE
76,WO,A2,WO 2008/130604 A2,172-483-223-516-490,2008-10-30,2008,US 2008/0004976 W,2008-04-17,US 92398807 P,2007-04-17,HYDROGEL ARTHROPLASTY DEVICE,"An arthroplasty device is provided having an interpenetrating polymer network (IPN) hydrogel that is strain-hardened by swelling and adapted to be held in place in a joint by conforming to a bone geometry. The strain-hardened IPN hydrogel is based on two different networks: (1) a non-silicone network of preformed hydrophilic non-ionic telechelic macromonomers chemically cross-linked by polymerization of its end-groups, and (2) a non-silicone network of ionizable monomers. The second network was polymerized and chemically cross-linked in the presence of the first network and has formed physical cross-links with the first network. Within the IPN, the degree of chemical cross-linking in the second network is less than in the first network. An aqueous salt solution (neutral pH) is used to ionize and swell the second network. The swelling of the second network is constrained by the first network resulting in an increase in effective physical cross-links within the IPN.",UNIV LELAND STANFORD JUNIOR;;MYUNG DAVID;;KOURTIS LAMPROS;;HARTMANN LAURA;;FRANK CURTIS W;;GOODMAN STUART B;;CARTER DENNIS R,MYUNG DAVID;;KOURTIS LAMPROS;;HARTMANN LAURA;;FRANK CURTIS W;;GOODMAN STUART B;;CARTER DENNIS R,,https://lens.org/172-483-223-516-490,Patent Application,yes,0,17,16,58,0,A61F2/30756;;A61F2/32;;A61F2/34;;A61F2/3603;;A61F2/38;;A61F2/3859;;A61F2/389;;A61F2002/30075;;A61F2002/30077;;A61F2002/30324;;A61F2002/30616;;A61F2002/30673;;A61F2002/3092;;A61F2002/30937;;A61F2002/30971;;A61F2002/3225;;A61F2002/4631;;A61F2210/0061;;A61F2210/0066;;A61F2250/0036;;A61F2310/00796;;A61L27/425;;A61L27/52;;A61L27/56;;A61F2002/349,A61F2/30;;A61L27/52,,0,0,,,,PENDING
77,EP,B1,EP 2457539 B1,015-259-681-091-179,2019-12-25,2019,EP 12156562 A,2008-04-17,US 92398807 P;;EP 08743019 A;;US 2008/0004976 W,2007-04-17,Hydrogel arthroplasty device,,UNIV LELAND STANFORD JUNIOR;;THE US GOV AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS,MYUNG DAVID;;KOURTIS LAMPROS;;HARTMANN LAURA;;FRANK CURTIS W;;GOODMAN STUART B;;CARTER DENNIS R,THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIO (2019-09-18);;THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE (2019-09-18),https://lens.org/015-259-681-091-179,Granted Patent,yes,1,0,16,58,0,A61F2/30756;;A61F2/32;;A61F2/34;;A61F2/3603;;A61F2/38;;A61F2/3859;;A61F2/389;;A61F2002/30075;;A61F2002/30077;;A61F2002/30324;;A61F2002/30616;;A61F2002/30673;;A61F2002/3092;;A61F2002/30937;;A61F2002/30971;;A61F2002/3225;;A61F2002/4631;;A61F2210/0061;;A61F2210/0066;;A61F2250/0036;;A61F2310/00796;;A61L27/425;;A61L27/52;;A61L27/56;;A61F2002/349,A61F2/30;;A61L27/52,,0,0,,,,ACTIVE
78,EP,B1,EP 3628275 B1,163-909-761-444-809,2023-03-01,2023,EP 19207798 A,2008-04-17,EP 12156562 A;;EP 08743019 A;;US 92398807 P;;US 2008/0004976 W,2007-04-17,HYDROGEL ARTHROPLASTY DEVICE,,UNIV LELAND STANFORD JUNIOR;;THE US GOV AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS,MYUNG DAVID;;KOURTIS LAMPROS;;HARTMANN LAURA;;FRANK CURTIS W;;GOODMAN STUART B;;CARTER DENNIS R,,https://lens.org/163-909-761-444-809,Granted Patent,yes,2,0,16,58,0,A61F2/30756;;A61F2/32;;A61F2/34;;A61F2/3603;;A61F2/38;;A61F2/3859;;A61F2/389;;A61F2002/30075;;A61F2002/30077;;A61F2002/30324;;A61F2002/30616;;A61F2002/30673;;A61F2002/3092;;A61F2002/30937;;A61F2002/30971;;A61F2002/3225;;A61F2002/4631;;A61F2210/0061;;A61F2210/0066;;A61F2250/0036;;A61F2310/00796;;A61L27/425;;A61L27/52;;A61L27/56;;A61F2002/349,A61F2/30;;A61L27/52,,0,0,,,,ACTIVE
79,AU,B2,AU 2008/241487 B2,009-444-508-468-929,2013-08-22,2013,AU 2008/241487 A,2008-04-17,US 92398807 P;;US 2008/0004976 W,2007-04-17,Hydrogel arthroplasty device,"An arthroplasty device is provided having an interpenetrating polymer network (IPN) hydrogel that is strain-hardened by swelling and adapted to be held in place in a joint by conforming to a bone geometry. The strain-hardened IPN hydrogel is based on two different networks: (1) a non-silicone network of preformed hydrophilic non-ionic telechelic macromonomers chemically cross-linked by polymerization of its end-groups, and (2) a non-silicone network of ionizable monomers. The second network was polymerized and chemically cross-linked in the presence of the first network and has formed physical cross-links with the first network. Within the IPN, the degree of chemical cross-linking in the second network is less than in the first network. An aqueous salt solution (neutral pH) is used to ionize and swell the second network. The swelling of the second network is constrained by the first network resulting in an increase in effective physical cross-links within the IPN.",UNIV LELAND STANFORD JUNIOR;;THE US GOV AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS,CARTER DENNIS R;;MYUNG DAVID;;FRANK CURTIS W;;KOURTIS LAMPROS;;HARTMANN LAURA;;GOODMAN STUART B,THE BOARD OF TRUSTEES OF LELAND STANFORD JUNIOR UN (2011-03-17),https://lens.org/009-444-508-468-929,Granted Patent,no,1,0,16,58,0,A61F2/30756;;A61F2/32;;A61F2/34;;A61F2/3603;;A61F2/38;;A61F2/3859;;A61F2/389;;A61F2002/30075;;A61F2002/30077;;A61F2002/30324;;A61F2002/30616;;A61F2002/30673;;A61F2002/3092;;A61F2002/30937;;A61F2002/30971;;A61F2002/3225;;A61F2002/4631;;A61F2210/0061;;A61F2210/0066;;A61F2250/0036;;A61F2310/00796;;A61L27/425;;A61L27/52;;A61L27/56;;A61F2002/349,A61F2/30;;A61L27/52,,0,0,,,,INACTIVE
80,US,A1,US 2014/0172098 A1,156-627-309-014-707,2014-06-19,2014,US 201414188257 A,2014-02-24,US 201414188257 A;;US 201213418294 A;;US 14853408 A;;US 7033608 A;;US 24395205 A;;US 63611406 A;;US 40921806 A;;US 63904906 A;;US 92398807 P;;US 90180507 P;;US 61626204 P;;US 67317205 P;;US 84394206 P;;US 78330706 P;;US 67360005 P,2004-10-05,HYDROGEL ARTHROPLASTY DEVICE,"An arthroplasty device is provided having an interpenetrating polymer network (IPN) hydrogel that is strain-hardened by swelling and adapted to be held in place in a joint by conforming to a bone geometry. The strain-hardened IPN hydrogel is based on two different networks: (1) a non-silicone network of preformed hydrophilic non-ionic telechelic macromonomers chemically cross-linked by polymerization of its end-groups, and (2) a non-silicone network of ionizable monomers. The second network was polymerized and chemically cross-linked in the presence of the first network and has formed physical cross-links with the first network. Within the IPN, the degree of chemical cross-linking in the second network is less than in the first network. An aqueous salt solution (neutral pH) is used to ionize and swell the second network. The swelling of the second network is constrained by the first network resulting in an increase in effective physical cross-links within the IPN.",MYUNG DAVID;;KOURTIS LAMPROS;;HARTMANN LAURA;;FRANK CURTIS W;;GOODMAN STUART B;;CARTER DENNIS R,MYUNG DAVID;;KOURTIS LAMPROS;;HARTMANN LAURA;;FRANK CURTIS W;;GOODMAN STUART B;;CARTER DENNIS R,,https://lens.org/156-627-309-014-707,Patent Application,yes,13,12,7,58,0,A61F2/30756;;A61F2/30756;;A61F2/34;;A61F2/34;;A61F2/36;;A61F2/3603;;A61F2/3603;;A61F2/3872;;A61F2/3872;;A61F2/4202;;A61F2/4202;;A61F2/4225;;A61F2/4225;;A61F2/4241;;A61F2/4241;;A61F2/4405;;A61F2/4405;;A61F2002/30075;;A61F2002/30075;;A61F2002/30448;;A61F2002/30448;;A61F2002/30593;;A61F2002/30593;;A61F2002/30754;;A61F2002/30754;;A61F2210/0061;;A61F2210/0061;;A61F2220/005;;A61F2220/005;;A61F2310/00293;;A61F2310/00293;;A61L27/18;;A61L27/34;;A61L27/3843;;A61L27/3843;;A61L27/50;;A61L27/52;;A61L27/52;;A61L2430/24;;A61L2430/24,A61F2/30,623/14.12,0,0,,,,ACTIVE
81,EP,B1,EP 2148637 B1,176-845-849-658-467,2012-05-16,2012,EP 08743019 A,2008-04-17,US 2008/0004976 W;;US 92398807 P,2007-04-17,HYDROGEL ARTHROPLASTY DEVICE,,UNIV LELAND STANFORD JUNIOR;;US DEPT VETERANS AFFAIRS,MYUNG DAVID;;KOURTIS LAMPROS;;HARTMANN LAURA;;FRANK CURTIS W;;GOODMAN STUART B;;CARTER DENNIS R,THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIO (2011-05-04);;THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE (2011-05-04),https://lens.org/176-845-849-658-467,Granted Patent,yes,4,0,16,58,0,A61F2/30756;;A61F2/32;;A61F2/34;;A61F2/3603;;A61F2/38;;A61F2/3859;;A61F2/389;;A61F2002/30075;;A61F2002/30077;;A61F2002/30324;;A61F2002/30616;;A61F2002/30673;;A61F2002/3092;;A61F2002/30937;;A61F2002/30971;;A61F2002/3225;;A61F2002/4631;;A61F2210/0061;;A61F2210/0066;;A61F2250/0036;;A61F2310/00796;;A61L27/425;;A61L27/52;;A61L27/56;;A61F2002/349,A61F2/30;;A61L27/52,,0,0,,,,ACTIVE
82,US,B2,US 9387082 B2,199-063-358-372-710,2016-07-12,2016,US 201414188257 A,2014-02-24,US 201414188257 A;;US 201213418294 A;;US 14853408 A;;US 7033608 A;;US 24395205 A;;US 63611406 A;;US 40921806 A;;US 63904906 A;;US 92398807 P;;US 90180507 P;;US 61626204 P;;US 67317205 P;;US 84394206 P;;US 78330706 P;;US 67360005 P,2004-10-05,Hydrogel arthroplasty device,"An arthroplasty device is provided having an interpenetrating polymer network (IPN) hydrogel that is strain-hardened by swelling and adapted to be held in place in a joint by conforming to a bone geometry. The strain-hardened IPN hydrogel is based on two different networks: (1) a non-silicone network of preformed hydrophilic non-ionic telechelic macromonomers chemically cross-linked by polymerization of its end-groups, and (2) a non-silicone network of ionizable monomers. The second network was polymerized and chemically cross-linked in the presence of the first network and has formed physical cross-links with the first network. Within the IPN, the degree of chemical cross-linking in the second network is less than in the first network. An aqueous salt solution (neutral pH) is used to ionize and swell the second network. The swelling of the second network is constrained by the first network resulting in an increase in effective physical cross-links within the IPN.",UNIV LELAND STANFORD JUNIOR;;US DEPT VETERANS AFFAIRS,MYUNG DAVID;;KOURTIS LAMPROS;;HARTMANN LAURA;;FRANK CURTIS W;;GOODMAN STUART B;;CARTER DENNIS R,,https://lens.org/199-063-358-372-710,Granted Patent,yes,113,10,7,58,0,A61F2/30756;;A61F2/30756;;A61F2/34;;A61F2/34;;A61F2/36;;A61F2/3603;;A61F2/3603;;A61F2/3872;;A61F2/3872;;A61F2/4202;;A61F2/4202;;A61F2/4225;;A61F2/4225;;A61F2/4241;;A61F2/4241;;A61F2/4405;;A61F2/4405;;A61F2002/30075;;A61F2002/30075;;A61F2002/30448;;A61F2002/30448;;A61F2002/30593;;A61F2002/30593;;A61F2002/30754;;A61F2002/30754;;A61F2210/0061;;A61F2210/0061;;A61F2220/005;;A61F2220/005;;A61F2310/00293;;A61F2310/00293;;A61L27/18;;A61L27/34;;A61L27/3843;;A61L27/3843;;A61L27/50;;A61L27/52;;A61L27/52;;A61L2430/24;;A61L2430/24,A61F2/30;;A61F2/34;;A61F2/36;;A61F2/38;;A61F2/42;;A61F2/44;;A61L27/38;;A61L27/52,,63,44,063-440-980-376-104;;026-221-330-748-664;;024-610-290-282-842;;034-565-565-651-524;;055-393-317-064-498;;147-758-768-412-476;;052-458-971-568-741;;086-616-276-695-612;;102-621-678-354-743;;047-150-476-278-585;;021-087-351-885-127;;041-887-716-096-173;;002-086-020-836-183;;027-980-109-653-854;;024-534-382-956-398;;148-912-488-076-585;;088-697-366-745-134;;052-298-833-496-073;;077-749-852-128-708;;033-300-048-467-956;;039-257-370-430-040;;010-334-848-861-637;;036-811-735-564-321;;021-495-822-971-922;;042-967-615-404-76X;;125-902-525-714-117;;008-077-011-442-899;;105-214-375-338-413;;068-006-961-102-650;;134-793-990-456-906;;047-218-379-035-635;;066-655-257-455-652;;002-972-405-137-267;;077-816-749-102-187;;012-614-261-367-145;;106-535-937-889-932;;008-933-788-504-381;;044-946-847-534-221;;161-184-573-455-924;;039-339-388-695-45X;;058-283-542-774-076;;027-814-601-459-101;;065-276-280-452-699;;069-606-723-534-680,10.1097/00003086-198007000-00045;;12115467;;10.1002/jbm.10201;;12122211;;pmc124906;;10.1038/news020722-3;;10.1073/pnas.162124199;;13855642;;10.1302/0301-620x.42b1.28;;10.1016/s0043-1648(03)00113-3;;10.1002/app.1981.070260601;;10.1002/app.1983.070280703;;10.1016/s0142-9612(01)00255-1;;11808538;;10.1002/adma.200304907;;14613229;;10.1002/jbm.a.10148;;10.1089/ten.2006.12.1247;;16771638;;16701828;;10.1016/j.actbio.2005.02.007;;10.1071/ch02168;;10.1002/(sici)1097-4636(199802)39:2<266::aid-jbm14>3.0.co;2-b;;9457557;;10.1002/pola.10554;;15348824;;10.1023/a:1018596109061;;10.1016/j.biomaterials.2004.02.065;;15282140;;10.1016/s1381-5148(02)00216-x;;10.1002/app.12327;;10.1002/app.20133;;10.1302/0301-620x.88b1.16600;;16365134;;10.1016/j.urology.2004.03.005;;15245923;;10.1016/s0144-8617(99)00088-0;;9178743;;10.1002/(sici)1097-4636(199722)38:2<155::aid-jbm10>3.0.co;2-c;;10.1007/bf01178451;;10.1021/ma9915024;;5677422;;10.1038/2191260a0;;11311697;;10.1016/s0021-9290(01)00011-2;;10.1016/j.polymer.2007.06.070;;10.1016/j.jbiomech.2006.11.020;;17257604;;10.1016/s0142-9612(03)00055-3;;12742733;;10.1016/s0969-806x(03)00067-7;;15972363;;10.1177/0885328205048647;;10.1002/app.13015;;16898216;;10.1243/09544119h06404;;2970907;;10.1016/s0142-9612(00)00242-8;;11246948;;10.1097/00008877-200412000-00007;;15577457;;10.1385/1-59259-169-8:477;;10.1016/s8756-3282(99)00142-8;;10458285;;10.1039/b300607g;;7066466;;10.1016/0142-9612(82)90060-6;;10397967;;10.1002/(sici)1097-4636(199905)45:2<133::aid-jbm8>3.0.co;2-d;;15335001;;10.1023/b:jmsm.0000015489.27261.f0,"Bobyn et al., The optimum pore size for the fixation of porous-surfaced metal implants by the ingrowth of bone. Clin Orthop Relat Res, Jul./Aug. 1980(150): p. 263-70.;;Borden et al.; The sintered microsphere matrix for bone tissue engineering: In vitroosteoconductivity studies; J. Biomed. Mat. Res.; 61(3); pp. 421-429; Sep. 2002.;;Brodbeck et al., Biomaterial adherent macrophage apoptosis is increased by hydrophilic and anionic substrates in vivo. Proc Natl Acad Sci U S A, Aug. 6, 2002. 99(16): p. 10287-92.;;Causton et al.; Dental materials: 1981 literature review Part 1; Journal of Dentistry; vol. 12; Issue 1; pp. 1R28; Mar. 1984.;;Charnley, J.; Anchorage of the femoral head prosthesis to the shaft of the femur; J Bone Joint Surg Br.; 42-B:28-30; Feb. 1960.;;Chen et al.; Mechanical Properties of Polyepichlorohydrin Polyurethane/Poly(methyl methacrylate) IPNs; Chinese J Appl Chem; 12(4):66-69; Aug. 1995 (wEngAbs).;;Covert et al.; Friction characteristics of a potential articular cartilage biomaterial. Wear, Aug. 2003. 255: p. 1064-1068.;;Depuy Orthopaedics; Bone Cement Time Setting Chart; product file; date of publication unknown; available to applicants at least as of Jul. 2012.;;Dror et al.; Gradient interpenetrating polymer networks. I. Poly(ether urethane) and polyacrylamide IPN; J of Applied Polymer Science; 26; pp. 1741-1757; Jun. 1981.;;Elmer's Products Inc.; Material Safety Data Sheet; ""Elmer's Nano Glue""; Jun. 13, 2007.;;Elsabee et al.; Gradient interpenetrating polymer networks. II. Polyacrylamide gradients in poly(ether urethane); J of Applied Polymer Science; 28(7); pp. 2151-2166; Jun. 1983.;;Evans et al.; The use of corneal organ culture in biocompatibility studies; Biomaterials; vol. 23; pp. 1359-1367; Mar. 2002.;;Frank, Curt; Structure-property relationships for hydrogels with applications to biomedical devices; Presentation at American Chemical Society Mtg; San Francisco, CA; Sep. 11, 2006.;;Gao et al.; Grafting of hydrophilic monomers onto polyurethane membranes by solution or pre-absorbing methods for acceleration of cell compatibility; Chinese Journal of Polymer Science; vol. 19; No. 5; pp. 493-498; Oct. 20, 2001.;;Gong et al.; Double-network hydrogels with extremely high mechanical strength; Adv. Mater.; vol. 15; No. 14; pp. 1155-1158; Jul. 17, 2003.;;Gorna et al.; Preparation, degradation, and clarification of biodegradable polyurethane foams for bone graft substitutes; J. Biomed Mater Res A; 67(3); pp. 813-827; Dec. 1, 2003.;;Guelcher et al.; Synthesis and in vitro biocompatibility of injectable polyurethane foam scaffolds; Tissue Engineering; 12(5); pp. 1247-1259; May 2006.;;Guelcher et al.; Synthesis of biocompatible segmented polyurethanes from aliphatic diisocyanates and diurea diol chain extenders; Acta biomaterialia; 1(4); pp. 471-484; Jul. 2005.;;Gunatillake et al.; Designing biostable polyurethane elastomers for biomedical implants; Aust. J. Chem.; vol. 56; pp. 545-557; Jun. 2003.;;Hern et al.; Incorporation of adhesion peptides into nonadhesive hydrogels useful for tissue resurfacing; J. Biomed. Materials Research; vol. 39; No. 1; pp. 266-276; Feb. 1998.;;Ithaca College Gross Anatomy; Joints of the Back; ; 4 pgs. (downloaded Dec. 1, 2013 from http://www.ithaca.edu/faculty/lahr/LE2000/Back/Jointpage.htm).;;Iwasaki et al., Hydrogel like elastic membrane consisting of semi-interpenetrating polymer networks based on a phosphorylcholine polymer and a segmented polyurethane; J. Polym. Sci Part A: Polym Chem; 41; pp. 68-75; Jan. 2003.;;Jones et al.; Sequential Polyurethane-Poly(Methylmethacrylate) Interpenetrating Polymer Networks as Ureteral Biomaterials: Mechanical Properties and Comparative Resistance to Urinaryencrustation; J Mater Sci Mater Med; 8(11):713-717; Nov. 1997.;;Khan et al., Analysis and evaluation of a biomedical polycarbonate urethane tested in an in vitro study and an ovine arthroplasty model. Part I: materials selection and evaluation. Biomaterials, Feb. 2005. 26(6): p. 621-31.;;Kim et al.; Water sorption of ploy(propylene glycol)/poly(acrylic acid) interpenetrating polymer network hydrogels; Reactive & Functional Polymers; vol. 55; pp. 69-73; Feb. 2003.;;Kim et al.; Electrochemical behavior of an interpenetrating polymer network hydrogel composed of poly (propylene glycol) and poly(acrylic acid); Journal of Applied Polymer Science; vol. 89; pp. 2301-2305; Aug. 2003.;;Kim et al.; Electrical/pH Responsive Properties of Poly(2-acrylamido-2-methylpropane sulfonic acid)/Hyaluronic Acid Hydrogels; Journal of Applied Polymer Science; vol. 92; issue 3; pp. 1731-1736; May 2004.;;Kwong et al.; A comparison of the shrinkage of commercial bone cements when mixed under vacuum; J Bone Joint Surg Br.; 88(1):120-2; Jan. 2006.;;Lam et al.; Update on Ureteral Stents; Urology; 64:9-15; Jul. 2004.;;Lamba et al.; Polyurethanes in Biomedical Application; CRC Press; pp. 11, 14, 16, 18-20, 57-59, 73, 79 & 104; Nov. 1997.;;Lee et al.; Interpenetrating polymer network hydrogels based on poly (ethylene glycol) macromer and chitosan; Carbohydrate Polymer; vol. 41; No. 2; pp. 197-205; Feb. 2000.;;Lewis G.; Properties of acrylic bone cement: state of the art review; J Biomed Mater Res.; 38(2):155-82; Summer(Jun.-Aug. 1997).;;Lipatov et al.; Gradient interpenetrating polymer networks; Journal of Materials Science; 30(4); pp. 1095-1104; Feb. 1995.;;Lu et al.; Release behavior of high molecular weight solutes from poly(ethylene glycol)-based degradable networks; Macromolecules; vol. 33(7); pp. 2509-2515; Mar. 2000.;;Maroudas et al.; Permeability of articular cartilage; Nature; vol. 219(5160); pp. 1260-1261; Sep. 21, 1968.;;MIT.edu; Material Modulus Properties; 2pgs.; Feb. 8, 2007 (downloaded Nov. 27, 2013 from http://web.archive.org/web/*/http://web.mit.edu/course/3/3.11/www/modules/props.pdf).;;Morgan et al.; Dependence of yield strain of human trabecular bone on anatomic site; J Biomech.; 34(5):569-77; May 2001.;;Mow et al., Basic Orthopaedic Biomechanics and Mechano-Biology, Lippincot Williams and Wilkins, 3rd Edition, Apr. 2005, pp. 459-461.;;Myung, David; Structure, properties, and medical device applications of mechanically enhanced, biometric hydrogel alloys; Doctoral Thesis; Stanford University; Dec. 2007.;;Myung et al.; Biomimetic strain hardening in interpenetrating polymer network hydrogels; Polymer, ; vol. 48; No. 18; pp. 5376-5387; Jun. 2007.;;Neurosurgical.com; Spinal Anatomy: The Regions of the Spine; 5pgs. (downloaded Dec. 1, 2013 http://www.neurosurgical.com/neuro-medical-info/spinal-anatomy.htm).;;Ohman et al.; Mechanical testing of cancellous bone from the femoral head: experimental errors due to off-axis measurements; J Biomech.; 40(11):2426-33; (year of publication is sufficiently earlier than the effective U.S. filing date and any foreign priority date) 2007.;;Orr et al.; Shrinkage stresses in bone cement; Biomaterials; 24 (17):2933-40; Aug. 2003.;;Park et al.; Synthesis of PVA/PVP hydrogels having two-layer by radiation and their physical properties; Radiation Physics and Chemistry; 67(3-4); pp. 361-365; Jun. 2003.;;Puska et al.; Exothermal Characteristics and Release of Residual Monomers from Fiber-reinforced Oligomer-modified Acrylic Bone Cement; J Biomat App; 20:51-64; Jul. 2005.;;Realdictionary; Definition of Implant; 4pgs. (downloaded Dec. 1, 2013 from www.realdictionary.com/?q=implant).;;Saito et al.; Preparation and properties of transparent cellulose hydrogels; J. Applied Polymer Science; 90(11); pp. 3020-3025; Dec. 2003.;;Scholes et al.; Compliant layer acetabular cups: friction tsting of a range of materials and designs for a new generation of prosthesis that mimics the natural joint; Proc. IMechE; vol. 220(5); Part H; J. Engineering in Medicine; pp. 583-596, Jul. 2006.;;Shalaby; U.S. Appl. No. 61/069,046 entitled ""Hydroswellable, segmented, aliphatic polyurethanes and polyurethane ureas,"" filed Mar. 12, 2008.;;Spector et al.; Porous polymers for biological fixation. Clin Orthop Relat Res, Oct. 1988 (235): p. 207-19.;;Stammen et al., Mechanical properties of a novel PVA hydrogel in shear and unconfined compression. Biomaterials, Apr. 2001. 22(8): p. 799-806.;;Stryker Orthopaedics; SimplexTM P Bone Cement; Product Literature LSB Rev. 3, Mar. 2006.;;Tariq et al.; (Abstract) Sodium benzoate attenuates iminodipropionitrile-induced behavioral syndrome in rats. Behav pharmacol; Dec. 2004.;;Tawfik, Dan; Amidation of carboxyl groups; The Protein Protocols Handbook, 2nd Ed.; Humana Press; pp. 477-478; Feb. 2002.;;The Engineering Toolbox; Polyurethane insulation: {http://www.engineeringtoolbox.com/polyurethane-insulation-k-values-d-1174.html} pp. 1-3; printed Oct. 21, 2011.;;The Engineering Toolbox;Thermal conductivity of some common materials and gases: {http://www.engineeringtoolbox.com/thrmal-conductivity-d-429.html} pp. 1-2; printed Oct. 21, 2011.;;The Gorilla Glue Company; Material Safety Data Sheet; ""New Fast Cure-Dries White Gorilla Glue®""; Jan. 30, 2007.;;The Gorilla Glue Company; Material Safety Data Sheet; ""New Stronger-Faster Gorilla Glue®""; Jan. 26, 2007.;;Van Landuyt et al.; Reinforcement of Osteosynthesis Screws with Brushite Cement; Bone; 25(2)(Suppl 1):95S-98S; Aug. 1999.;;Wittemann et al.; Adsorption of proteins on spherical polyelectrolyte brushes in aqueous solution; Phys. Chem. Chem. Phys., Mar. 2003, vol. 5(8), pp. 1671-1677.;;Wright et al., Wear studies on prosthetic materials using the pin-on-disc machine. Biomaterials, vol. 3, Issue 1, Jan. 1982, pp. 41R48.;;Yang et al.; Preparation of poly(acrylic acid) modified polyurethane membrane for biomaterial by UV radiation without degassing; J. Biomed. Mater. Res.; vol. 45(2); pp. 133-139; May 1999.;;Zhu et al.; (Abstract) Promoting the cytocompatibility of polyurethane scaffolds via surface photo-grafting polymerization of acrylamide; J. Mater. Sci. Mater. Med.; vol. 15; No. 3; pp. 283-289; Mar. 2004.",ACTIVE
83,US,B2,US 8679190 B2,053-785-551-793-875,2014-03-25,2014,US 201213418294 A,2012-03-12,US 201213418294 A;;US 14853408 A;;US 7033608 A;;US 24395205 A;;US 63611406 A;;US 40921806 A;;US 63904906 A;;US 92398807 P;;US 90180507 P;;US 61626204 P;;US 67317205 P;;US 84394206 P;;US 78330706 P;;US 67360005 P,2004-10-05,Hydrogel arthroplasty device,"An arthroplasty device is provided having an interpenetrating polymer network (IPN) hydrogel that is strain-hardened by swelling and adapted to be held in place in a joint by conforming to a bone geometry. The strain-hardened IPN hydrogel is based on two different networks: (1) a non-silicone network of preformed hydrophilic non-ionic telechelic macromonomers chemically cross-linked by polymerization of its end-groups, and (2) a non-silicone network of ionizable monomers. The second network was polymerized and chemically cross-linked in the presence of the first network and has formed physical cross-links with the first network. Within the IPN, the degree of chemical cross-linking in the second network is less than in the first network. An aqueous salt solution (neutral pH) is used to ionize and swell the second network. The swelling of the second network is constrained by the first network resulting in an increase in effective physical cross-links within the IPN.",MYUNG DAVID;;KOURTIS LAMPROS;;HARTMANN LAURA;;FRANK CURTIS W;;GOODMAN STUART B;;CARTER DENNIS R;;UNIV LELAND STANFORD JUNIOR;;US DEPT VETERANS AFFAIRS,MYUNG DAVID;;KOURTIS LAMPROS;;HARTMANN LAURA;;FRANK CURTIS W;;GOODMAN STUART B;;CARTER DENNIS R,THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (2008-11-17);;THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS OFFICE OF GENERAL COUNSEL - PSG IV (024) (2008-11-19),https://lens.org/053-785-551-793-875,Granted Patent,yes,112,30,7,58,0,A61F2/30756;;A61F2/30756;;A61F2/34;;A61F2/34;;A61F2/36;;A61F2/3603;;A61F2/3603;;A61F2/3872;;A61F2/3872;;A61F2/4202;;A61F2/4202;;A61F2/4225;;A61F2/4225;;A61F2/4241;;A61F2/4241;;A61F2/4405;;A61F2/4405;;A61F2002/30075;;A61F2002/30075;;A61F2002/30448;;A61F2002/30448;;A61F2002/30593;;A61F2002/30593;;A61F2002/30754;;A61F2002/30754;;A61F2210/0061;;A61F2210/0061;;A61F2220/005;;A61F2220/005;;A61F2310/00293;;A61F2310/00293;;A61L27/18;;A61L27/34;;A61L27/3843;;A61L27/3843;;A61L27/50;;A61L27/52;;A61L27/52;;A61L2430/24;;A61L2430/24,A61F2/30,623/23.58;;623/23.6;;623/13.11;;623/18.11,67,43,063-440-980-376-104;;026-221-330-748-664;;024-610-290-282-842;;055-393-317-064-498;;147-758-768-412-476;;052-458-971-568-741;;086-616-276-695-612;;102-621-678-354-743;;047-150-476-278-585;;021-087-351-885-127;;041-887-716-096-173;;002-086-020-836-183;;027-980-109-653-854;;024-534-382-956-398;;088-697-366-745-134;;052-298-833-496-073;;077-749-852-128-708;;036-811-735-564-321;;042-967-615-404-76X;;125-902-525-714-117;;008-077-011-442-899;;068-006-961-102-650;;066-655-257-455-652;;077-816-749-102-187;;012-614-261-367-145;;106-535-937-889-932;;008-933-788-504-381;;044-946-847-534-221;;161-184-573-455-924;;058-283-542-774-076;;027-814-601-459-101;;065-276-280-452-699;;069-606-723-534-680;;034-565-565-651-524;;039-257-370-430-040;;021-495-822-971-922;;105-214-375-338-413;;134-793-990-456-906;;047-218-379-035-635;;002-972-405-137-267;;148-912-488-076-585;;010-334-848-861-637;;039-339-388-695-45X,10.1097/00003086-198007000-00045;;12115467;;10.1002/jbm.10201;;12122211;;pmc124906;;10.1038/news020722-3;;10.1073/pnas.162124199;;10.1016/s0043-1648(03)00113-3;;10.1002/app.1981.070260601;;10.1002/app.1983.070280703;;10.1016/s0142-9612(01)00255-1;;11808538;;10.1002/adma.200304907;;14613229;;10.1002/jbm.a.10148;;10.1089/ten.2006.12.1247;;16771638;;16701828;;10.1016/j.actbio.2005.02.007;;10.1071/ch02168;;10.1002/(sici)1097-4636(199802)39:2<266::aid-jbm14>3.0.co;2-b;;9457557;;10.1002/pola.10554;;10.1016/j.biomaterials.2004.02.065;;15282140;;10.1016/s1381-5148(02)00216-x;;10.1002/app.12327;;10.1016/s0144-8617(99)00088-0;;10.1007/bf01178451;;10.1021/ma9915024;;5677422;;10.1038/2191260a0;;10.1016/j.polymer.2007.06.070;;10.1016/s0969-806x(03)00067-7;;10.1002/app.13015;;16898216;;10.1243/09544119h06404;;2970907;;10.1016/s0142-9612(00)00242-8;;11246948;;10.1097/00008877-200412000-00007;;15577457;;10.1385/1-59259-169-8:477;;10.1039/b300607g;;7066466;;10.1016/0142-9612(82)90060-6;;10397967;;10.1002/(sici)1097-4636(199905)45:2<133::aid-jbm8>3.0.co;2-d;;15335001;;10.1023/b:jmsm.0000015489.27261.f0;;13855642;;10.1302/0301-620x.42b1.28;;10.1302/0301-620x.88b1.16600;;16365134;;9178743;;10.1002/(sici)1097-4636(199722)38:2<155::aid-jbm10>3.0.co;2-c;;11311697;;10.1016/s0021-9290(01)00011-2;;10.1016/j.jbiomech.2006.11.020;;17257604;;10.1016/s0142-9612(03)00055-3;;12742733;;15972363;;10.1177/0885328205048647;;15348824;;10.1023/a:1018596109061;;10.1016/j.urology.2004.03.005;;15245923;;10.1016/s8756-3282(99)00142-8;;10458285,"Kim et al. Journal of Applied Polymer Science. vol. 92, Issue 3 pp. 1731-1736.;;Bobyn et al., The optimum pore size for the fixation of porous-surfaced metal implants by the ingrowth of bone. Clin Orthop Relat Res, Jul./Aug. 1980(150): p. 263-70.;;Borden et al.; The sintered microsphere matrix for bone tissue engineering: In vitroosteoconductivity studies; J. Biomed. Mat. Res.; 61(3); pp. 421-429; Sep. 2002.;;Brodbeck et al., Biomaterial adherent macrophage apoptosis is increased by hydrophilic and anionic substrates in vivo. Proc Natl Aced Sci U S A, Aug. 6, 2002. 99(16): p. 10287-92.;;Covert et al.; Friction characteristics of a potential articular cartilage biomaterial. Wear, Aug. 2003. 255: p. 1064-1068.;;Dror et al.; Gradient interpenetrating polymer networks. I. Poly(ether urethane) and polyacrylamide IPN; J of Applied Polymer Science; 26; pp. 1741-1757; Jun. 1981.;;Elmer's Products Inc.; Material Safety Data Sheet; ""Elmer's Nano Glue""; Jun. 13, 2007.;;Elsabee et al.; Gradient interpenetrating polymer networks. II. Polyacrylamide gradients in poly(ether urethane); J of Applied Polymer Science; 28(7); pp. 2151-2166; Jun. 1983.;;Evans et al.; The use of corneal organ culture in biocompatibility studies; Biomaterials; vol. 23; pp. 1359-1367; Mar. 2002.;;Frank, Curt; Structure-property relationships for hydrogels with applications to biomedical devices; Presentation at American Chemical Society Mtg; San Francisco, CA; Sep. 11, 2006.;;Gao et al.; Grafting of hydrophilic monomers onto polyurethane membranes by solution or pre-absorbing methods for acceleration of cell compatibility; Chinese Journal of Polymer Science; vol. 19; No. 5; pp. 493-498; Oct. 20, 2001.;;Gong et al.; Double-network hydrogels with extremely high mechanical strength; Adv. Mater.; vol. 15; No. 14; pp. 1155-1158; Jul. 17, 2003.;;Gorna et al.; Preparation, degradation, and clarification of biodegradable polyurethane foams for bone graft substitutes; J. Biomed Mater Res A; 67(3); pp. 813-827; Dec. 1, 2003.;;Guelcher et al.; Synthesis and in vitro biocompatibility of injectable polyurethane foam scaffolds; Tissue Engineering; 12(5); pp. 1247-1259; May 2006.;;Guelcher et al.; Synthesis of biocompatible segmented polyurethanes from aliphatic diisocyanates and diurea diol chain extenders; Acta biomaterialia; 1(4); pp. 471-484; Jul. 2005.;;Gunatillake et al.; Designing biostable polyurethane elastomers for biomedical implants; Aust. J. Chem.; vol. 56; pp. 545-557; Jun. 2003.;;Hern et al.; Incorporation of adhesion peptides into nonadhesive hydrogels useful for tissue resurfacing; J. Biomed. Materials Research; vol. 39; No. 1; pp. 266-276; Feb. 1998.;;Iwasaki et al., Hydrogel like elastic membrane consisting of semi-interpenetrating polymer networks based on a phosphorylcholine polymer and a segmented polyurethane; J. Polym. Sci Part A: Polym Chem; 41; pp. 68-75; Jan. 2003.;;Khan et al., Analysis and evaluation of a biomedical polycarbonate urethane tested in an in vitro study and an ovine arthroplasty model. Part I: materials selection and evaluation. Biomaterials, Feb. 2005. 26(6): p. 621-31.;;Kim et al.; Water sorption of ploy(propylene glycol)/poly(acrylic acid) interpenetrating polymer network hydrogels; Reactive & Functional Polymers; vol. 55; pp. 69-73; Feb. 2003.;;Kim et al.; Electrochemical behavior of an interpenetrating polymer network hydrogel composed of poly (propylene glycol) and poly(acrylic acid); Journal of Applied Polymer Science; vol. 89; pp. 2301-2305; Aug. 2003.;;Lamba et al.; Polyurethanes in Biomedical Application; CRC Press; pp. 11, 14, 16, 18-20, 57-59, 73, 79 & 104; Nov. 1997.;;Lee et al.; Interpenetrating polymer network hydrogels based on poly (ethylene glycol) macromer and chitosan; Carbohydrate Polymer; vol. 41; No. 2; pp. 197-205; Feb. 2000.;;Lipatov et al.; Gradient interpenetrating polymer networks; Journal of Materials Science; 30(4); pp. 1095-1104; Feb. 1995.;;Lu et al.; Release behavior of high molecular weight solutes from poly(ethylene glycol)-based degradable networks; Macromolecules; vol. 33(7); pp. 2509-2515; Mar. 2000.;;Maroudas et al.; Permeability of articular cartilage; Nature; vol. 219(5160); pp. 1260-1261; Sep. 21, 1968.;;Mow et al., fBasic Orthopaedic Biomechanics and Mechano-Biology, Lippincot Williams and Wilkins, 3rd Edition, Apr. 2005, pp. 459-461.;;Myung, David; Structure, properties, and medical device applications of mechanically enhanced, biometric hydrogel alloys; Doctoral Thesis; Stanford University; Dec. 2007.;;Myung et al.; Biomimetic strain hardening in interpenetrating polymer network hydrogels; Polymer, ; vol. 48; No. 18; pp. 5376-5387; Jun. 2007.;;Park et al.; Synthesis of PVA/PVP hydrogels having two-layer by radiation and their physical properties; Radiation Physics and Chemistry; 67(3-4); pp. 361-365; Jun. 2003.;;Saito et al.; Preparation and properties of transparent cellulose hydrogels; J. Applied Polymer Science; 90(11); pp. 3020-3025; Dec. 2003.;;Scholes et al.; Compliant layer acetabular cups: friction tsting of a range of materials and designs for a new generation of prosthesis that mimics the natural joint; Proc. IMechE; vol. 220(5); Part H; J. Engineering in Medicine; pp. 583-596, Jul. 2006.;;Shalaby; U.S. Appl. No. 61/069,046 entitled ""Hydroswellable, segmented, aliphatic polyurethanes and polyurethane ureas,"" filed Mar. 12, 2008.;;Spector et al.; Porous polymers for biological fixation. Clin Orthop Relat Res, Oct. 1988 (235): p. 207-19.;;Stammen et al., Mechanical properties of a novel PVA hydrogel in shear and unconfined compression. Biomaterials, Apr. 2001. 22(8): p. 799-806.;;Tariq et al.; (Abstract) Sodium benzoate attenuates iminodipropionitrile-induced behavioral syndrome in rats. Behav pharmacol; Dec. 2004.;;Tawfik, Dan; Amidation of carboxyl groups; The Protein Protocols Handbook, 2nd Ed.; Humana Press; pp. 477-478; Feb. 2002.;;The Engineering Toolbox; Polyurethane insulation: {http://www.engineeringtoolbox.com/polyurethane-insulation-k-values-d-1174.html} pp. 1-3; printed Oct. 21, 2011.;;The Engineering Toolbox;Thermal conductivity of some common materials and gases: {http://www.engineeringtoolbox.com/thrmal-conductivity-d-429.html} pp. 1-2; printed Oct. 21, 2011.;;The Gorilla Glue Company; Material Safety Data Sheet; ""New Fast Cure-Dries White Gorilla Glue®""; Jan. 30, 2007.;;The Gorilla Glue Company; Material Safety Data Sheet; ""New Stronger-Faster Gorilla Glue®""; Jan. 26, 2007.;;Wittemann et al.; Adsorption of proteins on spherical polyelectrolyte brushes in aqueous solution; Phys. Chem. Chem. Phys., Mar. 2003, vol. 5(8), pp. 1671-1677.;;Wright et al., Wear studies on prosthetic materials using the pin-on-disc machine. Biomaterials, vol. 3, Issue 1, Jan. 1982, pp. 41R48.;;Yang et al.; Preparation of poly(acrylic acid) modified polyurethane membrane for biomaterial by UV radiation without degassing; J. Biomed. Mater. Res.; vol. 45(2); pp. 133-139; May 1999.;;Zhu et al.; (Abstract) Promoting the cytocompatibility of polyurethane scaffolds via surface photo-grafting polymerization of acrylamide; J. Mater. Sci. Mater. Med.; vol. 15; No. 3; pp. 283-289; Mar. 2004.;;Myung et al.; U.S. Appl. No. 13/347,647 entitled ""Orthopedic implants having gradient polymer alloys,"" filed Jan. 10, 2012.;;Causton et al.; Dental materials: 1981 literature review Part 1; Journal of Dentistry; vol. 12; Issue 1; pp. 1R28; Mar. 1984.;;Charnley, J.; Anchorage of the femoral head prosthesis to the shaft of the femur; J Bone Joint Surg Br.; 42-B:28-30; Feb. 1960.;;Depuy Orthopaedics; Bone Cement Time Setting Chart; product file; date of publication unknown; available to applicants at least as of Jul. 2012.;;Kwong et al.; A comparison of the shrinkage of commercial bone cements when mixed under vacuum; J Bone Joint Surg Br.; 88(1):120-2; Jan. 2006.;;Lewis G.; Properties of acrylic bone cement: state of the art review; J Biomed Mater Res.; 38(2):155-82; Summer(Jun.-Aug.) 1997.;;Morgan et al.; Dependence of yield strain of human trabecular bone on anatomic site; J Biomech.; 34(5):569-77; May 2001.;;Ohman et al.; Mechanical testing of cancellous bone from the femoral head: experimental errors due to off-axis measurements; J Biomech.; 40(11);2426-33; (year of publication is sufficiently earlier than the effective U.S. filing date and any foreign priority date) 2007.;;Orr et al.; Shrinkage stresses in bone cement; Biomaterials; 24 (17):2933-40; Aug. 2003.;;Puska et al.; Exothermal Characteristics and Release of Residual Monomers from Fiber-reinforced Oligomer-modified Acrylic Bone Cement; J Biomat App; 20:51-64; Jul. 2005.;;Stryker Orthopaedics; SimplexTM P Bone Cement; Product Literature LSB Rev. 3, Mar. 2006.;;Kourtis et al.: U.S. Appl. No. 13/573,788 entitled ""Polymeric adhesive for anchoring compliant materials to another surface,"" filed Oct. 3, 2012.;;Kourtis et al.: U.S. Appl. No. 13/683,731 entitled ""Systems, Devices, and Methods for Anchoring Orthopaedic Implants to Bone,"" filed Nov. 21, 2012.;;Myung et al.; U.S. Appl. No. 13/816,537 entitled ""Hydrophobic and Hydrophilic Interpenetrating Polymer Networks Derived From Hydrophobic Polymers and Methods of Preparing the Same,"" filed Apr. 24, 2013.;;Chen et al.; Mechanical Properties of Polyepichlorohydrin Polyurethane/Poly(methyl methacrylate) IPNs; Chinese J Appl Chem; 12(4):66-69; Aug. 1995 (wEngAbs).;;Ithaca College Gross Anatomy; Joints of the Back; 4 pgs. (downloaded Dec. 1, 2013 from http://www.ithaca.edu/faculty/lahr/LE2000/Back/Jointpage.htm).;;Jones et al.; Sequential Polyurethane-Poly(Methylmethacrylate) Interpenetrating Polymer Networks as Ureteral Biomaterials: Mechanical Properties and Comparative Resistance to Urinaryencrustation; J Mater Sci Mater Med; 8(11):713-717; Nov. 1997.;;Lam et al.; Update on Ureteral Stents; Urology; 64:9-15; Jul. 2004.;;MIT.edu; Material Modulus Properties; 2pgs.; Feb. 8, 2007 (downloaded Nov. 27, 2013 from http://web.archive.org/web/*/http://web.mit.edu/course/3/3.11/www/modules/props.pdf).;;Neurosurgical.com; Spinal Anatomy: The Regions of the Spine; 5pgs. (downloaded Dec. 1, 2013 http://www.neurosurgical.com/neuro-medical-info/spinal-anatomy.htm).;;Realdictionary; Definition of Implant; 4pgs. (downloaded Dec. 1, 2013 from www.realdictionary.com/?q=implant).;;Van Landuyt et al.; Reinforcement of Osteosynthesis Screws with Brushite Cement; Bone; 25(2)(Suppl 1):95S-98S; Aug. 1999.",ACTIVE
84,AU,A1,AU 2008/241487 A1,130-477-608-021-46X,2008-10-30,2008,AU 2008/241487 A,2008-04-17,US 92398807 P;;US 2008/0004976 W,2007-04-17,Hydrogel arthroplasty device,,UNIV LELAND STANFORD JUNIOR,FRANK CURTIS W;;GOODMAN STUART B;;MYUNG DAVID;;KOURTIS LAMPROS;;HARTMANN LAURA;;CARTER DENNIS R,THE BOARD OF TRUSTEES OF LELAND STANFORD JUNIOR UN (2011-03-17),https://lens.org/130-477-608-021-46X,Patent Application,no,0,0,16,58,0,A61F2/30756;;A61F2/32;;A61F2/34;;A61F2/3603;;A61F2/38;;A61F2/3859;;A61F2/389;;A61F2002/30075;;A61F2002/30077;;A61F2002/30324;;A61F2002/30616;;A61F2002/30673;;A61F2002/3092;;A61F2002/30937;;A61F2002/30971;;A61F2002/3225;;A61F2002/4631;;A61F2210/0061;;A61F2210/0066;;A61F2250/0036;;A61F2310/00796;;A61L27/425;;A61L27/52;;A61L27/56;;A61F2002/349,A61F2/30;;A61L27/52,,0,0,,,,INACTIVE
85,US,A1,US 2016/0346089 A1,141-027-763-980-389,2016-12-01,2016,US 201615206060 A,2016-07-08,US 201615206060 A;;US 201414188257 A;;US 201213418294 A;;US 14853408 A;;US 7033608 A;;US 24395205 A;;US 63611406 A;;US 40921806 A;;US 63904906 A;;US 92398807 P;;US 90180507 P;;US 61626204 P;;US 67317205 P;;US 84394206 P;;US 78330706 P;;US 67360005 P,2004-10-05,HYDROGEL ARTHROPLASTY DEVICE,"An arthroplasty device is provided having an interpenetrating polymer network (IPN) hydrogel that is strain-hardened by swelling and adapted to be held in place in a joint by conforming to a bone geometry. The strain-hardened IPN hydrogel is based on two different networks: (1) a non-silicone network of preformed hydrophilic non-ionic telechelic macromonomers chemically cross-linked by polymerization of its end-groups, and (2) a non-silicone network of ionizable monomers. The second network was polymerized and chemically cross-linked in the presence of the first network and has formed physical cross-links with the first network. Within the IPN, the degree of chemical cross-linking in the second network is less than in the first network. An aqueous salt solution (neutral pH) is used to ionize and swell the second network. The swelling of the second network is constrained by the first network resulting in an increase in effective physical cross-links within the IPN.",MYUNG DAVID;;KOURTIS LAMPROS;;HARTMANN LAURA;;FRANK CURTIS W;;GOODMAN STUART B;;CARTER DENNIS R,MYUNG DAVID;;KOURTIS LAMPROS;;HARTMANN LAURA;;FRANK CURTIS W;;GOODMAN STUART B;;CARTER DENNIS R,,https://lens.org/141-027-763-980-389,Patent Application,yes,5,9,7,58,0,A61F2/30756;;A61F2/30756;;A61F2/34;;A61F2/34;;A61F2/36;;A61F2/3603;;A61F2/3603;;A61F2/3872;;A61F2/3872;;A61F2/4202;;A61F2/4202;;A61F2/4225;;A61F2/4225;;A61F2/4241;;A61F2/4241;;A61F2/4405;;A61F2/4405;;A61F2002/30075;;A61F2002/30075;;A61F2002/30448;;A61F2002/30448;;A61F2002/30593;;A61F2002/30593;;A61F2002/30754;;A61F2002/30754;;A61F2210/0061;;A61F2210/0061;;A61F2220/005;;A61F2220/005;;A61F2310/00293;;A61F2310/00293;;A61L27/18;;A61L27/34;;A61L27/3843;;A61L27/3843;;A61L27/50;;A61L27/52;;A61L27/52;;A61L2430/24;;A61L2430/24,A61F2/30;;A61F2/34;;A61F2/36;;A61F2/38;;A61F2/42;;A61F2/44;;A61L27/18;;A61L27/34;;A61L27/50;;A61L27/52,,0,0,,,,DISCONTINUED
86,US,B2,US 11246890 B2,188-527-226-752-336,2022-02-15,2022,US 201916371371 A,2019-04-01,US 201916371371 A;;US 201862652176 P,2018-04-03,Systemic targeting of inflammatory sites and enhanced immunomodulatory function by introducing the chimeric antigen receptor (CAR) into mesenchymal stem cells for inflammatory and autoimmune diseases,"Mesenchymal stromal cells are engineered to express a chimeric antigen receptor (CAR), that specifically binds a marker of activated myeloid cells, including without limitation folate receptor beta; and are administered to an individual for treatment of inflammation at sites characterized by the presence of activated myeloid cells.",UNIV LELAND STANFORD JUNIOR,LIN TZUHUA DENNIS;;GOODMAN STUART B;;TANG SAI-WEN;;MEYER EVERETT HURTEAU;;PÉREZ CRUZ MAGDIEL,THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (2019-04-03),https://lens.org/188-527-226-752-336,Granted Patent,yes,10,0,3,3,0,A61P3/10;;C07K14/5406;;C07K2319/03;;C07K16/44;;C07K16/28;;C07K2317/622;;C07K14/7051;;C12N2510/00;;C07K2319/33;;A61K35/28;;A61K38/2026;;A61K2239/26;;A61K39/4631;;A61K39/4621;;A61K39/461;;A61K39/464402;;A61K39/46433;;A61K35/28;;A61K47/6849;;A61P3/10;;C07K14/5406;;C07K16/28;;A61K2039/5156,A61K35/28;;A61K39/00;;A61K47/68;;A61P3/10;;C07K14/54;;C07K16/28,,5,5,005-396-715-232-629;;005-412-652-838-769;;069-215-913-922-280;;012-921-351-664-565;;013-337-058-375-346,pmc3933792;;10.3389/fimmu.2014.00071;;24611065;;28583168;;pmc5460436;;10.1186/s13287-017-0593-3;;25887778;;10.1182/blood-2014-11-612721;;pmc4447861;;22568986;;pmc3427232;;10.4161/cam.20341;;pmc4792550;;26496034;;10.18632/oncotarget.6175,"Bhatt et al. (2014) “Regulation of the NF-kB-mediated transcription of inflammatory genes” Immunology 5:71 1-9.;;Lu et al. (2017) Mesenchymal stem cells for treating autoimmune dacryoadenitis. Stem Cell Research & Therapy 8:1 126.;;Lynn et al. (2015) “Targeting of folate receptor beta on acute myeloid leukemia blasts with chimeric antigen receptor expressing T cells” Blood., vol. 125(22): 3466-76.;;Payne et al. (2012) “Early intervention with gene modified mesenchymal stem cells overexpressing interleukin-4 enhances anti-inflammatory responses and functional recovery in experimental autoimmune demyelination” Cell Adhesion & Migration 6:3 179-189.;;Tang et al. (2015) “Therapeutic potential of CAR-T cell-derived exosomes: a cell-free modality for targeted cancer therapy” Oncotarget 6:42 44179-44190.",ACTIVE
87,US,A1,US 2012/0232657 A1,000-132-559-767-064,2012-09-13,2012,US 201213418294 A,2012-03-12,US 201213418294 A;;US 14853408 A;;US 7033608 A;;US 24395205 A;;US 63611406 A;;US 40921806 A;;US 63904906 A;;US 92398807 P;;US 90180507 P;;US 61626204 P;;US 67317205 P;;US 84394206 P;;US 78330706 P;;US 67360005 P,2004-10-05,Hydrogel Arthroplasty Device,"An arthroplasty device is provided having an interpenetrating polymer network (IPN) hydrogel that is strain-hardened by swelling and adapted to be held in place in a joint by conforming to a bone geometry. The strain-hardened IPN hydrogel is based on two different networks: (1) a non-silicone network of preformed hydrophilic non-ionic telechelic macromonomers chemically cross-linked by polymerization of its end-groups, and (2) a non-silicone network of ionizable monomers. The second network was polymerized and chemically cross-linked in the presence of the first network and has formed physical cross-links with the first network. Within the IPN, the degree of chemical cross-linking in the second network is less than in the first network. An aqueous salt solution (neutral pH) is used to ionize and swell the second network. The swelling of the second network is constrained by the first network resulting in an increase in effective physical cross-links within the IPN.",MYUNG DAVID;;KOURTIS LAMPROS;;HARTMANN LAURA;;FRANK CURTIS W;;GOODMAN STUART B;;CARTER DENNIS R,MYUNG DAVID;;KOURTIS LAMPROS;;HARTMANN LAURA;;FRANK CURTIS W;;GOODMAN STUART B;;CARTER DENNIS R,THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (2008-11-17);;THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS OFFICE OF GENERAL COUNSEL - PSG IV (024) (2008-11-19),https://lens.org/000-132-559-767-064,Patent Application,yes,13,18,7,58,0,A61F2/30756;;A61F2/30756;;A61F2/34;;A61F2/34;;A61F2/36;;A61F2/3603;;A61F2/3603;;A61F2/3872;;A61F2/3872;;A61F2/4202;;A61F2/4202;;A61F2/4225;;A61F2/4225;;A61F2/4241;;A61F2/4241;;A61F2/4405;;A61F2/4405;;A61F2002/30075;;A61F2002/30075;;A61F2002/30448;;A61F2002/30448;;A61F2002/30593;;A61F2002/30593;;A61F2002/30754;;A61F2002/30754;;A61F2210/0061;;A61F2210/0061;;A61F2220/005;;A61F2220/005;;A61F2310/00293;;A61F2310/00293;;A61L27/18;;A61L27/34;;A61L27/3843;;A61L27/3843;;A61L27/50;;A61L27/52;;A61L27/52;;A61L2430/24;;A61L2430/24,A61F2/02,623/14.12,1,0,,,"Kim et al. Journal of Applied Polymer Science. Volume 92, Issue 3 pp. 1731-1736.",ACTIVE
88,JP,A,JP 2013116324 A,059-374-804-636-870,2013-06-13,2013,JP 2013000685 A,2013-01-07,US 92398807 P,2007-04-17,HYDROGEL ARTHROPLASTY DEVICE,"PROBLEM TO BE SOLVED: To provide a device and material useful for orthopaedic prostheses.SOLUTION: There is provided an arthroplasty device having an interpenetrating polymer network (IPN) hydrogel that is strain-hardened by swelling and adapted to be held in place in a joint by conforming to a bone geometry. The strain-hardened IPN hydrogel is formed of: (1) a non-silicone network of preformed hydrophilic non-ionic telechelic macromonomers chemically cross-linked by polymerization of its end-groups, and (2) a non-silicone network of ionizable monomers. The second network 11 was polymerized and chemically cross-linked in the presence of the first network 10 and has formed physical cross-links with the first network 10.",UNIV LELAND STANFORD JUNIOR;;US GOVERNMENT,MYUNG DAVID;;KOURTIS LAMPROS;;HARTMANN LAURA;;FRANK CURTIS W;;GOODMAN STUART B;;CARTER DENNIS R,,https://lens.org/059-374-804-636-870,Patent Application,no,16,0,16,58,0,A61F2/30756;;A61F2/32;;A61F2/34;;A61F2/3603;;A61F2/38;;A61F2/3859;;A61F2/389;;A61F2002/30075;;A61F2002/30077;;A61F2002/30324;;A61F2002/30616;;A61F2002/30673;;A61F2002/3092;;A61F2002/30937;;A61F2002/30971;;A61F2002/3225;;A61F2002/4631;;A61F2210/0061;;A61F2210/0066;;A61F2250/0036;;A61F2310/00796;;A61L27/425;;A61L27/52;;A61L27/56;;A61F2002/349,A61L27/00;;A61F2/30,,0,0,,,,ACTIVE
89,EP,A1,EP 3628275 A1,089-721-356-955-326,2020-04-01,2020,EP 19207798 A,2008-04-17,EP 12156562 A;;EP 08743019 A;;US 92398807 P;;US 2008/0004976 W,2007-04-17,HYDROGEL ARTHROPLASTY DEVICE,"An arthroplasty device is provided having an interpenetrating polymer network (IPN) hydrogel that is strain-hardened by swelling and adapted to be held in place in a joint by conforming to a bone geometry. The strain-hardened IPN hydrogel is based on two different networks: (1) a non-silicone network of preformed hydrophilic non-ionic telechelic macromonomers chemically cross-linked by polymerization of its end-groups, and (2) a non-silicone network of ionizable monomers. The second network was polymerized and chemically cross-linked in the presence of the first network and has formed physical cross-links with the first network. Within the IPN, the degree of chemical cross-linking in the second network is less than in the first network. An aqueous salt solution (neutral pH) is used to ionize and swell the second network. The swelling of the second network is constrained by the first network resulting in an increase in effective physical cross-links within the IPN.
",UNIV LELAND STANFORD JUNIOR;;THE US GOV AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS,MYUNG DAVID;;KOURTIS LAMPROS;;HARTMANN LAURA;;FRANK CURTIS W;;GOODMAN STUART B;;CARTER DENNIS R,,https://lens.org/089-721-356-955-326,Patent Application,yes,2,0,16,58,0,A61F2/30756;;A61F2/32;;A61F2/34;;A61F2/3603;;A61F2/38;;A61F2/3859;;A61F2/389;;A61F2002/30075;;A61F2002/30077;;A61F2002/30324;;A61F2002/30616;;A61F2002/30673;;A61F2002/3092;;A61F2002/30937;;A61F2002/30971;;A61F2002/3225;;A61F2002/4631;;A61F2210/0061;;A61F2210/0066;;A61F2250/0036;;A61F2310/00796;;A61L27/425;;A61L27/52;;A61L27/56;;A61F2002/349,A61F2/30;;A61L27/52,,0,0,,,,ACTIVE
90,US,A1,US 2019/0298774 A1,074-389-587-607-787,2019-10-03,2019,US 201916371371 A,2019-04-01,US 201916371371 A;;US 201862652176 P,2018-04-03,SYSTEMIC TARGETING OF INFLAMMATORY SITES AND ENHANCED IMMUNOMODULATORY FUNCTION BY INTRODUCING THE CHIMERIC ANTIGEN RECEPTOR (CAR) INTO MESENCHYMAL STEM CELLS FOR INFLAMMATORY AND AUTOIMMUNE DISEASES,"Mesenchymal stromal cells are engineered to express a chimeric antigen receptor (CAR), that specifically binds a marker of activated myeloid cells, including without limitation folate receptor beta; and are administered to an individual for treatment of inflammation at sites characterized by the presence of activated myeloid cells.",UNIV LELAND STANFORD JUNIOR,LIN TZUHUA DENNIS;;GOODMAN STUART B;;TANG SAI-WEN;;MEYER EVERETT HURTEAU;;PÉREZ CRUZ MAGDIEL,THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (2019-04-03),https://lens.org/074-389-587-607-787,Patent Application,yes,0,2,3,3,0,A61P3/10;;C07K14/5406;;C07K2319/03;;C07K16/44;;C07K16/28;;C07K2317/622;;C07K14/7051;;C12N2510/00;;C07K2319/33;;A61K35/28;;A61K38/2026;;A61K2239/26;;A61K39/4631;;A61K39/4621;;A61K39/461;;A61K39/464402;;A61K39/46433;;A61K35/28;;A61K47/6849;;A61P3/10;;C07K14/5406;;C07K16/28;;A61K2039/5156,A61K35/28;;A61K47/68;;A61P3/10;;C07K14/54;;C07K16/28,,0,0,,,,ACTIVE
91,EP,A1,EP 2457539 A1,032-145-173-528-38X,2012-05-30,2012,EP 12156562 A,2008-04-17,US 92398807 P;;EP 08743019 A;;US 2008/0004976 W,2007-04-17,Hydrogel arthroplasty device,"An arthroplasty device is provided having an interpenetrating polymer network (IPN) hydrogel that is strain-hardened by swelling and adapted to be held in place in a joint by conforming to a bone geometry. The strain-hardened IPN hydrogel is based on two different networks: (1) a non-silicone network of preformed hydrophilic non-ionic telechelic macromonomers chemically cross-linked by polymerization of its end-groups, and (2) a non-silicone network of ionizable monomers. The second network was polymerized and chemically cross-linked in the presence of the first network and has formed physical cross-links with the first network. Within the IPN, the degree of chemical cross-linking in the second network is less than in the first network. An aqueous salt solution (neutral pH) is used to ionize and swell the second network. The swelling of the second network is constrained by the first network resulting in an increase in effective physical cross-links within the IPN.
",UNIV LELAND STANFORD JUNIOR;;US GOV VETERANS AFFAIRS,MYUNG DAVID;;KOURTIS LAMPROS;;HARTMANN LAURA;;FRANK CURTIS W;;GOODMAN STUART B;;CARTER DENNIS R,THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIO (2019-09-18);;THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE (2019-09-18),https://lens.org/032-145-173-528-38X,Patent Application,yes,1,3,16,58,0,A61F2/30756;;A61F2/32;;A61F2/34;;A61F2/3603;;A61F2/38;;A61F2/3859;;A61F2/389;;A61F2002/30075;;A61F2002/30077;;A61F2002/30324;;A61F2002/30616;;A61F2002/30673;;A61F2002/3092;;A61F2002/30937;;A61F2002/30971;;A61F2002/3225;;A61F2002/4631;;A61F2210/0061;;A61F2210/0066;;A61F2250/0036;;A61F2310/00796;;A61L27/425;;A61L27/52;;A61L27/56;;A61F2002/349,A61F2/30;;A61L27/52,,1,1,102-621-678-354-743,10.1002/adma.200304907,"GONG J P ET AL: ""Double-network hydrogels with high mechanical strength"", ADVANCED MATERIALS, WILEY VCH VERLAG, DE, vol. 15, no. 14, 17 July 2003 (2003-07-17), pages 1155 - 1158, XP002572762, ISSN: 0935-9648, DOI: 10.1002/ADMA.200304907",ACTIVE
92,US,A1,US 2009/0088846 A1,187-653-286-888-930,2009-04-02,2009,US 14853408 A,2008-04-17,US 14853408 A;;US 7033608 A;;US 92398807 P,2007-04-17,Hydrogel arthroplasty device,"An arthroplasty device is provided having an interpenetrating polymer network (IPN) hydrogel that is strain-hardened by swelling and adapted to be held in place in a joint by conforming to a bone geometry. The strain-hardened IPN hydrogel is based on two different networks: (1) a non-silicone network of preformed hydrophilic non-ionic telechelic macromonomers chemically cross-linked by polymerization of its end-groups, and (2) a non-silicone network of ionizable monomers. The second network was polymerized and chemically cross-linked in the presence of the first network and has formed physical cross-links with the first network. Within the IPN, the degree of chemical cross-linking in the second network is less than in the first network. An aqueous salt solution (neutral pH) is used to ionize and swell the second network. The swelling of the second network is constrained by the first network resulting in an increase in effective physical cross-links within the IPN.",MYUNG DAVID;;KOURTIS LAMPROS;;HARTMANN LAURA;;FRANK CURTIS W;;GOODMAN STUART B;;CARTER DENNIS R,MYUNG DAVID;;KOURTIS LAMPROS;;HARTMANN LAURA;;FRANK CURTIS W;;GOODMAN STUART B;;CARTER DENNIS R,BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY THE (2008-11-17);;VETERAN AFFAIRS THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF (2008-11-19),https://lens.org/187-653-286-888-930,Patent Application,yes,80,101,7,58,0,A61F2/30756;;A61F2/30756;;A61F2/34;;A61F2/34;;A61F2/36;;A61F2/3603;;A61F2/3603;;A61F2/3872;;A61F2/3872;;A61F2/4202;;A61F2/4202;;A61F2/4225;;A61F2/4225;;A61F2/4241;;A61F2/4241;;A61F2/4405;;A61F2/4405;;A61F2002/30075;;A61F2002/30075;;A61F2002/30448;;A61F2002/30448;;A61F2002/30593;;A61F2002/30593;;A61F2002/30754;;A61F2002/30754;;A61F2210/0061;;A61F2210/0061;;A61F2220/005;;A61F2220/005;;A61F2310/00293;;A61F2310/00293;;A61L27/18;;A61L27/34;;A61L27/3843;;A61L27/3843;;A61L27/50;;A61L27/52;;A61L27/52;;A61L2430/24;;A61L2430/24,A61F2/08,623/14.12;;424/486;;424/423;;424/426,0,0,,,,DISCONTINUED
93,CA,A1,CA 2684730 A1,143-532-923-475-227,2008-10-30,2008,CA 2684730 A,2008-04-17,US 92398807 P;;US 2008/0004976 W,2007-04-17,HYDROGEL ARTHROPLASTY DEVICE,"An arthroplasty device is provided having an interpenetrating polymer net work (IPN) hydrogel that is strain-hardened by swelling and adapted to be he ld in place in a joint by conforming to a bone geometry. The strain-hardened IPN hydrogel is based on two different networks: (1) a non-silicone network of preformed hydrophilic non-ionic telechelic macromonomers chemically cros s-linked by polymerization of its end-groups, and (2) a non-silicone network of ionizable monomers. The second network was polymerized and chemically cr oss-linked in the presence of the first network and has formed physical cros s-links with the first network. Within the IPN, the degree of chemical cross -linking in the second network is less than in the first network. An aqueous salt solution (neutral pH) is used to ionize and swell the second network. The swelling of the second network is constrained by the first network resul ting in an increase in effective physical cross-links within the IPN.",UNIV LELAND STANFORD JUNIOR,CARTER DENNIS R;;HARTMANN LAURA;;MYUNG DAVID;;KOURTIS LAMPROS;;FRANK CURTIS W;;GOODMAN STUART B,,https://lens.org/143-532-923-475-227,Patent Application,no,0,0,16,58,0,A61F2/30756;;A61F2/32;;A61F2/34;;A61F2/3603;;A61F2/38;;A61F2/3859;;A61F2/389;;A61F2002/30075;;A61F2002/30077;;A61F2002/30324;;A61F2002/30616;;A61F2002/30673;;A61F2002/3092;;A61F2002/30937;;A61F2002/30971;;A61F2002/3225;;A61F2002/4631;;A61F2210/0061;;A61F2210/0066;;A61F2250/0036;;A61F2310/00796;;A61L27/425;;A61L27/52;;A61L27/56;;A61F2002/349,A61F2/30;;A61L27/52,,0,0,,,,DISCONTINUED
94,US,A1,US 2019/0015211 A1,069-240-243-808-167,2019-01-17,2019,US 201815981761 A,2018-05-16,US 201815981761 A;;US 201615206060 A;;US 201414188257 A;;US 201213418294 A;;US 14853408 A;;US 7033608 A;;US 24395205 A;;US 63611406 A;;US 40921806 A;;US 63904906 A;;US 92398807 P;;US 90180507 P;;US 61626204 P;;US 67317205 P;;US 84394206 P;;US 78330706 P;;US 67360005 P,2004-10-05,HYDROGEL ARTHROPLASTY DEVICE,"An arthroplasty device is provided having an interpenetrating polymer network (IPN) hydrogel that is strain-hardened by swelling and adapted to be held in place in a joint by conforming to a bone geometry. The strain-hardened IPN hydrogel is based on two different networks: (1) a non-silicone network of preformed hydrophilic non-ionic telechelic macromonomers chemically cross-linked by polymerization of its end-groups, and (2) a non-silicone network of ionizable monomers. The second network was polymerized and chemically cross-linked in the presence of the first network and has formed physical cross-links with the first network. Within the IPN, the degree of chemical cross-linking in the second network is less than in the first network. An aqueous salt solution (neutral pH) is used to ionize and swell the second network. The swelling of the second network is constrained by the first network resulting in an increase in effective physical cross-links within the IPN.",UNIV LELAND STANFORD JUNIOR,MYUNG DAVID;;KOURTIS LAMPROS;;HARTMANN LAURA;;FRANK CURTIS W;;GOODMAN STUART B;;CARTER DENNIS R,THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (2008-11-17);;THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS OFFICE OF GENERAL COUNSEL - PSG IV (024) (2008-11-19),https://lens.org/069-240-243-808-167,Patent Application,yes,0,2,7,58,0,A61F2/30756;;A61F2/30756;;A61F2/34;;A61F2/34;;A61F2/36;;A61F2/3603;;A61F2/3603;;A61F2/3872;;A61F2/3872;;A61F2/4202;;A61F2/4202;;A61F2/4225;;A61F2/4225;;A61F2/4241;;A61F2/4241;;A61F2/4405;;A61F2/4405;;A61F2002/30075;;A61F2002/30075;;A61F2002/30448;;A61F2002/30448;;A61F2002/30593;;A61F2002/30593;;A61F2002/30754;;A61F2002/30754;;A61F2210/0061;;A61F2210/0061;;A61F2220/005;;A61F2220/005;;A61F2310/00293;;A61F2310/00293;;A61L27/18;;A61L27/34;;A61L27/3843;;A61L27/3843;;A61L27/50;;A61L27/52;;A61L27/52;;A61L2430/24;;A61L2430/24,A61F2/30;;A61F2/34;;A61F2/36;;A61F2/38;;A61F2/42;;A61F2/44;;A61L27/18;;A61L27/34;;A61L27/38;;A61L27/50;;A61L27/52,,0,0,,,,DISCONTINUED
95,EP,A2,EP 2148637 A2,075-876-150-936-777,2010-02-03,2010,EP 08743019 A,2008-04-17,US 2008/0004976 W;;US 92398807 P,2007-04-17,HYDROGEL ARTHROPLASTY DEVICE,,UNIV LELAND STANFORD JUNIOR,MYUNG DAVID;;KOURTIS LAMPROS;;HARTMANN LAURA;;FRANK CURTIS W;;GOODMAN STUART B;;CARTER DENNIS R,THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIO (2011-05-04);;THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE (2011-05-04),https://lens.org/075-876-150-936-777,Patent Application,yes,0,0,16,58,0,A61F2/30756;;A61F2/32;;A61F2/34;;A61F2/3603;;A61F2/38;;A61F2/3859;;A61F2/389;;A61F2002/30075;;A61F2002/30077;;A61F2002/30324;;A61F2002/30616;;A61F2002/30673;;A61F2002/3092;;A61F2002/30937;;A61F2002/30971;;A61F2002/3225;;A61F2002/4631;;A61F2210/0061;;A61F2210/0066;;A61F2250/0036;;A61F2310/00796;;A61L27/425;;A61L27/52;;A61L27/56;;A61F2002/349,A61F2/30;;A61L27/52,,0,0,,,,ACTIVE
96,WO,A1,WO 2023/164480 A1,091-762-893-613-041,2023-08-31,2023,US 2023/0063026 W,2023-02-22,IT 202200003305 A;;IT 202200015177 A,2022-02-22,FRONTHAUL BANDWIDTH REDUCTION IN RADIO ACCESS NETWORK,"Various techniques for reducing fronthaul bandwidth usage or contention in radio access networks are described. A base station is configured so that each of RUs is configured to: receive, at that RU, an SRS transmission from a UE; perform, by the RU, at least some of a high physical layer (PHY) baseband processing for the received SRS transmission; and transmit fronthaul data for the received SRS transmission to the distributed unit over the fronthaul network, wherein the fronthaul data comprises a payload including data generated in connection with performing at least some of the high PHY based processing for the received SRS transmission.",COMMSCOPE TECHNOLOGIES LLC,SALAHUDDEEN IRFAAN AHAMED;;SANDBERG STUART D;;RANSON CHRISTOPHER GOODMAN;;PIANKA BOAZ;;ARMAO CALOGERO;;SHARMA SUNIT KUMAR,,https://lens.org/091-762-893-613-041,Patent Application,yes,4,0,1,1,0,H04W74/0833;;H04L5/0048,H04L5/00;;H04W74/08,,1,1,151-072-708-965-616,10.23919/ondm.2018.8396126,"LI LONGSHENG; BI MEIHUA; WANG WEI; FU YAN; MIAO XIN; HU WEISHENG: ""SINR-oriented flexible quantization bits for optical-wireless deep converged eCPRI"", 2018 INTERNATIONAL CONFERENCE ON OPTICAL NETWORK DESIGN AND MODELING (ONDM), IFIP, 14 May 2018 (2018-05-14), pages 172 - 177, XP033367059, DOI: 10.23919/ONDM.2018.8396126",PENDING
97,WO,A1,WO 2003/004162 A1,076-717-173-528-838,2003-01-16,2003,US 0220607 W,2002-07-02,US 30182301 P,2001-07-02,"FLOW-THRU CHIP CARTRIDGE, CHIP HOLDER, SYSTEM & METHOD THEREOF","A system for performing hybridization assays is disclosed which has a cartridge for housing an array device. The cartridge may include a test fluid chamber for facilitating a substantially uniform flow of a test fluid mixture through the flow through device, and may include a fluidics station to deliver the test fluid mixture to the cartridge. The cartridge has a plurality of channels to receive fluids used in the performance of hybridization assays and to keep them separate, if desired.",GENE LOGIC INC;;PAUL ERIC A;;TORRES MATTHEW;;SMITH IAN STUART RICHARD;;GOODMAN JACK;;YANG HONGJUN;;MATEER DAVID G,PAUL ERIC A;;TORRES MATTHEW;;SMITH IAN STUART RICHARD;;GOODMAN JACK;;YANG HONGJUN;;MATEER DAVID G,,https://lens.org/076-717-173-528-838,Patent Application,yes,2,0,3,14,0,B01J2219/00274;;B01L3/5025;;B01L3/5027;;B01L3/502715;;B01L7/52;;B01L9/527;;B01L2300/0636;;B01L2300/0816;;B01L2300/0877;;B01L2300/18;;B01L2400/0487;;B01L2400/06;;B01L2400/0622;;G01N21/253;;G01N21/05;;G01N2021/0346,B01L3/00;;B01L7/00;;B01L9/00;;G01N21/05;;G01N21/25,,0,0,,,,PENDING
98,US,A1,US 2011/0191848 A1,123-252-246-081-981,2011-08-04,2011,US 69907310 A,2010-02-03,US 69907310 A,2010-02-03,PREVENTING MALICIOUS JUST-IN-TIME SPRAYING ATTACKS,"A method disclosed herein includes acts of receiving code at a Just-in-Time compiler executing in an application on a computing device and compiling the code to generate machine code and causing the machine code to be placed on at least one page that is accessible by at least one processor on the computing device, wherein the Just-in-Time compiler compiles the code utilizing at least one technique for preventing a Just-in-Time spraying attack.",MICROSOFT CORP,ZORN BENJAMIN GOTH;;LIVSHITS BENJAMIN;;BORSUK REID;;LAMBERT JOHN JOSEPH;;MILLER MATTHEW RYAN;;LAFRENIERE LOUIS;;BECK PETER STUART;;GOODMAN JOSHUA THEODORE;;BURRELL TIMOTHY WILLIAM;;LUCCO STEVEN EDWARD,MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14);;MICROSOFT CORPORATION (2010-01-29),https://lens.org/123-252-246-081-981,Patent Application,yes,9,43,1,1,0,G06F11/00;;G06F21/54;;G06F21/56;;G06F11/00,G06F11/00;;G06F9/45,726/22;;717/148,0,0,,,,DISCONTINUED
